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InTroducTIon
Kidney transplantation is the preferred treatment option for most patients suffering 
from end stage renal disease (ESRD), since transplantation is associated with improved 
quality of life and reduced mortality compared to either haemodialysis or peritoneal 
dialysis.1 Since the first successful kidney transplantation in the Netherlands in 1966, 
results have improved substantially with current one-year graft survival rates around 
86% for recipients of a deceased donor kidney and 95% for recipients of a living-donor 
kidney (NOTR, Dutch Organ Transplant Registry) (Figure 1). This improvement in first year 
graft survival is mainly attributed to development of more potent immunosuppressive 
drugs and the associated decrease in acute rejection episodes. At the beginning of the 
transplant era, the combination of prednisone and the anti-metabolite azathioprine 
was the standard immunosuppressive regimen. The calcineurin inhibitors (CNI) were 
introduced in the late seventies (cyclosporine) and early nineties (tacrolimus), and 
the anti-metabolite mycophenolate mofetil has been increasingly used in multidrug 
immunosuppression protocols since the mid-nineties. In parallel, the incidence of 
rejection episodes within the first three months after transplantation has decreased 
from 50-60% in the early eighties to 10-20% in most centres nowadays (NOTR). In the last 
decade even newer immunosuppressive agents have been introduced such as sirolimus 
or Belatacept. Although some may offer hope to further decrease the incidence of acute 
rejections, it is likely that the newer agents are best suited as alternatives for the current 
immunosuppressive drugs, and chosen based on the side effect profile. Graft  survival  rates  of  kidney  transplantations  performed  between  
1-­‐1-­‐2005  and  1-­‐1-­‐2011,  stratified  by  donor  type,  in  the  Netherlands.
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figure 1. Graft survival rates of kidney transplantations performed between 1-1-2005 and 1-1-2011, stratified 
by donor type, in the Netherlands
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Despite the excellent results of kidney transplantation, many unsolved problems remain.
1. A major drawback of kidney transplantation is the need for immunosuppressive 
therapy. Although immunosuppressive drugs are the cornerstone of therapy and 
pivotal to obtain good outcome  of kidney transplantation, their use is accompanied 
with severe side effects such as:
a. Nephrotoxicity is a major side effect of the widely used CNI, and contributes to 
graft function loss. The development of effective, non-nephrotoxic immuno-
suppressive drugs may help to avoid CNI as part of the immunosuppressive 
scheme and thus circumvent this problem. Sirolimus is suggested as a good 
candidate to replace the CNI.
b. The use of immunosuppressive therapy after kidney transplantation is largely 
responsible for the increased incidence of cancer, particularly skin cancer. Newer 
drugs, with lower carcinogenic potential but equal immunosuppressive potency, 
may help to overcome this problem. Again, sirolimus may play a role in the newer 
immunosuppressive regimens. 
2. The short-term results of kidney transplantation are excellent, but the long-term 
results have not been improved to the same extent. Thus, in many patients the 
clinical course after kidney transplantation is characterized by a slow, but progressive 
and unrelentless deterioration of graft function. One possibility to improve the long-
term results of kidney transplantation is to develop biomarkers that would allow 
predicting late allograft loss, thus allowing to identify and treat patients at highest 
risk in an early stage.
3. Another problem with kidney transplantation is the shortage of organs and the long 
waiting time. Transplantation with a kidney of a living-donor may circumvent this 
problem, but the question is whether this procedure is safe for the donor, particularly 
in the light of the now broadly used laparoscopic nephrectomy.
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bAckground
chronic allograft nephropathy and calcineurin inhibitor nephrotoxicity
The term “chronic allograft nephropathy (CAN)” is often used to define the process that is 
responsible for the relentless progressive kidney failure, often associated with proteinuria 
and hypertension that is observed in many patients after kidney transplantation and 
responsible for late graft failure, accounting for up to 40% of graft losses. A kidney 
biopsy shows a histological picture characterized by an obliterative vasculopathy, 
glomerulosclerosis and interstitial fibrosis with tubular atrophy. Histological changes 
are already present before clinically apparent renal dysfunction.2 The pathogenesis of 
CAN is multifactorial, and includes (humoral) rejection, hypertension, hyperlipidaemia, 
aging, and smoking. Of special concern is the contribution of the CNI to the 
development of CAN. CNI have added greatly to the reduction in acute rejections after 
solid organ transplantation. The use of CNI is however hampered by several side effects, 
including acute and chronic nephrotoxicity, hypertension and hyperlipidaemia, thereby 
increasing the risk for the development of graft failure and for cardiovascular disease. 
The nephrotoxicity of CNI became apparent since its first use in transplantation in the 
early 1980s. In the Canadian multicentre study the serum creatinine at both 1 and 3 
years was significantly higher in cyclosporine-treated than in the azathioprine-treated 
patients.3 Several years later, Myers et al.4 reported chronic renal insufficiency in cardiac 
transplant recipients that had received cyclosporine, some of whom subsequently 
required haemodialysis. The renal histological findings of arteriolar hyalinosis, 
glomerulosclerosis and interstitial fibrosis and tubular atrophy were attributed to 
CNI nephrotoxicity. Similar histologic findings were reported by Nankivell et al.2 By 
10 years virtually all patients were reported to have CNI nephrotoxicity and declining 
renal function. Both cyclosporine and tacrolimus result in increased synthesis of the 
fibrogenic cytokine transforming growth factor FGF-β1, which has been implicated as a 
key factor in the pathogenesis of chronic CNI nephropathy.5,6 
With improvements in short-term outcomes, attention has increasingly turned to 
strategies that optimize long-term allograft survival by minimizing the side effects 
of immunosuppressants. Thus, while many transplant centres begin maintenance 
immunosuppression with a combination of three drugs, efforts are now focused on 
immunosuppressive strategies with CNI minimization or elimination that can optimize 
long-term graft function without increasing rejection rates. 
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Malignancy
The reported cancer risk in renal transplant recipients (RTR) is two- to six-fold greater 
than in the general population.7-9 Cutaneous squamous cell carcinomas (SCCs) are 
the most common post-transplantation cancers, occurring 65 to 250 times more 
often than in the general population and are a serious complication of long-term 
organ transplantation.10-12 Moreover, SCCs appear to be more aggressive in transplant 
recipients. They often grow rapidly, recur locally in 13% of patients,13 and metastasize 
in 5 to 8 percent of patients.14 The incidence of skin malignancies in RTR increases 
progressively with intensity and duration of immunosuppression and therefore the 
overall time elapsed after transplantation. Duration of immunosuppressive therapy 
influences SCC risk, with compelling evidence for the carcinogenic mechanisms 
associated with cyclosporine15-17 and azathioprine.18
RTR should be educated in using sunscreen and should be strongly discouraged 
from smoking, as this is a risk factor for SCC and many other malignancies. Still, these 
preventive measures are insufficient. Recent guidelines from the American Academy 
of Dermatology have reviewed treatment options for SCC.19 Topical therapies include 
5-fluorouracil, imiquimod, cryosurgery or photodynamic therapy in areas of pre- or 
early-malignant change. Adjuvant radiotherapy may play a role in selected cases. This 
is usually undertaken in conjunction with a reduction in immunosuppression if SCC 
is recurrent or metastatic. Systemic retinoids have been demonstrated in small short-
term prospective and in long-term retrospective studies to play a role in the secondary 
prevention of SCC, but are teratogenic and poorly tolerated at higher doses.  
sirolimus
Sirolimus is a macrocyclic compound with potent immunosuppressive properties. It 
binds to the same FK-binding protein as tacrolimus. The sirolimus-FK-binding protein 
complex has no effect on calcineurin, and instead inhibits the mammalian target of 
rapamycin (mTOR), a cytosolic enzyme that regulates growth and proliferation of 
lymphocytes during the G1 phase of the cell cycle. When used in combination with 
cyclosporine and steroids, sirolimus has been proven to be safe and efficacious in 
reducing acute rejection rates in clinical trials,20,21 which served as the basis for the 
initial approval of the product in the United States and elsewhere. Continuation of 
dual therapy with sirolimus and steroids was shown to be effective in preventing acute 
rejection episodes and allowed successful withdrawal of cyclosporine 3 months after 
renal transplantation, a regimen that formed the basis for regulatory approval in the 
European Union.22 Moreover, sirolimus has been reported to be less nephrotoxic than 
CNI.23,24 Thus the introduction of sirolimus could facilitate withdrawal or avoidance of 
CNI, thus preventing CNI induced graft function deterioration. Moreover, it has been 
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hypothesized that sirolimus may prevent CAN by inhibiting the expression of growth 
factor mRNAs, or by inhibiting the proliferation of smooth muscle cells involved in the 
characteristic vasculopathy.25 Sirolimus has also important anti-neoplastic properties, 
and may be a drug that can be safely continued to prevent allograft rejection in 
transplant recipients who have developed a malignancy.26
Common dose-dependent side effects of sirolimus include thrombocytopenia and 
hyperlipidaemia. Idiosyncratic reactions include aphtous ulcer formation, interstitial 
pneumonitis, and rash. The anti-proliferative effects of the drug may be responsible for 
impaired wound healing, including a relatively high incidence of lymfoceles. 
Some reports showed that (CNI) treated kidney transplant recipients developed a 
significant increase of proteinuria when switched to sirolimus. The pathogenesis of this 
proteinuria is unknown, but has (partly) been attributed to the hemodynamic renal 
effects of CNI withdrawal.27-29 
biomarkers of renal function deterioration
The short-term results of kidney transplantation are excellent, but the long-term 
results have not improved to the same extent. Thus, in many patients the clinical 
course after kidney transplantation is characterized by a slow, but progressive and 
unrelentless deterioration of graft function. In the first ten years after transplantation, 
CAN is the most prevalent cause of allograft dysfunction, though its pathogenesis 
remains elusive.30 Already before clinically apparent kidney dysfunction, histological 
changes are present.3 Although any anatomical compartment can be involved in CAN, 
interstitial accumulation of extracellular matrix in association with progressive tubular 
atrophy is mostly observed.31 One possibility to improve the long-term results of kidney 
transplantation is to develop biomarkers that would allow predicting late allograft loss, 
thus allowing to identify and treat patients at highest risk in an early stage. It is known 
that deterioration of kidney function is best correlated with tubulointerstitial injury. 
Tubular injury is characterized by increased urinary losses of low-molecular weight 
proteins (LMWPs). Of the LMWPs α1-microglobulin and β2-microglobulin, it is known that 
they are readily filtered by the glomerulus and reabsorbed and catabolized by proximal 
tubular cells. When the proximal tubular handling of these LMWPs is disturbed, they 
appear in the urine.32 LMWPs and IgG are valuable in predicting the progression of renal 
function decline in patients with proteinuric glomerular diseases such as focal segmental 
glomerulosclerosis or membranous nephropathy.33,34 However, little is known about the 
possible value of measuring these proteins in the transplantation setting.
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living-donor transplantation
The gap between the demand and supply of deceased donor kidneys continues to 
grow. Living-donor programs have gradually become an attractive strategy to expand 
the donor pool for kidney transplantation. Renine, a Dutch registry of data concerning 
dialysis and kidney transplantation patients, shows that nowadays over 50% of all renal 
transplantations are living-donor transplantations (Figure 2). Grafts from living-related 
donors display superior function and longer survival than those obtained from deceased 
donors.35,36 As the beginning of living-donor kidney transplantation, physicians have 
expressed concern about the possibility that unilateral nephrectomy can be harmful to 
a healthy individual although survival and the risk of ESRD in carefully screened kidney 
donors appear to be similar to those in the general population.37 Living-donor surgery 
has changed radically in the past decade as laparoscopic techniques have supplanted 
open nephrectomy. Laparoscopic donor nephrectomy was found to be associated 
with reduced analgetic consumption, shorter hospital stay, and faster return to normal 
physical functioning as compared to the open technique.38 Whether the elevated intra-
abdominal pressure during the laparoscopic procedure can be harmful to the donated 
or remaining kidney is not known. 
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figure 2. Number of transplantations per year, grouped per donor type, in the Netherlands
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The studies described in this thesis address the abovementioned problems and were 
aimed at answering the following questions:
1. Can sirolimus improve outcome after kidney transplantation?
a. With the use of sirolimus, is it possible to perform kidney transplantations using 
a CNI-free immunosuppressive regimen, thus avoiding CNI nephrotoxicity and 
CAN-associated graft failure? We specifically evaluated the effects of sirolimus 
on proteinuria. 
b. Does sirolimus reduce the rate of skin malignancies?  
2. Can deterioration of kidney function after kidney transplantation be predicted?
3. Is laparoscopic donor kidney nephrectomy safe?
ouTlIne of THe THesIs
We have studied whether the nephrotoxicity that occurs under the current standard 
immunosuppressive regimen with tacrolimus, low-dose steroids and MMF can be 
decreased by a regimen with sirolimus, daclizumab, low-dose steroids and MMF without 
an increased incidence of acute rejections (chapter 2). 
In chapter 3 we report the evolution of proteinuria in RTR in whom azathioprine was 
replaced by sirolimus. Based on the findings in this study, we performed experimental 
studies to examine the effect of sirolimus on proteinuria in a mouse model (chapter 4).
In light of the significant morbidity and mortality of cutaneous invasive SSCs in RTR 
we performed a randomized, prospective, multicentre study to examine whether 
conversion to sirolimus-based immunosuppression from standard immunosuppression 
can reduce the recurrence rate of these skin cancers (chapter 5).
We investigated whether graft function deterioration and graft loss can be predicted by 
measuring urinary protein markers (chapter 6).
As the beginning of living-donor kidney transplantation, physicians have expressed 
concern about the possibility that unilateral nephrectomy can be harmful to a healthy 
individual. To investigate whether the elevated intra-abdominal pressure during 
laparoscopic donor nephrectomy causes early damage to the remaining kidney, we 
evaluated sensitive urine biomarkers after laparoscopic donor nephrectomy (chapter 7).
In chapter 8 we summarize the studies and discuss the implications for future research 
and patient care.
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AbsTrAcT
background
The introduction of sirolimus has provided the opportunity to develop an 
immunosuppressive regimen without the nephrotoxic calcineurin inhibitors.
Methods
We conducted a first trial in 30 renal allograft recipients. Ten patients were followed 
prospectively and received sirolimus, to achieve a target blood level of 10 to 15 ng/ml, 
induction therapy with one dose of daclizumab, low-dose steroids and mycophenolate 
mofetil. We compared this group with a historical control group of 20 patients who 
received our standard treatment consisting of tacrolimus, low-dose steroids, and 
mycophenolate mofetil.
results
After a mean follow-up of 15 weeks, seven patients developed an acute rejection in 
the sirolimus group (70%) compared with three patients in the tacrolimus group (15%) 
(p<0.01). 
Because of this unacceptable high rate of acute rejections we conducted a second 
prospective pilot study in nine patients. These patients received sirolimus in combination 
with two doses of daclizumab, high-dose steroids and mycophenolate mofetil. 
No rejections occurred under this immunosuppressive regimen; however, many 
immunosuppression-related adverse events were seen.
conclusion
The present study demonstrates an unacceptable high rate of acute rejections (70%) 
in patients treated with sirolimus, daclizumab, mycophenolate mofetil and low-dose 
prednisolone. No rejections but many adverse events were seen when sirolimus was 
given in combination with high-dose steroids.
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InTroducTIon
Immunosuppressive regimens including calcineurin inhibitors have greatly improved 
the results of kidney transplantations. Tacrolimus in combination with mycophenolate 
mofetil (MMF) and prednisolone decreased the number of acute rejection episodes 
within the first three months after transplantation to 15 to 20%. The incidence of graft 
failure from intractable acute rejections within one year after transplantation has dropped 
under the current regimen to below 5%. Therefore, tacrolimus combined with MMF and 
prednisolone is the standard regime in the first four months after transplantation in our 
centres. However, calcineurin inhibitors are nephrotoxic, which may eventually lead to 
loss of graft function. Long-term results are therefore disappointing. The introduction 
of sirolimus has provided the opportunity to develop an immunosuppressive regimen 
without nephrotoxic calcineurin inhibitors.1
Obviously, removing calcineurin inhibitors from the immunosuppressive regime should 
not lead to a higher percentage of rejections. On the other hand, the additional amount 
of immunosuppression needed beside sirolimus to prevent acute rejection should 
not lead to an unacceptable amount of immunosuppression-related adverse events. 
Recently, Flechner et al.2 demonstrated in kidney transplant recipients that treatment 
with sirolimus, prednisolone, MMF, and additional IL-2 receptor blocker (basiliximab) 
was accompanied with an acute rejection percentage of 6.4%. However, the additional 
immunosuppression given, high-doses of steroids and two induction therapies, is much 
more than we are used to giving in combination with tacrolimus.
The main purpose of our study was to investigate whether the nephrotoxicity that 
occurs under the current standard immunosuppressive regimen with tacrolimus, low-
dose steroids and MMF can be decreased by a regimen with sirolimus, daclizumab, low-
dose steroids and MMF without an increased incidence of acute rejections.
MATerIAls And MeTHods
Patients
We included primary and secondary adult (age above 18 years) renal allograft recipients 
in Nijmegen and Utrecht. Exclusion criteria consisted of HLA-identical living-donor 
kidney; haemolytic uraemic syndrome as original renal disease; pregnancy or lactation; 
total white blood cell count <3*109/l or platelet count <100*109/l or haemoglobin level 
<5 mmol/l; current panel reactive antibodies (PRA) (last screening sample) >85%; the 
use of non-registered medication during the last four weeks preceding transplantation 
and during the study; a renal allograft transplant as part of a multiorgan transplantation; 
or treatment with CYP3A4 inhibitors or inductors. All recipients had a negative visual 
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complement dependent cytotoxicity crossmatch. Flow cytometry T-cell crossmatching 
did not take place.
The patients who gave their informed consent were prospectively followed and treated 
with a calcineurin inhibitor free immunosuppressive protocol including sirolimus, 
daclizumab, MMF, and low-dose steroids. This group was compared with a historical 
control group consisting of patients who met the same inclusion and exclusion 
criteria and had been treated directly before the start of the study with our standard 
immunosuppressive regimen including the calcineurin inhibitor tacrolimus, MMF and 
low-dose steroids. 
The study was approved by both ethical committees of the participating centres and 
performed in accordance with the standards of the Declaration of Helsinki.
Immunosuppressive protocol and methods
First study
The patients in the calcineurin inhibitor free intervention group were treated with 
sirolimus at a loading dose of 15 mg prior to transplant surgery. As soon as a patient was 
capable of taking oral medication a second loading dose of 12 mg was given, followed 
by a daily dose of 6 mg, to achieve a target blood level of 10 to 15 ng/ml. The target 
trough level remained steady throughout the study.
The patients in the sirolimus treatment arm also received daclizumab during the 
transplant surgery intravenously at a dose of 1 mg/kg. At weekly intervals during the first 
ten weeks following transplantation, the coverage of IL-2 receptors was measured by 
flow cytometry.3 If free IL-2 receptors were detected on the lymphocytes (reappearance 
of CD3posCD25pos lymphocytes) in the first four weeks, an extra dose of daclizumab at 1 
mg/kg was given. 
The steroid regimen in the sirolimus treatment arm consisted of 100 mg prednisolone 
intravenously on day 0 (day of transplantation); on day 1 to 5 prednisolone 4 times 25 
mg orally/iv. From day 6 till week 17 the steroids were slowly reduced from the starting 
dose (determined by weight: > 70 kg: 25 mg; 50 to 70 kg: 20 mg; <50 kg: 15 mg) to zero.
Patients in the historical control group were treated with tacrolimus at a dose of 0.2 mg/
kg/day orally, divided over the morning and evening doses, to be started on day 1 or 2 
after transplantation.  The target blood level in the first 14 days was between 15 and 20 
ng/ml, from week 3 to 7 between 10 and 15 ng/ml and starting from week 7 the trough 
level should be 6 to 10 ng/ml.
The steroid regimen in the tacrolimus treatment group consisted of 100 mg prednisolone 
intravenously on day 0 (day of transplantation); on day 1 and 2 prednisolone 25 mg 
four times orally/iv. From day 3 till week 17 the steroids were slowly reduced from the 
starting dose (determined by weight: > 70 kg: 25 mg; 50 to 70 kg: 20 mg; <50 kg: 15 mg) 
to 0.1 mg/kg.
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All patients were given MMF 750 mg twice daily from day 1 or 2 onwards. For patients 
with a body weight of ≥90, the dose was 1000 mg twice daily. In case of leucopenia or 
abdominal complaints, the dose was lowered (the minimal dose is 250 mg twice daily). 
All patients in whom a rejection was suspected underwent renal transplant biopsy, 
which were scored according the BANFF97 criteria.4 The primary study endpoints were 
the difference in renal function and the number of acute rejections between both 
treatment groups. 
Second study
Because of the unacceptably high rate of acute rejections in the above-described 
patients treated with sirolimus (see results) we conducted a second prospective pilot 
study in nine patients. They received sirolimus and MMF following the same protocol 
as described above. Besides the daclizumab given during the transplant surgery, they 
received an additional dose daclizumab of 1 mg/kg ten days after transplantation. The 
steroid regimen consisted of 500 mg methylprednisolone intravenously on day 0 (day of 
transplantation) to 2, and then oral prednisolone from 120 mg to 30 mg by day 8, 27.5 
mg by day 21, 25 mg by day 30, tapered by 2.5 mg each month to a maintenance of 7.5 
mg daily.
resulTs
first study
Ten patients included in the sirolimus group were compared with 20 patients who were 
treated with tacrolimus. Patient characteristics are summarised in table 1. Apart from 
more older donors and an unfavourable donor type profile in the sirolimus group, no 
significant differences were found. After a mean follow-up of 15 weeks, seven patients 
in the sirolimus group had developed an acute rejection (70%; 95% confidence interval 
42 to 98%). This was significantly more than the 15% rejection rate in the control group 
(p<0.01; Fisher’s exact test). Characteristics of the rejection episodes that occurred in 
the sirolimus group are mentioned in table 2. In four patients the renal allograft function 
recovered after three pulses of solumedrol alone. Two patients required a second 
course of solumedrol and one patient required antithymocyte globulin (ATG) after the 
solumedrol treatment before renal function improved. All patients were converted to 
tacrolimus and returned to a stable allograft function, with a mean serum creatinine of 
159 μmol/l at one year after transplantation.
Four rejection episodes occurred within two weeks after transplantation. One of them 
was not biopsy proven because of the absence of renal tissue in the biopsy. In one of 
these patients there appeared to be no IL-2 receptor blockade because the patient did 
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not receive any daclizumab by mistake. In all the patients who received daclizumab, the 
IL-2 receptor was fully blocked at two and three months after transplantation after one 
dose of daclizumab.
Three rejections occurred between 8 and 15 weeks after transplantation. In all these 
cases the trough sirolimus level appeared to be below the target range at the time of 
rejection. The mean sirolimus trough levels were within the target range in the different 
time periods (table 3), but 21% of the measurements were below target. This was 
comparable with 19% of the measurements below target in the tacrolimus treatment 
group.
One sirolimus-treated patient had a serious wound-healing problem. Two of the three 
rejections in the tacrolimus group occurred within one week after transplantation. The 
third rejection occurred after 11 weeks. All of the patients required ATG after the course 
of solumedrol. One of them died as a consequence of this therapy.
Table 1. Demographics of the first study
Sirolimus
(n=10)
Tacrolimus
(n=20)
P
recipients
Gender (M:F) 7:3 10:10 NS
Age (years)(mean ± sd) 54 ± 14 46 ± 13 NS
Age >65 years 3 1 NS
donors
Gender (M:F) 2:8 8:12 NS
Age (years)(mean ± sd) 52 ± 15 47 ± 12 NS
Age >65 years 3 0 0.03
secondary transplant 1 1 NS
PrA NS
0% 10 18
>0 and <50% 0 2
HlA mismatches (mean ± sd) 2.8 ± 0.9 2.5 ± 1.5 NS
donor type <0.05
Low-risk (HB+LR) 3 14
High-risk (NHB+LUR) 7 6
M=male; F=female; PRA=panel reactive antibodies; HLA=human leucocyte antigen; NHB=non-heart 
beating; HB=heart beating; LR=living related; LUR=living unrelated; NS=not significant.
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Table 2. Sirolimus-treated patients with acute rejections in the first study (n=7)
Rejections 1 2 3 4 5 6 7
Week after KTx 2 1 14 15 8 2 1
Donor type NHB HB LUR LUR LUR LR LR
HLA mismatches
(A-B-Dr)
1-0-0 0-2-1 1-1-1 1-1-2 0-1-2 1-1-1 1-1-1
Sirolimus level at rejection
(ng/ml)
12 11 7.3 6.8 7.3 23 12
IL-2R blockade at 3 months No Yes Yes Yes Yes Yes Yes
Doses MMF at rejection
mg/day
1500 1500 1500 1500 1500 1500 2000
Steroid dose at rejection
mg/day
20 25 2.5 2.5 7.5 22.5 25
Banff score:
First biopsy IIa+ ATN Ib Ib IIa Ib No renal 
tissue
IIa
Second biopsy IIa Ia
Therapy 3g Sol
(twice)
3g Sol 3g Sol
(twice)
3g Sol 3g Sol 3g Sol 
ATG
3g Sol
Creatinine one year
after transplantation
(μmol/L)
230 168 130 160 147 126 150
KTx=kidney transplantation; NHB=non-heart beating; HB=heart beating; LUR=living unrelated; 
LR=living related; HLA=human leucocyte antigen; IL-2R blockade=interleukin 2 receptor blockade; 
MMF=mycophenolate mofetil; ATN=acute tubular necrosis; Sol=solumedrol; ATG=antithymocyte globulin.
Table 3. Sirolimus and tacrolimus trough levels in the first and second study
0-14 days 2-7 weeks 7 weeks-3 months
Tacrolimus trough level (ng/ml):
- Target
- Actually reached (mean ± SEM)
15-20
16.4 ± 0.9
10-15
12.3 ± 0.4
5-10
9.3 ± 0.3
Sirolimus trough level (ng/ml):
- Target
- Actually reached (mean ± SEM):
-  First study
-  Second study
10-15
13.4 ± 1.1
10.8 ± 0.8
10-15
14.9 ± 1.0
15.6 ± 0.9
10-15
11.8 ± 1.0
13.1 ± 0.9
SEM=standard error of the mean.
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second study 
No acute rejections occurred in the second sirolimus treatment group (n=9) with 
high-dose additional immunosuppression after a mean follow-up of ten months. On 
the contrary, many serious adverse events were seen in this group, as summarised in 
table 4. Six patients (67%) suffered delayed wound healing, with a secondary wound 
infection in three of them. Operative abscess drainage was necessary in one of them. 
Four patients (44%) developed a lymphocele requiring drainage. In one patient a 
secondary infection developed in the lymphocele. One patient developed a pulmonary 
embolus and thereafter, during anticoagulation therapy, a bleeding in the transplant. 
After insertion of a vena cava filter, a vena cava inferior syndrome occurred and because 
of continuous bleeding in the kidney transplant a transplantectomy was performed 
and haemodialysis was restarted. Three patients (33%) developed proteinuria after 
transplantation. One of them is the above-described patient with pulmonary embolus. 
Another patient developed proteinuria of 12 g/day one week after transplantation. A 
kidney biopsy showed tubulointerstitial damage without glomerular damage. The 
proteinuria disappeared within one month after switching to tacrolimus. The third 
patient with proteinuria developed proteinuria till 1.5 g/day, which also disappeared 
after switching to cyclosporine. Three patients developed diarrhoea (33%), two of them 
requiring hospitalisation.
Table 4. Adverse events in sirolimus-treated patients (second study)
Patient no. 1 2 3 4 5 6 7 8 9
Acute rejection - - - - - - - - -
Graft loss - + - - - - - - -
Surgical complications
     - Delayed wound healing
     - Haematoma
     - Wound abscess/infection
     - Lymphocele
+
+
+
-
+
-
+
-
+
-
-
+
-
-
-
-
+
-
+
+
+
-
-
+
+
-
-
+
-
-
-
-
-
-
-
-
Hypercholesterolaemia
(>6 mmol/l)
- - - - + + + + -
Hyperglycaemia
(fasting glucose>7 mmol/l)
+ + - - - + - - -
Pulmonary embolus - + - - - - - - -
Proteinuria (>1g/day) - + - + - + - - -
Candidiasis (oral) + - - - - - - - -
Diarrhoea - - + - + + - - -
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Three patients could be maintained on the sirolimus regimen during the mean 
follow-up period of ten months. The other six patients were switched to another 
immunosuppressive regimen because of severe complications. The time till the switch 
of immunosuppression and the main reason for switching is shown in figure 1. Two 
patients were switched to cyclosporine (after two and four months), three patients were 
switched to tacrolimus (one after one week and two after nine months), and one patient 
restarted haemodialysis after nephrectomy (seven weeks after transplantation).
figure 1. Time frame (in months) for sirolimus-treated patients: reason for switch of immunosuppression 
(second study) 
Figure 1. Time frame (in months) for sirolimus-treated patients: reason for switch of 
immunosuppression (second study)  
__________________________________________________________________________________ 
 
1 ________  CsA (wound abscess)   
             0       1         2      
 
2 ______  HD (transplant bleeding during anticoagulation for PE) 
 0          1 
 
3 ________________________________________ 
 0          1          2          3           4          5           6          7           8          9          10  
 
4 _   Tac (proteinuria 12g/day) 
 0           
 
5 ____________________________________________ 
 0          1          2          3           4          5           6          7           8          9          10         11  
 
6 ________________   CsA (lymphocele, proteinuria and diarrhoea) 
 0          1          2          3           4                
 
7 ____________________________________  Tac (bronchus carcinoma) 
 0          1          2          3           4          5           6          7           8          9 
 
8 ________________________________________ 
 0          1          2          3           4          5           6          7           8          9          10  
 
9 ____________________________________   Tac (oedema) 
 0          1          2          3           4          5           6          7           8          9  
__________________________________________________________________________________ 
CsA=cyclosporine; HD=haemodialysis; PE=pulmonary embolus; Tac=tacrolimus. 
 
CsA=cyclosporine; HD=haemodialysis; PE=pulmonary embolus; Tac=tacrolimus.
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dIscussIon
The use of calcineurin inhibitors has resulted in improved graft survival following kidney 
transplantation. However, this is associated with acute and chronic nephrotoxicity 
and may be an important contributor to the development of chronic transplant 
nephropathy and chronic graft loss.5 Calcineurin inhibitor nephrotoxicity is becoming 
increasingly prevalent, and is virtually universal by ten years after transplantation and 
progressive despite mild to moderate reductions in calcineurin doses.6 The introduction 
of sirolimus has provided the opportunity to develop an immunosuppressive regimen 
without nephrotoxic calcineurin inhibitors. Recently, Flechner et al.2 demonstrated in 
kidney transplant recipients that treatment with sirolimus, prednisolone, MMF and 
additional IL-2 receptor blocker (basiliximab) was accompanied with an acute rejection 
percentage of 6.4 vs 16.6% in the control arm (cyclosporine, prednisolone, MMF and IL-2 
receptor blocker). At 12 months their sirolimus-treated patients enjoyed significantly 
better creatinine clearances than their cyclosporine-treated patients (81.1 and 61.1 
ml/min, respectively). However, the additional amount of immunosuppression given 
beside sirolimus is very high.
In our first study we achieved a rejection percentage of 70% in the sirolimus group 
compared with a 15% rejection rate in the tacrolimus group (p<0.01) within a mean 
follow-up of 15 weeks. Because of this unacceptably high rejection rate we ended the 
study prematurely and switched the patients to the standard immunosuppressive 
regimen including tacrolimus. To date, none of the patients have lost their grafts in the 
mean follow-up of 18 months. This high percentage of rejections cannot be explained by 
the fact that only patients with a high rejection risk were included in the sirolimus group. 
All rejections occurred in patients who underwent a first kidney transplantation with a 
PRA of 0% and there were no significant differences in the number of HLA mismatches 
and number of non-heart beating donors between the groups. However, when we 
divided the donors into a low-risk group (heart beating and living related donors) and 
a high-risk group (non-heart beating and living unrelated donors) significantly more 
patients with an unfavourable donor type were found in the sirolimus-treated patients. 
Although this can be partly responsible for the bad outcome in the sirolimus group we 
do not think this can totally explain the very high rejection rate of 70%.
Four of the seven rejections in the sirolimus group occurred within two weeks after 
transplantation. One of these rejection episodes occurred in a patient who did not 
receive any daclizumab by mistake. In all other patients the IL-2 receptor was fully 
blocked at two and three months after transplantation by one infusion of daclizumab 
during transplant surgery. Three of the seven rejections occurred between 8 and 15 
weeks after transplantation. These three rejections occurred when the prednisolone 
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was reduced to below 10 mg/day, in accordance with the protocol. All patients used 
at least 1500 mg MMF during the study period. At the time of rejection the sirolimus 
levels appeared to be lower than the target level in all three of them. The sirolimus 
levels were below target in 21% of all measured levels in the sirolimus group, but 
were never measured below 6.8 ng/ml. In the tacrolimus group 19% of all measured 
levels were below the target level. Some fluctuation in (sirolimus) trough levels is 
inevitable, but we must conclude that this seems immediately catastrophic in our 
low immunosuppressive regimen of the sirolimus group. There have been reports of 
calcineurin inhibitor free therapy, even without using antibody induction, that describe 
lower rates of acute rejection than we found. Kreis et al.7 using sirolimus, MMF and 
steroids reported an acute rejection rate of 27.5% one year after transplantation and 
Groth et al.8 using sirolimus, azathioprine and steroids reported an acute rejection rate 
of 41% at one year. In comparison with our protocol the target trough sirolimus level 
amounted to 30 ng/ml for the first two months in both studies and they started with 
500 mg of methylprednisolone tapered to a maintenance dose of 10 mg daily. In the 
Symphony trial standard immunosuppression with normal dose cyclosporine (target 
trough level 150 to 300 ng/ml) was compared with three regimens with low doses of 
either cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and 
corticosteroids in 1645 de-novo renal transplant patients. The rate of biopsy-proven 
acute rejections with low-dose sirolimus (target trough level 4 to 8 ng/ml) at one year 
(35%) was higher than the other groups (15 to 25%). The conclusion of this study was 
that the room for increasing sirolimus immunosuppression should be evaluated against 
the specific sirolimus toxicity profile.9,10 Contrary to our study, Flechner et al. started with 
500 mg methylprednisolone intravenously on day 0 to 2, and then oral prednisolone 
from 120 mg to 30 mg by day 8, and thereafter slowly tapered to a maintenance dose of 
7.5 mg daily at eight months. Their mean trough sirolimus levels appeared to be 13.2 ± 
7.9 ng/ml at one month after transplantation and 11.2 ± 5.8 ng/ml at three months after 
transplantation. They also gave a higher dose of MMF of 1 g twice daily instead of the 
750 mg twice daily in our study and they used two gifts of basiliximab. These differences 
might explain the high rejection rate we found.
To prove this supposition we conducted a second prospective trial in nine patients. 
This protocol differed from the first by an additional dosage of daclizumab 1 mg/kg at 
ten days after transplantation and higher doses of MMF and steroids according to the 
Flechner protocol. No acute rejections occurred under this treatment regimen. On the 
contrary, many serious adverse events were seen, likely to be related to the combination 
of sirolimus and high-dose steroids. These findings are in accordance with Dean et al.9 
using sirolimus, six gifts of antithymocyte globulin induction, MMF, and prednisone. 
They achieved an acute rejection rate of 9% at one year, but a wound complication 
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rate of 35% in comparison with 10% in the tacrolimus control group. These adverse 
events and the interventions needed to treat them might also lead to a decline in renal 
function. This takes away the advantage of sirolimus, no nephrotoxicity, in the first 
place. However, the number of treated patients in our study is too small to compare 
renal function under the different regimens. In the Symphony trial where renal function 
was determined at 12 months they showed that low-dose tacrolimus was significantly 
superior to low-dose sirolimus with respect to glomerular filtration rate.11 The results 
from our study showed that in order to replace a calcineurin inhibitor by sirolimus 
aiming to avoid calcineurin nephrotoxicity, higher additional immunosuppression is 
needed to prevent an unacceptable rejection rate. Because of the immunosuppression-
related adverse events we experienced under such a regimen we do not think there 
should be a place for a sirolimus-based regimen without calcineurin inhibitor in the 
direct post-transplant period.
conclusIon
The present study demonstrates an unacceptably high rate of acute rejections (70%) 
in patients treated with sirolimus, daclizumab, MMF and low-dose prednisolone in the 
first months after transplantation and no rejections but many adverse events when 
sirolimus was combined with two times induction therapy and high-dose prednisolone. 
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AbsTrAcT
Recent studies have reported a significant increase of proteinuria in kidney transplant 
recipients who were switched from a calcineurin inhibitor (CI) to sirolimus. This has 
(partly) been ascribed to the hemodynamic renal effects of CI withdrawal. We have 
evaluated the evolution of proteinuria in renal transplant recipients who underwent 
conversion from azathioprine to sirolimus.
In a randomized, prospective, multicenter study called RESCUE (Recurrent cutanEous 
Squamous cell Carcinoma Under RapamunE) the efficacy and safety is investigated of 
conversion to sirolimus in stable renal transplant recipients with a cutaneous squamous 
cell carcinoma (SCC). In our center, 25 patients were included in this study of which 13 
patients were randomized to continue their current immunosuppressive treatment and 
12 to conversion to sirolimus.
After a mean follow-up of 360 days, mean proteinuria increased from 0.37±0.34 to 
1.81±1.73 g/24h after conversion to sirolimus (P<0.005). In the control group there 
was no change in proteinuria. A significant increase of proteinuria was observed in 
all seven patients with proteinuria before conversion, whereas proteinuria remained 
absent in all patients without previous proteinuria. Two of the patients with proteinuria 
were converted from cyclosporine and five were converted from azathioprine to 
sirolimus. Sirolimus was discontinued in five patients with proteinuria, and in all of them 
proteinuria declined to baseline values.
Our study demonstrates that conversion from azathioprine to sirolimus after kidney 
transplantation may cause a reversible increase of proteinuria. Sirolimus-induced 
proteinuria therefore cannot be ascribed to the hemodynamic renal effects of CI 
withdrawal.
Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients
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InTroducTIon
Squamous cell carcinoma (SCC) is the most common form of malignancy after organ 
transplantation. The incidence of SCC increases with the duration of immunosuppressive 
therapy, ultimately affecting more than 50% of white transplant recipients.1 Evidence 
suggests that sirolimus, an effective immunosuppressive drug with antiproliferative 
properties, may confer a decreased risk of malignancy. In a randomized study the 
incidence of cancer, particularly skin cancer, was lower in patients receiving sirolimus 
in comparison with other immunosuppressive therapies.2 We initiated a randomized 
controlled study called RESCUE (Recurrent cutanEous Squamous cell Carcinoma Under 
RapamunE) to evaluate the efficacy of sirolimus in preventing new skin carcinomas in 
patients with at least one SCC in an earlier phase after transplantation.
Sirolimus has also been reported to be less nephrotoxic than other immuno-suppressive 
agents used in transplantation. However, recent reports indicate that calcineurin inhibitor 
(CI)-treated kidney transplant recipients may develop a significant increase of proteinuria 
when switched to sirolimus.3-10 The pathogenesis of this proteinuria is unknown. In these 
studies most patients switched from CI to sirolimus because of progressive renal injury 
(chronic allograft nephropathy with or without CI nephrotoxicity). Therefore, it was not 
possible to distinguish between the hemodynamic renal effects of withdrawal of CI or a 
direct toxic effect of sirolimus.
We have evaluated the evolution of proteinuria in patients who participated in the 
above-mentioned randomized controlled trial. Most of these patients were switched 
from azathioprine to sirolimus, thus excluding any effects of CI withdrawal. 
resulTs
In our center 25 patients have been included in the RESCUE study until now. Thirteen 
patients were randomized to continue their current immunosuppressive treatment and 
12 were randomized to conversion to sirolimus.
One patients converted to sirolimus dropped out because of the development of a 
hemolytic uremic syndrome. After a mean follow-up of 360 days the mean proteinuria 
level in the remaining 11 patients increased, whereas in the control group there was no 
difference in proteinuria at baseline and after a mean follow-up of 517 days (Table 1). 
An increase in proteinuria was observed in all patients (n=7) with proteinuria before 
conversion (from 0.57±0.26 g/24h to 2.84±1.36 g/24h; P<0.005)(Figure 1), whereas 
proteinuria remained absent in all patients without proteinuria (n=4). Two of the patients 
with proteinuria were converted from cyclosporine to sirolimus and five patients were 
converted from azathioprine to sirolimus. There was no difference in arterial blood 
pressure before and after the switch to sirolimus and during sirolimus therapy no 
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angiotensin-converting enzyme inhibitor or angiotensin receptor blocker was added to 
the medication except for one patient. For this patient 100 mg losartan was started after 
which proteinuria did not increase further. The increase in proteinuria started within 
3 months after conversion in six of the seven patients. Sirolimus was discontinued in 
five patients with proteinuria, and in all of them proteinuria declined to baseline values 
within 6 months. 
Table 1. Demographics
Sirolimus 
(n=11)
Control 
(n=13)
P
Gender (male:female) 5:6 9:4 ns
Age (years) 55 ± 10 57 ± 8 ns
Previous immunosuppressive therapy
Cyclosporine 3 1 ns
Azathioprine 8 11
MMF 0 1
Proteinuria (g/24h)
At baseline 0.37 ± 0.34 0.38 ± 0.63 ns
At follow-up 1.81 ± 1.73** 0.29 ± 0.35 <0.05
Creatinine (μmol/l)
At baseline 109 ± 31 102 ± 20 ns
At follow-up 118 ± 37* 103 ± 16 ns
** P<0.005 versus baseline, * P<0.05 versus baseline.
Values are given as mean ± s.d., ns=not significant
In four of seven patients who developed proteinuria the excretion of low molecular 
weight proteins, α1-microglobulin and β2-microglobulin, in urine was determined. The 
mean excretion of α1-microglobulin was 65 mg/10 mmol creatinine (range 29-133) 
and of β2-microglobulin 6.1 mg/10 mmol creatinine (range 0.2-20.4). These values are 
elevated compared with normal values (<10 mg/ 10 mmol creatinine and <0.3 mg/ 10 
mmol creatinine, respectively). The protein selectivity index, calculated as the clearance 
of immunoglobulin G divided by the clearance of transferrin, ranged from 0.16 to 0.31.  
In the control group (n=13), there was no difference in serum creatinine at baseline and 
after a mean follow-up of 517 days (102±20 and 103±16 μmol/l, respectively). The mean 
creatinine level in the sirolimus group (n=11) slightly increased from 109±31 before 
to 118±37 μmol/l after conversion (P=0.049) (Table 1). In the five patients who were 
switched back to their previous immunosuppressive regimen because of proteinuria 
serum creatinine increased after the introduction of sirolimus (from 118±33 to 135±37 
μmol/l; P<0.01) and stabilized after reconversion (131±34 μmol/l; P=0.19 compared 
with baseline).
Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients
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An increase in proteinuria was observed in all patients
(n¼ 7) with proteinuria before conversion (from
0.5770.26 g/24 h to 2.8471.36 g/24 h; Po0.005)(Figure 1),
whereas proteinuria remained absent in all patients without
proteinuria (n¼ 4). Two of the patients with proteinuria were
converted from cyclosporine to sirolimus and five patients
were converted from azathioprine to sirolimus. There was no
difference in arterial blood pressure before and after the
switch to sirolimus and during sirolimus therapy no
angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker was added to the medication except in one
patient. In this patient 100mg losartan was started after
which proteinuria did not increase further. The increase in
proteinuria started within 3 months after conversion in six of
the seven patients. Sirolimus was discontinued in five
patients with proteinuria, and in all of them proteinuria
declined to baseline values within 6 months.
In four of the seven patients who developed proteinuria
the excretion of low molecular weight proteins, a1-micro-
globulin and b2-microglobulin, in urine was determined. The
mean excretion of a1-microglobulin was 65mg/10mmol
creatinine (range 29–133) and of b2-microglobulin 6.1mg/
10mmol creatinine (range 0.2–20.4). These values are
elevated compared with normal values (o10mg/10mmol
creatinine and o0.3mg/10mmol creatinine, respectively).
The protein selectivity index, calculated as the clearance of
immunoglobulin G divided by the clearance of transferrin,
ranged from 0.16 to 0.31.
In the control group (n¼ 13) there was no difference in
serum creatinine at baseline and after a mean follow-up of
517 days (102720 and 103716 mmol/l, respectively). The
mean creatinine level in the sirolimus group (n¼ 11) slightly
increased from 109731 before to 118737 mmol/l after
conversion (P¼ 0.049)(Table 1). In the five patients who
were switched back to their old immunosuppressive regimen
because of proteinuria (n¼ 5) serum creatinine increased
after the introduction of sirolimus (from 118733 to
135737 mmol/l; Po0.01) and stabilized after reconversion
(131734 mmol/l; P¼ 0.19 compared with baseline).
DISCUSSION
Our results demonstrate that conversion from azathioprine
to sirolimus in stable renal transplant recipients with SCC
may cause a reversible increase of proteinuria. This increase
was seen only in patients with proteinuria at baseline.
Heavy glomerular proteinuria is an important and
independent predictor of progressive renal damage. Also in
the transplantation literature there is ample evidence that
persistent proteinuria is a strong risk factor for long-term
allograft loss and lower patient survival from cardiovascular
and all-cause mortality.11
Recent reports indicated that CI-treated kidney transplant
recipients might develop a significant increase of proteinuria
when switched to sirolimus.3–10 Diekmann et al.10 reported
that a proteinuria below 800mg/day at conversion from CI to
sirolimus is the only independent predictor for positive
outcome in chronic allograft dysfunction. In these studies
most patients were switched from CI to sirolimus because of
progressive renal damage (chronic allograft nephropathy with
or without CI nephrotoxicity). The pathogenesis of this
proteinuria is unknown, but has (partly) been ascribed to the
hemodynamic renal effects of CI withdrawal. Morelon et al.3
suggested that CI withdrawal may lead to an increase in renal
blood flow responsible for the development of previously
masked proteinuria in patients with preexisting glomerular
damage.
Our data clearly indicate that this is not a satisfactory
explanation. Because in our study most of the patients who
developed proteinuria were switched from azathioprine to
sirolimus there must also be some direct nephrotoxic effect of
sirolimus. Whether sirolimus itself could affect glomerular
permeability is not known. In vitro studies have demons-
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Figure 1 | Evolution of proteinuria in the sirolimus-treated
patients. Individual data are given for seven patients with an
increased proteinuria after start of sirolimus. Sirolimus was withdrawn
in five patients, accompanied by reduction of proteinuria in all. Upper
reference value is indicated by the dotted line (0.2 g/24 h¼ normal).
Table 1 | Demographics
Sirolimus
(n=11)
Control
(n=13) P
Gender (male:female) 5:6 9:4 ns
Age (years) 55710 5778 ns
Previous immunosuppressive
therapy
Cyclosporine 3 1 ns
Azathioprine 8 11
MMF 0 1
Proteinuria (g/24 h)
At baseline 0.3770.34 0.3870.63 ns
At follow-up 1.8171.73** 0.2970.35 o0.05
Creatinine (mmol/l)
At baseline 109731 102720 ns
At follow-up 118737* 103716 ns
**Po0.005 versus baseline, *Po0.05 versus baseline.
Values are given as means7s.d.
1356 Kidney International (2006) 70, 1355–1357
or ig ina l a r t i c l e JM van den Akker et al.: Proteinuria after switch from azathi prine to si olimus
figure 1. Evolution of proteinuria in the sirolimus-treated patients.
Individual data are given for seven p tients with increased proteinuri  after conversion to sirolimus. Sirolimus 
was subsequently withdrawn in five patients, accompanied by reduction of proteinuria in all. Upper reference 
value is indicated by the dotted line (0.2 g/24h=normal).
dIscussIon
Our results demonstrate that conversion from zathioprin  to sirolimus i  stable renal 
transplant recipients with SCC may cause a reversible increase of proteinuria. This 
increase was seen only in patients with proteinuria at baseline. 
Heavy glomerular proteinuria is an important and independent predictor of progressive 
renal damage. In the transplantation literature there is also ample evidence that 
persistent proteinuria is a strong risk factor for long-term allograft loss and lower patient 
survival from c rdiovascular and all-cause mortality.11 
Recent r ports indicated that CI-treated kidney transplant recipients might develop 
a significant increase of proteinuria when switched to sirolimus.3-10 Diekmann et al.10 
reported that a proteinuria below 800 mg/day at conversion from CI to sirolimus is the 
only independent predictor for positive outcome in chronic allograft dysfunction. In 
these studies most patients were switched from CI to sirolimus because of progressive 
renal damage (chronic allograft nephropathy with or without CI nephrotoxicity). 
The pathogenesis of this prot inuria is u known, but has (pa tly) been ascribed to 
the hemodynamic renal ffect  of CI withdrawal. Morelon et al3 suggested that CI 
withdrawal may lead to an increase in renal blood flow responsible for the development 
of previously masked proteinuria in patients with preexisting glomerular damage.
Our data clearly indicate that this is not a satisfactory explanation. Because in our study 
most of the patients who developed proteinuria were switched from azathioprine 
to sirolimus there must also be some direct nephrotoxic effect of sirolimus. Whether 
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sirolimus itself could affect glomerular permeability is not known. In vitro studies have 
demonstrated a tubulotoxic effect of sirolimus, especially in the setting of prior renal 
injury.12  Straathof et al.13 described a patient who developed heavy proteinuria during 
treatment with sirolimus. They showed that a decrease in tubular protein reabsorption 
contributed to the proteinuria. Experimental studies of Coombes et al.14 have indicated 
that sirolimus causes a specific pattern of acute renal injury characterized by increased 
intratubular cast formation in protein overload nephropathy.  The increased excretion 
of low molecular weight proteins α1-microglobulin and β2-microglobulin we found, 
might indicate that sirolimus promotes proteinuria by blocking the tubular protein 
reabsorption. Unfortunately, we have no information about the urinary excretion of 
small molecular weight proteins before conversion to sirolimus. Admittedly, we cannot 
exclude that tubular proteinuria is a consequence of tubular injury caused by glomerular 
protein leakage.
Sennesael et al.15 showed in renal transplant patients, converted from CI to sirolimus, that 
proteinuria can be treated succesfully with angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers. In only one of our patients on sirolimus an angiotensin 
receptor blocker was started after which proteinuria did not increase further. Probably, 
we could have kept more patients on sirolimus if we had started renin-angiotensin 
blockade.  
In conclusion, switching renal transplant recipients from azathioprine to sirolimus 
is associated with a reversible increase in proteinuria. The mechanism of this effect 
still remains unclear, but cannot be ascribed to the hemodynamic renal effects of CI 
withdrawal.
MATerIAls And MeTHods
In a randomized, prospective, multicenter study called RESCUE the efficacy and safety 
is investigated of conversion to sirolimus in stable renal transplant recipients with at 
least one cutaneous SCC. Patients are randomized to continue their current immuno-
suppressive regimen or conversion to sirolimus (trough levels of 5-10 ng/ml) and 
prednisolone.  We evaluated the evolution of proteinuria in patients in our hospital who 
were included in the RESCUE study. 
According to current guidelines we routinely used spot urine samples and calculated 
protein-creatinine ratios for the follow-up of our patients.16 All patients collected one 
or more 24h urine samples during the study period. Since renal function was stable, 
proteinuria per 24h can be calculated from the formula: proteinuria (g/24h)=protein-
creatinine ratio (g/10 mmol creatinine) * creatinine excretion (mmol/24h). 
Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients
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InTroducTIon
Sirolimus, or rapamycine, is a macrolide produced by Streptomyces Hygroscopicus. 
It possesses immunosuppressive and antiproliferative properties by blocking the 
proliferative responses of different cell types to growth factors through inhibition of the 
mammalian target of rapamycin (mTOR) signalling cascade. Thus, sirolimus inhibits IL-2 
induced lymphocyte proliferation, as well as the intima proliferation in the vasculature, 
which is a hallmark of chronic allograft nephropathy.1 Since sirolimus is a strong 
immunosuppressive agent it may offer an opportunity to avoid exposure to calcineurin 
inhibitors (CNI) and thus prevent the associated nephrotoxicity. 
In contrast, several studies showed that CNI-treated kidney transplant recipients 
developed significant proteinuria when switched to sirolimus.2-6 It was suggested that 
this increased proteinuria is not caused by sirolimus per se, but rather the consequence 
of altered hemodynamics after CNI withdrawal. However, data from our centre also 
demonstrated an increase in proteinuria after conversion from azathioprine to sirolimus 
in stable renal allograft recipients.7 This indicates that sirolimus itself may contribute to 
proteinuria.
Proteinuria can be a consequence of tubular and glomerular injury, and sirolimus 
thus could induce proteinuria by several mechanisms. In vitro studies using cultured 
mouse proximal tubular cells showed that sirolimus increases apoptosis and decreases 
the proliferative cell response.8 It is possible that, by its inhibitory effect on cellular 
proliferation coupled with an increased rate of apoptosis, rapamycine might actually 
tip the delicate survival balance, worsening the tubulointerstitial damage after tubular 
cell injury. Indeed some studies have demonstrated prolonged periods of delayed graft 
function (acute tubular necrosis) after renal transplantation.9  
Sirolimus induced proteinuria may thus be a consequence of tubular cell injury. Indeed, 
Straathof et al. described a transplant patient who developed heavy proteinuria during 
treatment with sirolimus. Histological analysis suggested that a decrease in tubular 
protein reabsorption contributed to the proteinuria.10 However, another report provided 
no evidence for sirolimus-dependent reduction of protein reabsorption in proximal 
tubular cells.11 Moreover, it is widely accepted that tubular diseases lead to a moderate 
proteinuria with a specific tubular profile. The described nephrotic range proteinuria in 
patients on sirolimus and the reduction observed after initiating angiotensin converting 
enzyme inhibitors rather suggest a glomerular origin of proteinuria.
Severe proteinuria is a hallmark of glomerular renal diseases. Proteinuria is generally 
attributed to a defect in the permselectivity of the glomerular filter. In recent years, many 
studies focused on the role of glomerular epithelial cells, the so-called podocytes, in the 
induction of proteinuria as well as in the development of focal glomerulosclerosis.12-15 
Several studies have shown that podocyte loss may be important in the initiation of 
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progressive glomerulosclerosis. Thus, also at the glomerular level sirolimus might cause 
injury by shifting the balance between apoptosis and repair. Letavernier et al. described 
focal segmental glomerulosclerosis (FSGS) lesions associated with nephrotic-range 
proteinuria within months after renal transplantation in patients who received sirolimus 
de novo after transplantation in the absence of CNI.16  Thus sirolimus may induce 
podocyte injury and proteinuria in some patients due to unidentified mechanisms. 
Importantly, the clinical studies suggested that sirolimus induced proteinuria 
particularly in patients with pre-existing proteinuria.17 The study of the role of sirolimus 
in inducing proteinuria and the possible pathogenic mechanisms would greatly benefit 
from experimental models. Therefore, we have initiated a set of pilot experiments with 
sirolimus in a mouse model of FSGS. 
Kollias et al. generated transgenic mice that express the Thy-1.1 antigen on the 
podocytes.18 These mice slowly and spontaneously develop albuminuria and focal 
glomerulosclerosis over a period of 26 weeks. Importantly, the process of FSGS 
development can be accelerated. Injection of anti-Thy-1.1 monoclonal antibodies in 
Thy-1.1 transgenic mice induces an acute albuminuria, which is followed by a rapid 
development of FSGS within 3 weeks after injection of the monoclonal antibody. This 
mouse model allowed us to investigate the effect of sirolimus in both non-proteinuric 
mice as well as in mice made proteinuric before start of sirolimus.   
MeTHods
Animals
Heterozygous Thy-1.1 transgenic mice were generated by injecting a hybrid human-
mouse Thy-1.1 gene into pronuclei of zygotes of Thy-1.2 CBA x C57BL/10 mice.18 These 
mice abnormally express the Thy-1.1 gene in podocytes, resulting in the presence of 
the Thy-1.1 antigen on podocytes. All mice were bred in our animal facility. Breading 
pairs always consist of a heterozygous (+/-) transgenic mouse and its non-transgenic 
(-/-) counterpart. To identify transgenic (+/-) and non-transgenic (-/-) mice, the 
presence of the transgene was examined by PCR on genomic DNA obtained from 
the tail, with a forward primer: 5’-CGCCTGAGTCCTGATCTCC-3’ and a reverse primer: 
5’-ACCTGCATCTTCACTGGGT-3’. The presence of the transgene resulted in a specific 
834 bp band. As a positive control for the presence of amplifiable genomic DNA a 
primerset for aminopeptidase A (APA; EC 3.4.11.7), consisting of the forward primer: 
5’-ACACAACCCCAGCTCCTTCC-3’ and reverse primer 5’-TCTTCTGCAGCCTGGATCAC-3’, 
was used. The amplification of the APA gene with these primers resulted in a 367-bp 
amplicon.
Sirolimus and proteinuria in Thy-1.1 transgenic mouse
45
Chapter
 4
sirolimus and the vehicle solution
The sirolimus suspension consisted of 1 mg/ml sirolimus in Phosal 50 PG. Phosal 50 PG is 
a standardized phosphatidylcholine concentrate with at least 50% phosphatidylcholine 
and propylene glycol and used as vehicle solution. Sirolimus suspension was further 
diluted with the vehicle solution till the daily dose to be given was dissolved in 0.1 or 0.2 
ml solution. The suspension could be stored at 4 °C for two weeks. 
Anti-Thy-1.1 mAb  
For in vivo experiments a mouse anti-mouse Thy-1.1 mAb (19XE5: subclass IgG3) was 
used. 19XE5 was generated in vitro, by hollow fibre culture, purified by protein-A column 
affinity chromatography and concentrated (Nematology Department, Agriculture 
University Wageningen, the Netherlands). The mAb was decomplemented at 56°C for 
45 min and sterilized by passage through a sterile 0.2 µm filter, and stored at –80°C. 
Animal experiments
First experiment: Thy-1.1 male transgenic mice were studied from five weeks after birth 
(at this time point albuminuria was absent) until week 19. Thirty–five transgenic mice 
were randomised in five groups of 7 mice each. The first experimental group received 
1 mg/kg/day of sirolimus orally by gavage (0.1 ml of a 4 times diluted suspension). 
The second experimental group received 4 mg/kg/day (0.1 ml) and the third group 
received 8 mg/kg/day of sirolimus (0.2 ml). The first control group daily received 0.1 ml 
of the vehicle solution alone and the second control group was untreated. Additionally, 
we studied a group of 7 non-transgenic mice treated with sirolimus (4 mg/kg/day). 
Albuminuria was measured at regular intervals. The 18-hour urine samples were 
collected by placing the animals individually in metabolic cages. The first measurement 
took place one week after the start of receiving sirolimus or vehicle solution. Thereafter 
albuminuria was measured every 2 weeks till the mice were 19 weeks old. At this time-
point all mice were sacrificed and their kidneys were processed for microscopy. Before 
the mice were sacrificed blood pressure was measured and blood samples were drawn 
for measurement of serum creatinine levels.
Second experiment: In the second experiment thirty five-week old male Thy-1.1 
transgenic mice received an intravenous injection with 2 mg anti-Thy-1.1 mAb (19XE5) 
in 0.1 ml 0.9% saline solution. In this experiment sirolimus 4 mg/kg/day (0.1 ml) or 
vehicle solution (0.1 ml) was started orally 11 days after injection of anti-Thy-1.1 mAb in 
mice who developed proteinuria (15 mice in each group). Albuminuria was measured 
in 18-hour urine samples collected at day 10, 17, 24 and 31 after anti-Thy-1.1 mAb 
injection. At day 31 all mice were sacrificed and kidneys were removed and processed 
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for histology. Before the mice were sacrificed blood pressure was measured and blood 
samples were drawn for measurement of serum creatinine levels. 
Measurement of albuminuria
Albuminuria, as a sign of glomerular protein leakage was measured in urine samples 
obtained by placing the animals in individual cages during 18 hours. During their 
confinement in the cages, mice had only access to tap water. Urinary albumin excretion 
was measured by radial immunodiffusion, using goat antiserum against mouse 
albumin.19
serum creatinine measurements
Serum creatinine levels were measured in serum sampled at the day the mice were 
sacrificed. Serum creatinine levels were measured using the Jaffe alkaline picrate 
method. Measurements were performed using the AEROSET creatinine assay and the 
AEROSET Clinical Chemistry System (Abbott Laboratories. Abbott Park, IL, USA).  
light microscopy, immunofluorescence, and immunohistochemistry
For light microscopy, kidney fragments were fixed in Bouin’s solution, dehydrated, and 
embedded in paraplast (Amstelstad, Amsterdam, the Netherlands). 4 µm sections were 
stained with periodic acid-Schiff, and 2 µm sections with silver methenamine.20 To obtain 
the FSGS-score, at least 60 glomeruli per mouse were evaluated for the presence of 
hypertrophy and hyperplasia of the glomerular epithelium, adhesions and/or sclerosis, 
and the percentage of abnormal glomeruli were calculated. 
resulTs
First experiment: Since some mice treated with the highest dose of sirolimus (8 mg/kg) 
died from aspiration, this experimental group was stopped. In addition, mice treated 
with sirolimus or vehicle solution gained less weight during this study, a reason to stop 
the study at 19 weeks. 
Albuminuria was measured regularly in untreated transgenic control mice and in mice 
treated with various doses of sirolimus and vehicle solution only (Figure 1). As expected, 
the untreated transgenic control mice spontaneously developed proteinuria. Transgenic 
mice treated with sirolimus developed less proteinuria than untreated transgenic mice. 
This effect on proteinuria was dose-dependent and more obvious in mice treated with 
4 mg/kg sirolimus than in mice treated with 1 mg/kg sirolimus. Also mice treated with 
vehicle solution only (Phosal 50) developed less proteinuria than untreated transgenic 
Sirolimus and proteinuria in Thy-1.1 transgenic mouse
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mice. Non transgenic mice treated with 4 mg/kg sirolimus did not develop proteinuria. 
After 14 weeks of treatment all mice were sacrificed. Before the mice were sacrificed 
intra-arterial blood pressure was measured after cannulation of the femoral artery 
in anesthesized mice. We observed blood pressures in the normal range. In light 
microscopy very few focal sclerotic lesions were seen in all groups (0-5%). In the Thy-1.1 
transgenic control group no more than 5% sclerotic lesions were seen. 
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figure 1. Albuminuria in sirolimus treated Thy-1.1 transgenic mice
Second experiment: In the second experiment thirty five-week old male Thy-1.1 
transgenic mice received an intravenous injection with 2 mg anti-Thy-1.1 mAb (19XE5) 
in 0.1 ml 0.9% saline solution. In this experiment sirolimus 4 mg/kg/day (0.1 ml) or 
vehicle solution (0.1 ml) was started orally 11 days after injection of 2 mg anti-Thy-1.1 
mAb in mice who developed proteinuria (15 mice in each group). 
Albuminuria was measured in 18-hour urine samples collected at day 10, 17, 24 and 31 
after anti-Thy-1.1 mAb injection. At all time points there was no difference in albuminuria 
between treatment groups (Table 1). At day 31 all mice were sacrificed and kidneys were 
removed and processed for histology. The percentage of normal glomeruli (without 
focal sclerotic or proliferative lesions) amounted 44 ± 23 % in the sirolimus treatment 
group and 46 ± 29 % in the vehicle solution treatment group (ns). 
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Table 1. Urinary albuminuria in male Thy-1.1 transgenic mice 
Albuminuria (µg/mmol creatinine)
Time
Sirolimus
4 mg/kg/day
Vehicle solution P value
Day 10 3929 ± 3377 4691 ± 2515 0.51
Day 17 4145 ± 3440 4023 ± 2392 0.34
Day 24 4213 ± 3221 4151 ± 2669 0.96
Day 31 2281 ± 1421 1752 ± 1012 0.32
Data are depicted as mean ± standard deviation.
The day of administration of the anti-Thy-1.1 antibodies is considered day 0. Sirolimus or vehicle solution 
was started on day 11 after injection of 2 mg anti-Thy-1.1 mAb in mice who developed proteinuria
dIscussIon
We set up these experimental studies in an effort to develop a suitable model for 
investigation of sirolimus-induced proteinuria. We did not observe any increase in 
proteinuria after administration of sirolimus: neither in experiment 1 nor in experiment 
2. We also did not detect differences in the occurrence of glomerulosclerosis. Thus, 
we were unable to replicate the finding of increased proteinuria observed in patients 
treated with sirolimus. 
Of note, we even observed some reduction of proteinuria in transgenic mice treated 
with sirolimus, which could not be explained by differences in blood pressure. Thus, 
our data might suggest a dose dependent protective effect of sirolimus on proteinuria 
in male Thy-1.1 transgenic mice. The mechanisms responsible for this protective effect 
were not further evaluated. 
In light microscopy very few focal sclerotic lesions were seen in all groups (0-5%). 
Since few control mice developed FSGS within the study period, no effect of sirolimus 
on development of FSGS could be demonstrated. Assmann et al. studied untreated 
transgenic mice and observed focal glomerulosclerosis in 17 +/- 6% of glomeruli at 
week 26.21 Because in our study the body weight of the sirolimus treated mice decreased 
during the study period we sacrificed them at week 19. This might be the explanation 
for the very few glomeruli with focal sclerotic lesions that we observed. Although we 
expected that sirolimus might worsen damage if administered in mice with existing 
glomerular damage, our experiments could not confirm this hypothesis. 
We thus were unable to create a mouse model that could replicate the finding of 
increased proteinuria that was observed in patients treated with sirolimus. Although 
the pathogenesis of proteinuria is likely multi-factorial and may involve tubular and 
glomerular damage, the latter seems much more likely. However, the pathways by which 
mTOR inhibition could induce podocyte injury remain speculative. The podocyte plays 
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a key role in both maintenance of the glomerular filtration barrier and in glomerular 
structural integrity. Various slit diaphragm and cytoskeletal proteins contribute to the 
maintenance of podocyte permeability functions, and podocyte secretion of growth 
factors such as vascular endothelial growth factor (VEGF) is necessary for endothelial 
cell survival. The podocyte itself also expresses numerous receptors and responds to 
many growth factors and metabolic products implicated in progressive kidney diseases. 
However, podocytes have limited proliferative capacity, and when glomerular growth 
and hemodynamic stresses exceed the ability of podocytes to undergo hypertrophy, 
they become irreversibly injured and disappear (apoptosis or detachment). Podocyte 
injury and loss contribute to proteinuria and progressive sclerosis. The studies by 
Gödel et al.22 and Inoki et al.23 demonstrated the importance of the mTOR pathway in 
podocytes. mTOR is a widely expressed protein kinase that mediates its functions in two 
complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)(Figure 2). The net 
consequences of mTOR activity for the podocyte and glomerular disease depend on the 
balance between these complexes. mTORC1 regulates proliferation and autophagy in 
response to various nutrients. mTORC1 is potently inhibited by the immunosuppressive 
drug sirolimus. mTORC2 controls cell survival, modulates the cytoskeleton and is largely 
(but not completely) sirolimus insensitive; its activation results in phosphorylation of 
AKT and protein kinase C (PKC).24 Both mTORC1 and mTORC2 are needed for podocyte 
development and podocyte maintenance. The lack of mTORC1 in mouse podocytes 
induced proteinuria and progressive glomerulosclerosis, which was aggravated when 
mTORC2 was concomitantly inactivated.22 Therefore, complete inhibition of mTORC1 
activity with sirolimus treatment may worsen podocyte function and fail to yield a better 
clinical outcome. Intriguingly, podocytes seem to be particularly sensitive to mTORC1 
deletion during glomerular development, indicating that mTORC1 is of particular 
importance during podocyte growth and adaptation. In podocyte specific mTORC2-
deficient mice no obvious clinical, histological, or ultrastructural abnormalities were 
observed. However, podocyte specific mTORC2-deficient mice exposed to stress such 
as BSA overload developed significantly higher albuminuria than control littermates, 
suggesting that mTORC2 might play a role in podocyte adaptation and foot process 
reorganization in response to stress.
The activity of mTOR must be tightly regulated, since overactivation also causes 
damage. mTORC1 activity in mature podocytes is very low under basal conditions. It 
has been shown that podocyte mTOR activity is increased in glomerular diseases, likely 
in an attempt to maintain podocyte homeostasis. In response to mTOR activation, 
podocytes change in a fairly stereotypical manner with cell hypertrophy, foot process 
effacement, and eventually detachment from the glomerular basement membrane. 
This mTOR activation, which may provide some short-term benefits, ultimately causes 
proteinuria and glomerulosclerosis and facilitates disease progression. Curtailing 
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mTORC1 signalling in mice by genetically reducing mTORC1 in podocytes prevented 
glomerulosclerosis and significantly ameliorated the progression of glomerular 
disease in diabetic nephropathy.22 The timing of mTOR inhibition in podocytes was 
also investigated. Adding rapamycin early prevented renal injury caused by mTORC1 
activation. However, progression of sclerosis was not affected if rapamycin was given 
when injury induced by mTORC1 activation in podocytes was already moderate.23 These 
results demonstrate the requirement for tightly balanced mTOR activity in podocyte 
homeostasis. 
 
figure 2. mTOR signaling in the podocyte
mTor is a component of two major intracellular signaling complexes: mTORC1 and mTORC2. These complexes 
contain two different scaffolding proteins (raptor and rictor) that “connect” them to different downstream 
targets. Podocyte maintenance is dependent on a fine-tuned balance of mTORC1 and mTORC2 activity. mTORC1 
signaling is normally activated by growth factors and amino acids, which activate phosphatidylinositol-
3-kinase (Pi3k), a lipid kinase. Pi3k activates AKT by phosphorylation it at Thr308. Rheb, a cytoplasmatic 
protein, activates mTORC1 and is regulated by the tuberous sclerosis complex (TSC). AKT activates mTORC1 
by inhibition of TSC. AKT is also phosphorylated on Ser473 by mTORC2. The primary signals for mTORC2 
activation are unknown. Rapamycin has an immediate inhibitory effect on mTORC1 and with chronic use 
may also inhibit mTORC2. Inhibition of mTORC1, especially during development or other physiologic or 
pathophysiologic growth, may cause podocyte injury. Added inhibition of mTORC2 activation causes more 
severe podocyte injury, sclerosis, and proteinuria, illustrating the dependence of normal podocyte function 
and structure on balance of the two complexes.
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Canaud et al.25 showed that upon nephron reduction podocytes are adapting to the 
stress of cell loss and undergo mTORC2-mediated phosphorylation of AKT at Ser473, 
delaying kidney disease progression by promoting podocyte survival and cytoskeleton 
integrity. Disruption of this adaptive mTORC2-AKT pathway via sirolimus resulted in 
podocyte apoptosis and foot process effacement after nephron reduction, leading to 
severe proteinuria and glomerulosclerosis in mice. Therefore, mTOR inhibitors should 
be used with caution in patients with nephron reduction to preserve the activity of the 
mTORC2-AKT axis and prevent podocyte apoptosis.
In experimental settings, the effects of sirolimus treatment on proteinuria are equivocal, 
with most studies reporting renoprotective effects26-42 whereas some studies showed an 
increase in proteinuria42-46 (Table 2). 
In experimental models of reduced renal mass low-dose mTOR inhibition prevented 
progressive renal fibrosis when mTOR inhibition was started after the acute effects of 
renal ablation and reparation have taken place.26-28 In contrast, when sirolimus was given 
in a high-dose early after surgery mTOR inhibition apparently inhibited the chronic 
glomerular repair reaction via inhibition of the proliferative but not apoptotic activity 
of the glomerular endothelial and mesangial cells. The inhibition of VEGF-mediated 
capillary and mesangial repair of ongoing complex glomerular injury and repair reaction 
seems to be critical for the adverse effects of mTOR inhibition.43 While antiproliferative 
effects are beneficial for hyperproliferative lesions, during the acute phase of renal 
injury these antiproliferative effects seem to be problematic. The timely requirements 
of complex glomerular repair reaction, especially involving both endothelium and 
mesangium, being transiently inhibited by mTOR inhibition, seems to be critical for its 
adverse effects.
Beneficial effects of low-dose mTOR inhibition were also reported in diabetes induced 
by streptozotocin. Treatment reduced phosphorylation of AKT (pAKT) and normalized 
mTOR, suggesting that the mTOR pathway has an important pathogenic role in diabetic 
nephropathy.29 Beneficial effects of mTOR inhibitors were also reported in other animal 
models such as anti-Thy 1 nephritis in rats30,31, lupus nephritis32-34 and membranous 
nephropathy.35-37 Stratakis et al.37 found that rapamycin monotherapy significantly 
improved proteinuria and histological lesions in experimental membranous 
nephropathy. This beneficial effect may be mediated by inhibition of the alloimmune 
response during the autologous phase of passive Heymann nephritis and by restoration 
of the normal expression of the podocyte proteins nephrin and podocin. In nephrotoxic 
serum nephritis, an anti-GBM nephritis model, the effect of rapamycin on proteinuria 
was influenced by timing of administration. When rapamycin was started before 
administration of the anti-GBM antiserum, mice were protected from glomerulonephritis, 
suggested by a dramatic decrease in albuminuria and reduced B and T cell responses. 
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In contrast, when rapamycin was started 14 days after infusion of the anti-GBM antiserum 
mice showed a significant increase in albuminuria and renal infiltration of inflammatory 
cells, and there were no differences in T and B cell responses. A significant decrease in 
vascular endothelial growth factor-A and an increase in IL-6 was detected indicating 
a disturbance of the endothelial cell/vascular endothelial growth factor system in the 
kidney.47 In the same model Kirsch et al.44 also found an increase in albuminuria when 
rapamycin administration was started 14 days after induction of nephrotoxic serum 
nephritis. This rapamycin-induced proteinuria seemed to be a result of the activation 
of the innate immune system rather than a direct toxicity to podocytes or glomerular 
endothelial cells.
In rats receiving a fixed high-dose of rapamycin, differences were found in the effects 
on renal function depending on the underlying injury. In minimal change disease, 
where podocyte structure has been damaged, rapamycin aggravates the disruption 
of the glomerular slit structure by lowering podocin expression, thus resulting in 
higher proteinuria. In contrast, in a chronic injury model rapamycin appears to have 
an important nephro-protective role associated with the maintenance of nephrin and 
podocin expression.42 
In Adriamycin-induced nephrotic syndrome, early, and to a lesser extent late treatment, 
with a low but not a high-dose of everolimus was effective in reducing proteinuria in 
nephrotic rats. The mechanism may be via nephrin/podocin.40
In the glomerular compartment, others have demonstrated reduced VEGF, particularly 
in patients with significant proteinuria.43 VEGF is synthesized by podocytes and has 
emerged during the past years as an essential autocrine/paracrine factor that promotes 
the survival of both endothelial cells and podocytes. Sirolimus has been demonstrated 
to inhibit production of VEGF through the inhibition of mTOR. A role for VEGF in the 
pathogenesis of chronic allograft dysfunction after kidney transplantation has been 
suggested, in particular, in promoting fibrosis. 
Ko et al.45 found that whilst both sirolimus and cyclosporine provided some protection 
against inflammation and fibrosis in a rat model of chronic kidney allograft dysfunction, 
sirolimus provided additional benefit in attenuating vasculopathy at the expense of 
proteinuria. Their observations of decreased expression of VEGF and VEGFR in glomeruli 
and vessels, plus inhibition of VEGF-stimulated proliferation of glomerular cells by 
sirolimus in vitro, suggest inhibition of VEGF signaling may be a key mechanism of both 
vascular protection and proteinuria in kidney transplant recipients.
Yan et al.48 demonstrated the possible linkage of an energy-consuming process in 
glomerular podocytes to the mechanism of proteinuria. Puromycin aminonucleoside 
nephrosis, a rat model of minimal change disease, revealed the activation of the unfolded 
protein response (UPR) in glomerular podocytes to be a cause of proteinuria. Of note, 
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activation of mTORC1 was related to energy consumption and increased UPR response. 
Indeed, pre-treatment of puromycin aminonucleoside treated podocytes with mTOR 
inhibitor everolimus decreased UPR activation and energy consumption. This finding 
was further confirmed, also in a model of minimal change disease, by Ito et al.41 They 
demonstrated that the mTORC1 inhibitor everolimus completely inhibited proteinuria 
through a reduction in both mTORC1 and UPR activity paralleled by preserved nephrin 
expression in glomerular podocytes. They concluded that mTORC1 activation may 
perturb the regulatory system of energy metabolism primarily by promoting energy 
consumption and inducing the UPR, which underlie proteinuria in minimal change 
disease.
It is apparent that our current understanding of the clinical significance and causative 
mechanisms of mTOR inhibitor-associated proteinuria is far from complete. The effect of 
mTOR inhibition on proteinuria in patients with kidney disease is probably influenced by 
multiple factors such as the nature and presence of pre-existing renal damage, timing of 
administration, dosage of rapamycin used and prior exposure to a calcineurin inhibitor. 
Additional basic and clinical studies are warranted to clarify the issue of rapamycin-
associated proteinuria. 
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AbsTrAcT
Purpose
In light of the significant morbidity and mortality of cutaneous invasive squamous cell 
carcinomas (SCCs) in renal transplant recipients, we investigated whether conversion 
to sirolimus-based immunosuppression from standard immunosuppression could 
diminish the recurrence rate of these skin cancers.
Patients and methods
In a 2-year randomized controlled trial, 155 renal transplant recipients with at least one 
biopsy-confirmed SCC were stratified according to age (< 55 v ≥ 55 years) and number 
of previous SCCs (one to nine v ≥ 10) and randomly assigned to conversion to sirolimus 
(n=74) or continuation of their original immunosuppression (n=81). Development of a 
new SCC within 2 years after random assignment was the primary end point.
results 
After 2 years of follow-up, the risk reduction of new SCCs in the multivariable analysis 
was not significant, with a hazard ratio (HR) of 0.76 (95% CI, 0.48-1.2; P=0.255), compared 
with a non-sirolimus-based regimen. After the first year, there was a significant 50% risk 
reduction, with an HR of 0.50 (95% CI, 0.28 to 0.90; P=0.021) for all patients together 
and an HR of 0.11 (95% CI, 0.01 to 0.94; P = 0.044) for patients with only one previous 
SCC. The tumor burden of SCC was reduced during the 2-year follow-up period in those 
receiving sirolimus (0.82 v 1.38 per year, relative risk 0.51; 95% CI, 0.32 to 0.82; P=0.006) 
if adjusted for the number of previous SCCs and age. Twenty-nine patients stopped 
taking sirolimus because of various adverse events. 
conclusions 
Conversion to sirolimus-based immunosuppression failed to show a benefit in terms of 
SCC-free survival at two years. 
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InTroducTIon
The reported cancer risk in renal transplant recipients (RTRs) is two- to six-fold greater 
than in the general population.1-3 Cutaneous squamous cell carcinomas (SCCs) are the 
most common post-transplantation cancers, occurring 65 to 250 times more often than 
in the general population.4-6 Invasive SCC may derive from SCC in situ (Bowen’s disease) 
or other intra-epidermal precursor lesions (actinic keratoses) and may metastasize.4 
The cumulative incidence of cutaneous SCC ranges from 2 to 24% after 5 years post-
transplantation.5,7 Once an individual develops a first SCC, the risk of developing 
subsequent independent SCCs is high.8,9 In addition to the clinical and economic 
burdens of multiple SCCs, transplantation skin cancers carry a worse prognosis than 
those from immunocompetent persons, with more aggressive behavior and increased 
mortality resulting from metastatic disease.10 
Causes of cutaneous SCCs in RTRs include: exposure to ultraviolet radiation, reduced 
immunosurveillance, skin type, age at transplantation, and human papillomavirus 
infection.4,11-13The intensity and duration of immunosuppressive therapy influence SCC 
risk, resulting in increased incidence in cardiac compared with renal or liver transplant 
recipients.14,15 There is also compelling evidence for carcinogenic mechanisms associated 
with cyclosporine 16-18 and azathioprine.19 
The antiproliferative response of mammalian target of rapamycin (mTOR) inhibitors may 
confer a lower risk of the development of malignancy, as shown in small pilot studies 
and short-term registry analyses.20-22 Sirolimus interferes with intracellular proteins, with 
influences on angiogenesis, cell growth, division, and survival.23 In addition, sirolimus 
has been shown to inhibit the ultraviolet B activation of metalloproteinases that may 
promote cancer formation and premature skin aging.24 Prospective randomized studies 
comparing efficacy of sirolimus with that of other immunosuppressive regimens have 
indicated a tendency for fewer skin tumors developed in the sirolimus group as a 
secondary outcome measure.20,22 Until recently, there has been a lack of prospective 
randomized studies of mTOR inhibitors evaluating the recurrence rate of cutaneous SCC 
as the primary outcome measure. A study in Australia included 86 patients with either 
SCC or basal cell carcinoma (BCC).25 At 1 year, there was a reduction in formation of 
new SCCs, of which most were SCC in situ. The incidence and pattern of skin tumors in 
Australia, however, is different from these in Western Europe because of differences in 
ultraviolet light exposure, which may affect the influence of sirolimus conversion.12 In 
the RESCUE (Recurrent Cutaneous Squamous Cell Carcinoma Under Rapamune) study, a 
2-year randomized, prospective, open-label, multicenter trial, we investigated whether 
conversion to sirolimus-based immunosuppression in long-term RTRs would diminish 
the rate of new cutaneous invasive SCCs.
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PATIenTs And MeTHods 
Patients studied
RTRs were recruited from five transplantation centers in the Netherlands and 16 in the 
United Kingdom. Inclusion criteria included: first or second kidney transplantation 
with ≥ 1 biopsy-confirmed cutaneous invasive SCC, age ≥ 18 years, >12 months post-
transplantation, stable graft function with estimated glomerular filtration rate ≥ 20 ml/
min/1.73m2, receiving maintenance calcineurin inhibitor, azathioprine, mycophenolate, 
and/or steroids for at least 12 weeks before random assignment, and no acute rejection 
episode within 12 weeks before random assignment.
Exclusion criteria included: metastatic cutaneous SCC, internal malignancies 
(documented after transplantation), serum creatinine at screening increased >30% 
above the last value obtained at least 12 weeks earlier, total WBC count < 3,000/µL, 
platelet count < 75,000/ µL, fasting-riglycerides >3.95 mmol/l, cholesterol >7.8 mmol/l 
(± statins), transaminases >2 x above normal, planned/present pregnancy, evidence of 
systemic infection or HIV infection at random assignment, or Fitzpatrick skin type V to VI. 
The independent ethics committee or institutional review board of each site approved 
the protocol. Participants provided written informed consent in accordance with the 
Declaration of Helsinki.
random assignment
After patient consent, random assignment took place using blinded envelopes 
containing treatment codes for either continuation of maintenance therapy or 
conversion to sirolimus. The random assignment (1:1) was stratified by transplantation 
center, number of biopsy-confirmed SCCs (< 10 v ≥ 10) before random assignment, and 
recipient age (< 55 v ≥ 55 years). For each of the defined stratification groups,  random 
assignment envelopes with a fixed random assignment order per stratum were available 
with a number of four per random assignment block. 
Procedures
The target blood level of sirolimus was 5 to 10 ng/ml; sirolimus was started the day the 
purine antagonist (azathioprine or mycophenolate mofetil) and/or calcineurin inhibitor 
(cyclosporine or tacrolimus) was withdrawn (loading dose, of 8 mg and maintenance 
dose, of 4 mg). Between days 5 to 7, a sirolimus trough level was measured and the 
dose adjusted to the defined range. All patients were also treated with at least 5 mg 
of prednisone daily. The immunosuppressive regimen was not changed in control 
patients. At regular three monthly intervals, a complete skin inspection was undertaken 
by a dermatologist, and renal function and adverse events were monitored by a 
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nephrologist. The dermatologists were blinded for the treatment arm, but patients and 
their nephrologists were unblinded.
Skin lesions clinically suspected to be invasive SCCs or BCCs were biopsied for histological 
interpretation by the local dermatopathologists. In RTRs, actinic keratoses and SCC in 
situ are clinically difficult to discern, and these lesions were not routinely biopsied. Only 
biopsy-confirmed invasive SCCs, SCCs in situ, and BCCs were included in the study.
Laboratory data were recorded every 3 months. Adverse events were evaluated during 
the study period, and the reasons for dropout were documented.
The development of cutaneous invasive SCC within 2 years after conversion was the 
primary end point of this study. Secondary end points included: incidence, severity, and 
reversibility of biopsy-confirmed acute rejection episodes; patient and graft survival; 
and renal function 2 years after random assignment.
statistical analyses
Sample size calculation was based on the risk to develop a subsequent cutaneous 
invasive SCC, which was reported earlier to be 50% in 2 years.8,9 In addition, a relative risk 
reduction of 50% was expected in the patients assigned to be converted to sirolimus 
compared with patients who would continue their original immunosuppressive 
regimen, based on results obtained on new skin lesions in de novo patients.20 To detect 
a difference in recurrence probability at 2 years of 50% versus 25% at a two-sided alpha 
level of 5% and a power of 0.9, assuming 25% loss to follow-up, 154 patients would 
be needed. Hence, we aimed at 80 patients per arm (NCSS Statistical Software; NCSS, 
Kaysville, Utah, UT).
The occurrence of SCC was assessed with Kaplan-Meier curves and Cox regression to 
calculate the hazard ratio (HR). The annualized per-patient SCC recurrence rate was 
modelled using a negative binomial regression model. All RTRs were included in the 
intention-to-treat (ITT) analyses and observed during the 2-year follow-up period or 
until death. The same analyses were performed for the first year and stratified for one 
previous SCC or > one SCC. We also performed per-protocol population (PPP) analyses 
including the RTRs until they dropped out because of adverse events or withdrew 
informed consent (Fig 1).
First analyses (Table 1) showed that sex was imbalanced despite random assignment 
(P=0.003), but this did not affect the other analyses. The unexpected low recruitment 
rate in two thirds of centers in the United Kingdom, in combination with the fixed 
order per stratum, resulted in the imbalance of the stratification factors. To analyze the 
impact of this imbalance on treatment outcome, we performed multivariable analyses 
and analyses stratified for sex, age at random assignment, immunosuppressive drugs, 
and country. Finally, adjustments were only made for age and number of invasive SCCs 
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before inclusion, the predefined characteristics for which we had stratified. For the 
analyses, we used the PASW Statistics software package (release 17.02; SPSS, Chicago, IL).
resulTs
We included 103 RTRs in the Netherlands and 52 in the United Kingdom between 
January 2004 and September 2009. The pathway of patients recruited and outcomes are 
shown in Figure 1. Demographic and baseline characteristics are presented in Table 1. 
Table 1. Patient demographics and baseline clinical characteristics.
Characteristic
Patients converting to 
sirolimus
(n = 74)
Patients 
continuing original 
immunosuppression
(n=81)
No. % No. %
Sex:*
 Female
 Male 
32
42
43
57
17
64
21
79
Age at random assignment, years
 <55 
 ≥55 
31
43
42
58
23
58
28
72
Functioning transplant at random assignment, years 
 Mean
 SD
19 
8
18
7
Serum creatinine, µmol/L 
 Mean
 SD
121
44
137
48
Immunosuppressive regimen at random assignment
-  One immunosuppressive drug ± prednisone
     Aza
     MMF
     Cyclosporine
     Tacrolimus
-  Two immunosuppressive drugs ± prednisone
     Calcineurin inhibitor with Aza
     Calcineurin inhibitor with MMF
63
42
10
7
4
11
9
2
85
15
64
33
3
21
7
17
13
4
79
21
Skin type (Fitzpatrick I to IV) 
 I (very fair skin; Celtic)
 II
 III
 IV (darker skin; Mediterranean)
9
39
26
0
12
53
35
0
9
44
25
3
11
54
31
4
No. of invasive SCCs before random assignment
 1
 2 to 9
 ≥10
30
33
11
40
45
15
23
52
6
29
64
7
Abbreviations: Aza, azathioprine; MMF, mycophenolate mofetil; SCC, squamous cell carcinoma; SD, standard 
deviation.
*Sex was imbalanced despite random assignment (P = 0.003), but this did not affect the additional analyses.
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Patients randomly assigned 
(n=155) 
Assigned to be converted to sirolimus 
(n=74) 
Assigned to remain on conventional immunosuppression 
(n=81) 
Drop outs       (n=39) 
 Died          (n=2) 
 Withdrew informed consent    (n=8)  
 Adverse events       (n=29) 
  Transplant rejection       (n=1) 
  Pneumonitis        (n=6) 
  Proteinuria      (n=11) 
  Miscellaneous*      (n=11) 
 
  
Drop outs          (n=14) 
 Died             (n=1) 
 Withdrew informed consent      (n=11) 
 Adverse events            (n=2) 
  Decline in renal function  (n=2) 
  
 
ITT: 72 patients  with complete 
24-month follow-up 
 (PPP: 35 patients) 
ITT: 80  patients with complete 
24-month follow-up 
 (PPP: 67 patients) 
 
figure 1. Patient disposition. 
ITT, intention to treat; PPP, per-protocol population.
* Slow wound healing (n=1), pulmonary embolus (n=1), pneumonia (n=1), edema (n=2),  diarrhea (n=2), 
fatigue (n=2), 1 skin rash (n=1), dyslipidemia (n=1), and diabetes mellitus (n=1).
Kaplan-Meier analysis of all 155 randomly assigned patients showed separation 
between the curves, but after 2 years, there was no significant difference for invasive 
SCC-free survival (P = 0.155; Figs 2A to 2C). In exploratory analyses at 1 year, statistical 
significance was still present (P = 0.006; Fig 2D). Sirolimus was especially effective during 
the first year after conversion in RTRs with only one previous SCC. In this subgroup, only 
one of 30 patients developed a new SCC 9 months after conversion compared with six 
of 23 patients in the control group (P = 0.015; Fig 2E). Conversion to sirolimus was much 
less effective in patients with multiple SCCs before inclusion (Figs 2C, 2F).
In multivariable analyses, the HR for SCC recurrence under sirolimus was 0.76 (95% 
CI, 0.48 to 1.2; P=0.255) after the 2-year follow-up period, representing a statistically 
nonsignificant 24% reduction in the estimated risk of developing at least one 
subsequent invasive SCC. In exploratory analyses at 1 year, the HR was 0.50 (95% CI, 0.28 
to 0.90; P = 0.021), a significant 50% reduction after the first year of follow-up (Table 
2). The ITT and PPP crude and adjusted analyses for invasive and/or in situ SCCs are 
summarized in the Appendix Table A1. The analyses of in situ SCCs resembled those of 
invasive SCCs, and the PPP analyses showed a slightly stronger risk reduction than the 
ITT analyses (Appendix Table A1). A total of 15 patients (20.3%) converted to sirolimus, 
and 27 (33.3%) of those continuing their original immunosuppression developed ≥ one 
BCC, which resulted in an HR for BCC recurrence with sirolimus of 0.56 (95% CI, 0.30 to 
1.1; P=0.076) and an adjusted HR of 0.67 (95% CI, 0.34 to 1.3; P=0.233).
Chapter 5
66
0
Re
cu
rr
en
ce
 S
CC
 (%
)
Time (months)
80
60
40
20
6 12 18 24
Controls
Sirolimus
No. at risk
Controls 81 53 43 40 35
Sirolimus 74 61 54 43 39
0
Re
cu
rr
en
ce
 S
CC
 (%
)
Time (months)
80
60
40
20
6 12 18 24
Controls
Sirolimus
No. at risk
Controls 23 18 17 16 16
Sirolimus 30 29 28 25 23
0
Re
cu
rr
en
ce
 S
CC
 (%
)
Time (months)
80
60
40
20
6 12 18 24
Controls
Sirolimus
No. at risk
Controls 58 35 26 25 19
Sirolimus 44 32 26 18 16
CBA
0
Re
cu
rr
en
ce
 S
CC
 (%
)
Time (months)
80
60
40
20
3 6 9 12
Controls
Sirolimus
No. at risk
Controls 81 67 53 47 43
Sirolimus 74 72 61 58 54
0
Re
cu
rr
en
ce
 S
CC
 (%
)
Time (months)
80
60
40
20
3 6 9 12
Controls
Sirolimus
No. at risk
Controls 23 20 18 18 17
Sirolimus 30 30 29 29 28
0
Re
cu
rr
en
ce
 S
CC
 (%
)
Time (months)
80
60
40
20
3 6 9 12
Controls
Sirolimus
No. at risk
Controls 58 47 35 29 26
Sirolimus 44 42 32 29 26
FED
Fig 2.Recurrence of squamous cell carcinoma (SCC) in patients converting to sirolimus and control patients who continued their original immunosuppressi ve regimen
according to the intention to treat analysis. (A) Follow-up until 2 years (primary end point for all patients together; P .155) and (B) stratified for one SCC at inclusion
(P .193) or (C) one SCC at inclusion ( P .854). (D) Follow-up until 1 year for all patients together ( P .006) and (E) in patients with one SCC ( P .015) and (F)
one SCC ( P .139).
figure 2. Recurrence of squamous cell carcinoma (SCC) in patients converting to sirolimus and control 
patients wh  continued their original immu osuppressiv  regim n accordi g to the intention to treat an lysis. 
(A) Follow-up until 2 years (primary end point for all patients together; P = 0.155) and (B) stratified for one 
SCC at inclusion (P = 0.193) or (C) > one SCC at inclusion (P = 0.854). (D) Follow-up until 1 year for all patients 
together (P = 0.006) and (E) in patients with one SCC (P = 0.015) and (F) > one SCC (P = 0.139).
The annualized per-patient invasive SCC recurrence rate, as shown in Appendix Table 
A2, was 0.82 in the sirolimus arm compared with 1.38 in controls. The relative risk for 
developing an invasive SCC was 0.60 (95% CI, 0.35 to 1.02; P = 0.057), and 0.51 (95% 
CI, 0.32 to 0.82; P = 0.006)  when adjusting for number of SSCs at inclusion and age, a 
49% reduction in the risk of developing an SCC compared with a non-sirolimus-based 
regimen. The adjusted and PPP analyses showed stronger risk reductions (Appendix 
Table A2).
The first sirolimus trough level (± standard deviation [SD]) was 12.0 ± 6.4 ng/mL, 
measured after a mean (± SD) of 10.6 ± 6.4 days, and was higher in patients who 
discontinued sirolimus (13.1 ± 6.8 v 10.9 ± 5.6; P=0.149). Mean trough levels (± SD) were 
9.4 ± 4.5, 7.8 ± 2.4, and 7.1 ± 1.9 ng/mL at 3, 12, and 24 months, respectively. Within 
these ranges, sirolimus trough levels did not significantly predict the risk for developing 
recurrent SCCs and were also not significantly associated with adverse effects or 
treatment discontinuation (data not shown).
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Table 2. Risk for developing ≥ one subsequent SCC.
Recurrence at 2-year follow-up *
Univariate Multivariable†
Factor HR 95% CI P HR 95% CI P
Sirolimus 
conversion
0.73 0.47 to 1.1 0.157 0.76 0.48 to 1.2 0.255
Age (per 10 years) 0.90 0.73 to 1.1 0.304 0.95 0.77 to 1.2 0.610
Male v female 0.94 0.60 to 1.5 0.781 0.97 0.59 to 1.6 0.886
No. of previous 
SSCs
1
2 to 9
≥10 
1
4.2
7.2
2.2 to 7.8
3.3 to 15.7
0.000
0.000
1
3.9
7.3
2.1 to 7.4
3.3 to 16.1
0.000
0.000
Recurrence at 1-year follow-up‡
Univariate Multivariable†
Factor HR 95% CI P HR 95% CI P
Sirolimus 
conversion
0.47 0.27 to 0.81 0.007 0.50 0.28 to 0.90 0.021
Age (per 10 years) 0.88 0.69 to 1.1 0.333 0.89 0.69 to 1.1 0.339
Male v female 1.5 0.79 to 2.7 0.229 1.4 0.73 to 2.6 0.321
No. of previous 
SSCs
1
2 to 9
≥10 
1
4.1
7.3
1.8 to 9.2
2.8 to 18.9
0.001
0.000
1
3.6
7.9
1.6 to 8.2
3.0 to 20.6
0.002
0.000
Stratified for patients with one and > one SCC‡§
Recurrence at 1-year follow-up Recurrence at 2-year follow-up
HR 95% CI P HR 95% CI P
 One SCC
 > One SCC
0.11
0.65
0.01 to 0.94
0.36 to 1.2
0.044
0.144
0.48
0.96
0.15 to 1.5
0.60 to 1.5
0.203
0.854
Abbreviations: HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma.
* Primary end point.
† Multivariable analyses included sirolimus conversion, age, sex and 3 categories of numbers of squamous 
cell carcinomas at inclusion of the study.
‡ Exploratory analyses.
§ Univariate analysis.
In the sirolimus arm, 8 RTRs (10.8%) withdrew consent after a median time of 3.5 months 
(range, 0.99 to 11.8 months) as compared with 11 (13.6%) after 8.4 months (range, 
0.03 to 21.2 months) months in controls (Fig 1). As expected in stable RTRs receiving 
immunosuppression for a mean of 18 years, there were fewer treatment-related adverse 
events in the patients who continued their original immunosuppression. Two RTRs in 
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this group had a decline in renal function, which was not treatment related, after 10.6 
and 12.8 months, respectively; one died after 16.1 months (cause unknown; Fig 1). In 
contrast, a total of 29 converted patients (39.1%) had to discontinue sirolimus because 
of adverse effects after a median time of 5.6 months (range, 0.69 to 18.0 months) or 
because of death resulting from a cerebrovascular accident after 5.9 months or from 
metastatic SCC after 6.6 months. One patient developed a borderline rejection with 
additional signs of chronic allograft nephropathy on a renal biopsy 6 months after 
conversion. After treatment, serum creatinine stabilized at 300 µmol/L (175 µmol/L at 
conversion). Other adverse effects are summarized in Table 3. 
Table 3. Adverse events not leading to discontinuation of treatment
Adverse event
Patients converting 
to sirolimus
Patients 
continuing original 
immunosuppression
(No.) (No.)
Infection 
 Respiratory
 Urinary
 Abdominal
 Septicemia
 Skin
 Other
17
3
2
1
14
6
6
4
1
1
9
0
Other 
 Pneumonitis 
 Proteinuria
 Skin
          Rash
          Acne
 Diarrhea
 Aphthous stomatitis
 Flu-like symptoms
 Fatigue
 Edema
 Deep venous thrombosis
 New onset diabetes mellitus
 Dyslipidemia (total cholesterol >7.8 mmol/L)
 Thrombocytopenia (< 100,000/µL)
 Leukopenia (< 4000/ µL )
1
5
5
3
7
4
2
1
7
1
0
13
2
11
0
0
1
0
0
0
0
1
2
1
1
3
3
5
Among the patients who finished the protocol on therapy in both treatment arms, serum 
creatinine did not change during the study period (control arm: start, 133 ± 49 µmol/L; 
end, 135 ± 51 µmol/L; sirolimus arm: start, 115 ± 38 µmol/L; end, 111 ± 37 µmol/L [± 
SD]). In addition, proteinuria did not change during the study period (control arm: start, 
0.3 ± 0.2 g/d; end, 0.4 ± 0.6 g/d; sirolimus arm: start, 0.5 ± 1.4 g/d; end, 0.4 ± 0.4 g/d 
[[± SD]), although 11 of the included patients stopped using sirolimus mainly because 
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of proteinuria. Other laboratory investigations (cholesterol, HDL cholesterol, LDL 
cholesterol, triglycerides, glucose, hemoglobin A1c, albumin, hemoglobin, leukocytes, 
and platelets) remained stable between start and end of the study.
dIscussIon
Cutaneous invasive SCC is a serious complication of long-term organ transplantation, 
with significant morbidity, along with mortality rates similar to those seen with post-
transplantation lymphoproliferative disease.4 The primary analysis in this study showed 
that conversion to sirolimus-based immunosuppression resulted in a nonsignificant 
24% reduced risk of a new cutaneous invasive SCC developing within 2 years after 
conversion. The exploratory analysis at 1 year resulted in a significant 50% risk reduction. 
There was a 49% reduction in risk of developing multiple invasive SCCs. Comparable risk 
reductions were observed for SCC in situ and BCC. The effect of conversion to sirolimus 
was especially eminent in patients with only one previous SCC at the time of conversion.
These results are similar to the preliminary findings of a small pilot study from Germany, 
in which only one of 16 RTRs in the sirolimus conversion group compared with eight of 
17 in the control group developed a skin cancer within 12 months of conversion.26 This 
study included all forms of nonmelanoma skin cancer and did not require the participant 
to have had previous skin cancer. A study from Australia included 86 patients with either 
SCC or BCC.25 There was a reduction in formation of new SCCs (most of which were SCC 
in situ) per year from 1.71 in the control group to 0.88 in the sirolimus group in the first 
year after conversion. The time since transplantation was much shorter (mean, 9.1 years), 
and skin cancers were mostly SCC in situ, not invasive SCC.25 A recent study from France 
included 120 patients with SCC and found a 44% risk reduction of new SCCs at 2 years.27 
Efficacy was restricted to RTRs with only one previous SCC, and the difference remained 
significant at 2 years. The French study included more patients with only one SCC (55% 
v our 34%), and analysis occurred earlier after transplantation (12 v 18 years). In the first 
year after conversion, we observed a comparable benefit for the risk of recurrent SCC.
The patient population included in our trial comprised a high-risk group for recurrent 
SCCs. In contrast to previous studies,25,27 our 2-year results indicated that conversion to 
sirolimus did not prevent the occurrence of new SCCs. This conclusion is in line with 
observations that with time, new SCCs occur earlier and are more often multiple.8-10 
Duration of immunosuppressive therapy influences SCC risk, with compelling evidence 
for the carcinogenic mechanisms associated with cyclosporine16-18 and azathioprine.19 
In addition, the impact of withdrawal of the calcineurin inhibitor and/or azathioprine 
may be more beneficial in patients earlier in their post-transplantation course (ie, those 
with only one SCC). 
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In our study the efficacy on skin cancer risk reduction is underestimated by the 42% 
discontinuation rate of sirolimus because of adverse effects. This is similar to the 
discontinuation rates of 35% in the Australian study25 and 25% in the French study27 
and to rates observed in trials designed to investigate the nephron-sparing potential 
of mTOR inhibitors.28,29 Several factors contributed to this high discontinuation rate. 
First, the protocol was designed in 2004 and included a loading dose (8mg) and initial 
maintenance dose (4mg), resulting in high levels in certain individuals with an increased 
risk of early toxicity. Subsequent studies, along with clinical practice, abandoned 
the loading dose and used lower maintenance doses and target levels. In addition, 
investigators in the early phase of this trial were concerned about the risk of secondary 
proteinuria and pneumonitis. The combination of high initial sirolimus levels and 
investigator caution led to early discontinuation of sirolimus in several participants with 
only mild to moderate proteinuria or other adverse effects who may have responded to 
dose adjustment and/or the addition of an angiotensin-converting enzyme inhibitor.30 
To prevent high initial sirolimus levels, we now recommend discontinuing the purine 
antagonist and/or calcineurin inhibitor and commencing sirolimus 2 to 3 mg once daily 
the next day. Alternatively, gradual conversion over weeks or months with lower initial 
dosing could result in a more tolerable regimen, but this carries the risk of drug-drug 
interactions, especially with cyclosporine.
There was no significant change in renal function or increase in proteinuria in the patients 
who continued sirolimus treatment, suggesting the safety of sirolimus conversion in 
RTRs many years post-transplantation. There were no deaths related to conversion, but 
six patients (8%) developed pneumonitis, which resolved with drug cessation (Fig 1); 
one patient with pneumonitis recovered despite continued treatment with sirolimus 
(Table 3). This serious complication is rare, but frequency may have been increased 
in this study as a result of initial higher sirolimus doses, because most cases occurred 
within a few weeks of sirolimus initiation.28
The incidence of skin malignancies in RTRs increases progressively with intensity and 
duration of immunosuppression and therefore with overall time since transplantation. 
Prospective cohort studies in transplant recipients have defined risk factors for skin 
cancer that are clinically robust, allowing reliable identification of patients at highest risk 
of future skin malignancies who may benefit from early conversion to sirolimus.8,9 The 
results of our and other studies examining reduction of skin and nonskin malignancies 
suggest a benefit in early conversion to sirolimus-based maintenance regimen. Such a 
proactive rather than reactive policy carries the additional benefit of reducing calcineurin 
inhibitor-induced progressive loss of renal function, both in RTRs and non-renal organ 
transplant recipients.31 In patients with proteinuria and/or already compromised renal 
allograft function, conversion to an mTOR inhibitor is no longer a valid option.22
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There are limitations to our study. As experienced by others, recruitment of the patients 
was unexpectedly difficult. The randomization procedure was implemented correctly, 
but recruitment of only one or two patients in several centers, in combination with 
the fixed order per stratum, jeopardized balanced random assignment. In addition, 
there were differences between the groups regarding the use of azathioprine and/or 
cyclosporine. Azathioprine in particular has been associated with the more frequent 
occurrence of SCC and/or may indicate a longer time after transplantation. However, the 
differences between the groups in the current cohort were not statistically significant, 
and adjustment had no impact on the results of the analyses.
In conclusion, conversion to low-dose mTOR-inhibition  with careful monitoring was 
not associated with increased risk of transplant dysfunction. However, in our study 
population, comprising patients with one or more previous SSCs, there was no benefit 
at 2 years in converting RTRs in terms of SCC-free survival.  Conversion in those with 
only one previous SCC should be carefully balanced against toxicities that can lead 
to relatively high dropout rates. The benefit afforded by the mTOR-based regimen 
after conversion in the subgroup of patients with only one previous invasive SCC27 
may suggest that an mTOR inhibitor has the potential to become an effective early 
immunosuppressive strategy to reduce the risk of cutaneous SCC in RTRs. 
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APPendIx
Table A1.  Risk reduction for developing ≥ one subsequent SCC after complete 2-year follow-up.
SCC
Patients 
converting to 
sirolimus
(n = 74)
Patients 
continuing 
original 
immuno-
suppression 
(n=81)
No. % No. % HR 95% CI P
Intention to Treat 
Invasive SCC
- No adjustment
- Adjustment for age and  
No. of SCCs before inclusion  
(1 to 9 v ≥10)
37 50.0 46 56.8
0.73
0.65
0.47 to 1.13 
0.42 to 1.01
0.157
0.055
SCC in situ (Bowen’s disease)
- No adjustment
-  Adjustment for age and  
No. of SCCs before inclusion  
(1 to 9 v  ≥10)
17 23.0 25 30.9
0.70
0.51
0.38 to 1.29
0.32 to 1.15
0.247
0.125
Invasive SCC and SCC in situ (Bowen’s 
disease)
- No adjustment
- Adjustment for age and   
No. of SCCs before inclusion  
(1 to 9 v  ≥10)
41 55.4 53 65.4
0.67
0.60
0.45 to 1.01
0.39 to 0.91
0.057
0.016
Per Protocol 
Invasive SCC
- No adjustment
- Adjustment for age and   
No. of SCCs before inclusion  
(1 to 9 v  ≥10)
23 31.1 45 55.6
0.63
0.54
0.38 to 1.04
0.32 to 0.91
0.070
0.020
SCC in situ (Bowen’s disease)
- No adjustment
- Adjustment for age and   
No. of SCCs before inclusion  
(1 to 9 v  ≥10)
8 10.8 24 29.6
0.46
0.38
0.21 to 1.03
0.17 to 0.86
0.058
0.020
Invasive SCC and SCC in situ  
(Bowen’s disease)
- No adjustment
- Adjustment for age and   
No. of SCCs before inclusion  
(1 to 9 v  ≥10)
26 35.1 51 63.0
0.59
0.51
0.37 to 0.95
0.31 to 0.83
0.028
0.006
Abbreviations: HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma.
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Table A2. Risk reduction for developing multiple SSCs after complete 2-year follow-up.
Patients 
converting to 
sirolimus 
(n = 74)
Patients 
continuing original 
immunosuppression 
(n=81)
SCC No. of SCCs per year RR 95% CI P
Intention to Treat 
Invasive SCC
- No adjustment
- Adjustment for age and   
No. of SCCs before inclusion  
(1 to 9 v  ≥10)
0.82 1.38
0.60
0.51
0.35 to 1.02
0.32 to 0.82
0.057
0.006
SCC in situ (Bowen’s disease)
- No adjustment
- Adjustment for age and   
No. of SCCs before inclusion  
(1 to 9 v  ≥10)
0.30 0.38
0.81
0.80
0.35 to 1.88
0.42 to 1.90
0.623
0.770
Invasive SCC and SCC in situ 
(Bowen’s disease)
- No adjustment
- Adjustment for age and   
No. of SCCs before inclusion  
(1 to 9 v  ≥10)
1.13 1.77
0.64
0.59
0.37 to 1.09
0.37 to 0.97
0.099
0.036
Per Protocol 
Invasive SCC
- No adjustment
- Adjustment for age and   
No. of SCCs before inclusion  
(1 to 9 v  ≥10)
0.62 1.43
0.43
0.38 
0.23 to 0.80
0.23 to 0.63
0.007
<0.001
SCC in situ (Bowen’s disease)
- No adjustment
- Adjustment for age and   
No. of SCCs before inclusion  
(1 to 9 v  ≥10)
0.17 0.38
0.44
0.47
0.16 to 1.24
0.17 to 1.30
0.122
0.148
Invasive SCC and SCC in situ 
(Bowen’s disease)
- No adjustment
- Adjustment for age and   
No. of SCCs before inclusion  
(1 to 9 v  ≥10)
0.78 1.81
0.43
0.39
0.24 to 0.77
0.24 to 0.66
0.004
<0.001
Abbreviations:  RR, relative risk; CI, confidence interval; SCC, squamous cell carcinoma.
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AbsTrAcT
background
Albuminuria is a marker of glomerular damage and a predictor of renal outcome 
in patients with kidney disease. However, deterioration of renal function is best 
correlated with tubulointerstitial injury. Urinary excretion of α1-microglobulin reflects 
tubulointerstitial damage and improves prediction of outcome in patients with 
glomerular diseases. Until now, little is known about the value of α1-microglobulin for 
predicting graft outcome in renal transplant patients.
Methods
In a cross sectional pilot study we evaluated α1-microglobulin in four different categories 
of transplant recipients (HLA-compatible, never transplant rejection, with transplant 
rejection and with chronic allograft nephropathy). In a prospective study samples 
were collected at 3 and 12 months after transplantation of patients who received a 
renal transplant between 2006 and 2010. Urinary α1-microglobulin, albumin, and IgG 
excretion were measured and related to progression of renal dysfunction.
results
Cross sectional study:  41 patients were studied of which 14 received an HLA-compatible 
kidney. Urinary α1-microglobulin excretion exceeded normal values in the majority of 
patients who had received an HLA compatible kidney transplant and had stable renal 
function. Urinary α1-microglobulin excretion was higher in patients with rejection or 
chronic allograft nephropathy and correlated with eGFR (r = -0.56; P < 0.001).
Prospective study: 139 patients were studied. Of these, 34 patients had graft rejection 
within 3 months after transplantation. Median follow-up after renal transplantation 
was 48 months, eGFR increased by 0.6 ml/min/1.73m2/yr during follow-up, 10 patients 
died and 3 patients developed graft failure. Urinary α1-microglobulin excretion was 
above normal in 86% of patients at 3 months and in 78% of patients at 12 months 
after transplantation. Increased urinary α1-microglobulin excretion at 12 months was 
associated with the type of donor, gender of the recipient, eGFR, albuminuria, α1-
microglobulin at 3 months and prior rejections. There was no correlation between 
urinary α1-microglobulin excretion and the change in eGFR during follow-up.
conclusions
The majority of patients after kidney transplantation has elevated levels of urinary 
α1–microglobulin excretion at 3 and 12 months after transplantation. Urinary α1-
microglobulin does not predict renal outcome. Our data suggest that elevated urinary 
α1-microglobulin reflects fibrosis and not active tubular cell injury.
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InTroducTIon
The number of patients requiring renal replacement therapy (RRT) because of end-
stage renal disease (ESRD) is still increasing. In 2010, the overall incidence rate of RRT 
among all registries reporting to the ERA–EDTA Registry was 123 per million population 
(pmp). The overall prevalence of RRT among all registries reporting to the ERA–EDTA 
Registry was 741 pmp. Five-year survival rates on RRT are low, at only 46%.1 Kidney 
transplantation is the preferred modality for renal replacement therapy, and graft loss 
due to acute rejection has been greatly reduced over the past few years. However, 
late graft loss remains an important problem and little progress has been achieved.2 
In the first ten years after transplantation, chronic allograft nephropathy (CAN) is 
the most prevalent cause of allograft dysfunction, though its pathogenesis remains 
elusive.3 Already before clinically apparent kidney dysfunction, histological changes are 
present.4 Although any anatomical compartment can be involved in CAN, interstitial 
accumulation of extracellular matrix in association with progressive tubular atrophy is 
mostly observed.5 
Proteinuria is a common finding in kidney diseases. An increased excretion of proteins 
can result from a loss of glomerular barrier function, a decrease of the tubular protein 
reabsorption, or a combination of both. In general, glomerular injury is characterized by 
urinary losses of high molecular weight proteins such as albumin, and IgG. In contrast, 
tubular disorders are characterized by increased urinary losses of low-molecular weight 
proteins (LMWPs). Of the LMWPs α1-microglobulin and β2-microglobulin, it is known 
that they are readily filtered by the glomerulus and reabsorbed and catabolized by 
proximal tubular cells. When the proximal tubular handling of these LMWPs is disturbed, 
they appear in the urine.6 LMWPs and IgG are valuable in predicting the progression 
of renal function decline in patients with proteinuric glomerular diseases such as focal 
segmental glomerulosclerosis or membranous nephropathy.7,8 However, little is known 
about the possible value of measuring these proteins in the transplantation setting.
Therefore, in a pilot experiment we measured α1-microglobulin and IgG in a cross 
sectional study. We subsequently measured α1-microglobulin and IgG in a prospective 
cohort of kidney transplant patients at 3 and 12 months after kidney transplantation, 
and correlated the levels with graft loss, and progression of renal dysfunction.
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MATerIAls And MeTHods
Population
We analysed the data of adult patients at the Department of Nephrology, Radboud 
University Nijmegen Medical Centre. All subjects gave informed consent according to 
Dutch ethical regulations
Cross sectional study: 
This study was conducted between February and July 2006. The study included renal 
transplant recipients with a minimum follow-up of at least one year. We tried to include 
patients from different categories, i.e. HLA-compatible, never transplant rejection, with 
transplant rejection and with chronic allograft nephropathy. Urine and serum samples 
were obtained at one of their regular visits in our outpatient clinic. After a follow-up 
period of 8 years renal function, graft rejection and graft failure were studied.
Prospective study:
This study included patients who received a renal transplant between 2006 and 2010. 
Initial immunosuppression consisted of standard triple therapy with prednisone, 
mycophenolate, and a calcineurin inhibitor. Six months after transplantation 
mycophenolate was withdrawn in the majority of patients with the exception of patients 
with a higher rejection risk where triple therapy was continued. During the first year 
post transplantation, all patients visit our centre frequently according to protocol. Urine 
and serum samples of patients were obtained at 3 and 12 months post-transplantation. 
After the first year post transplantation renal function, graft rejection and graft failure 
was studied prospectively till 2014.
laboratory Measurements
In the blood samples, we assessed creatinine, albumin, and IgG. In urine samples, we 
measured creatinine, albumin, α1-microglobulin, and IgG. The concentrations of serum 
creatinine, urinary albumin, and urinary creatinine were determined with standard 
automated techniques. The concentrations of albumin, α1-microglobulin, and IgG 
were measured by immunonephelometry on a BNII nephelometer (Behring, Marburg, 
Germany) using antibodies whose specificity was checked by Ouchterlony double 
immunodiffusion and immunoelectrophoresis (Dako, Glostrup, Denmark).
Urinary excretion of alpha-1-microglobulin and renal outcome in renal transplant recipients 
81
Chapter
 6
calculations and definitions
Body mass index (BMI) was calculated as the ratio between weight and height squared. 
Mean arterial pressure was calculated as the diastolic pressure plus one third of the pulse 
pressure. The glomerular filtration rate (eGFR) was estimated using the abbreviated 
Modification of Diet in Renal Disease equation.9 Change in kidney function was defined 
as eGFR at the last follow-up visit after renal transplantation subtracted by eGFR at 3 
or 12 months after renal transplantation, divided by time from 3 or 12 months to last 
follow-up and expressed in ml/min/1.73m2/yr. Graft failure was censored for death and 
defined as return to dialysis or re-transplantation.
statistical analysis
Parameters between groups were compared using the Kruskal-Wallis test for 
nonparametric continuous data, independent t-test for parametric data and chi-square 
test for categorical data. Spearman’s bivariate correlation test was used to examine 
correlations between nonparametric data. All values are given as mean (±SD) or median 
[interquartile range] where appropriate. All statistics were performed using SPSS 
software (IBM SPSS statistics 21).  P<0.05 was considered significant.
resulTs
Cross sectional study: 
Between February and July 2006 we studied 41 renal transplant recipients with a 
minimum follow-up of at least one year. The characteristics of the patients are presented 
in table 1. 
Patients with chronic allograft nephropathy excreted more albumin and IgG than other 
patient categories (P<0.001), reflecting the glomerular damage in chronic allograft 
nephropathy.
Urinary α1-microglobulin excretion was higher in the patients with previous rejection or 
chronic allograft nephropathy and correlated with eGFR (r = -0.56; P < 0.001).
It was evident that patients who received an HLA-compatible living related donor 
kidney also showed more or less proteinuria. Fifty percent of patients who received an 
HLA-compatible kidney had a urinary α1-microglobulin excretion exceeding 20 mg/10 
mmol creatinine (normal value < 15 mg/10 mmol creatinine). These patients did not 
differ significantly from patients with urinary α1-microglobulin excretion below  20 
mg/10 mmol creatinine with respect to gender (both groups  male:female 2:5), recipient 
age (48 in low vs 57 years in high urinary α1-microglobulin; P=0.08), mean arterial blood 
pressure (107 in low vs 103 mmHg in high urinary α1-microglobulin; P=0.54), eGFR 
(57 in low vs 65 ml/min/1.73m2 in high urinary α1-microglobulin; P=0.48), years after 
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transplantation (9.6 in low vs 9.0 years in high urinary α1-microglobulin; P=0.87), and 
donor age (38 in low vs 45 years in high urinary α1-microglobulin; P=0.22). All patients 
who received an HLA-compatible kidney had a stable renal function in the year before 
the measurements. Nobody developed transplant rejection in 8 years follow-up. Four 
patients died with a functional graft within 8 years follow-up. The remaining patients 
all kept a stable renal function in 8 years follow-up. Even the patient with the highest 
urinary α1-microglobulin excretion of 82 mg/10mmol creatinine had a stable renal 
function 8 years after the measurement took place (serum creatinine 109 µmol/l).
Table 1. Urinary proteinuria after renal transplantation in different patient categories (cross sectional data).
HLA-
compatible
Never transplant 
rejection
Transplant 
rejection
Chronic allograft 
nephropathy
No. of patients 14 10 9 8
Age (years) 53 ± 10 51 ± 20 42 ± 16 49 ± 12
Gender (male:female) 4:10 6:4 8:1 5:3
Mean arterial pressure (mmHg)
Amount of antihypertensiva
104 ± 13
1.5 ± 1.0
98 ± 9
2.4 ± 0.9
103 ± 7
2.0 ± 1.0
104 ± 7
2.6 ± 1.3
Immunosuppression:
- Calcineurin inhibitor and steroids
- Azathioprine/MMF and steroids
2
12
6
4
6
3
0
8
Donor:
- Age (years)
- Gender (male:female)
- Type (living:postmortal)
41 ± 11
5:9
14:0
53 ± 13
7:3
4:6
43 ± 18
4:5
5:4
39 ± 19
4:4
3:5
Serum creatinine (µmol/l) 104 ± 29 152 ± 47 187 ± 72 163 ± 79
eGFR MDRD (ml/min/1.73m2) 61 ± 19 44 ± 13 41 ± 14 48 ± 26
Albuminuria  
(mg/10 mmol creatinine)
35 [8-77] 9 [7-66] 164 [37-464] 1700 [397-696]
Urinary α-1-microglobulin  
(mg/10 mmol creatinine)
17 [8-24] 38 [7-78] 62 [17-96] 68 [10-149]
Urinary IgG (mg/10 mmol creatinine) 4.0 [2.0-9.0] 4.8 [2.0-11.1] 20.4 [7.8-24.8] 92.6 [24.4-82.1]
Time after transplantation (years) 9.9 [3.8-11.6] 4.5 [3.5-10.7] 7.5 [3.1-14.2] 9.8 [6.9-13.9]
Data are depicted as mean±standard deviation or median [interquartile range] where appropriate.
In the patient category without transplant rejection (not HLA compatible and no CAN) 
urinary α1-microglobulin was elevated >35 mg/10 mmol creatinine in six patients. None 
of these six patients kept a stable renal function in 8 years follow-up. In three of these 
six patients eGFR was already decreasing in the year prior to the measurement. The 
other four patients in this category had a α1-microglobulin excretion < 10 mg/10mmol 
creatinine of which three patients kept a stable renal function during 4 years follow-
up. In the fourth patient renal function deteriorated slowly, probably due to calcineurin 
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inhibitor toxicity. In this patient category without earlier transplant rejection urinary 
IgG was significantly correlated with albuminuria (r=0.90, P<0.01) and α1-microglobulin 
excretion (r=0.68, P=0.03). α1-microglobulin excretion significantly correlated with eGFR 
(r=-0.86, P<0.01). 
In the patient category with prior transplant rejection the two patients with urinary 
α1-microglobulin < 10 mg/10mmol creatinine kept a stable renal function during 
follow-up. Retrospectively five patients with urinary α1-microglobulin > 50 mg/10mmol 
creatinine already had albuminuria at the time measurements took place. In all these 
patients renal function deteriorated during follow-up. In this patient category with prior 
transplant rejection albuminuria was significantly correlated with urinary IgG (r=0.94, 
P<0.01) and α1-microglobulin excretion (r=0.79, P=0.04). 
In the patient category with chronic allograft nephropathy the three patients with 
urinary α1-microglobulin < 15 mg/10mmol creatinine kept a stable renal function 
during follow-up and in all of the four patients with α1-microglobulin > 80 mg/10mmol 
creatinine renal function deteriorated. In this patient category with chronic allograft 
nephropathy urinary IgG was significantly correlated with albuminuria (r=0.96, P<0.01) 
and α1-microglobulin excretion significantly correlated with eGFR (r=-0.81, P=0.02).
Prospective study:
We evaluated 139 patients who received a kidney transplant in the Radboud University 
Medical Centre between January 2006 and February 2010 and had urine samples 
available at 3 and 12 months. The characteristics of the patients are presented in table 
2. Initial immunosuppression consisted of standard triple therapy with prednisone, 
mycophenolate and a calcineurin inhibitor. Three months after transplantation 100% 
of the patients were on a calcineurin inhibitor and one year after transplantation in 
93% of patients a calcineurin inhibitor was part of the immune suppressive regimen. 
Median follow-up after renal transplantation was 48 months. Thirty-six patients suffered 
rejection, which occurred in the majority (n=34) within 3 months after transplantation. 
At 3 months patients who had developed graft rejection within 3 months after 
transplantation did differ significantly from patients without graft rejection with 
respect to albuminuria (43 [18-146] versus 38 [13-75] mg/10 mmol creatinine; P=0.021) 
and urinary α1-microglobulin (55 [22-101] versus 38 [22-59] mg/10 mmol creatinine; 
P=0.003).
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Table 2. Characteristics of patients in the prospective study.
No. of patients (% male) 139 (61)
Age at transplantation (yr) 47 ± 14     
BMI 3 months after transplantation (kg/m2) 25 ± 4       
MAP 3 months after transplantation (mmHg) 99 ± 10     
Calcineurin inhibitors (%)
- 3 months
- 12 months
- Last FU
100    
93    
79    
eGFR (ml/min/1.73 m2)
- 3 months
- 12 months
53 ± 16     
50 ± 15      
Albuminuria (mg/10 mmol creatinine)
- 3 months
- 12 months
38 [14-83]     
32 [11-85]     
Urine α1-microglobulin (mg/10 mmol creatinine)
- 3 months
- 12 months
40 [23-65]     
30 [16-50]
Urinary IgG (mg/10 mmol creatinine)
- 3 months
- 12 months
7.1 [4.2-11.1]     
8.4 [4.3-15.8]     
Rejection (n (%))
- within 3 months after tx
- after
36 (15.9)
34 (24.5)
2 (1.4)
Time to rejection (months) 0.3 [0.2-0.8]
Graft failure at max FU (n (%))
- recurrence (n (%)) 
- transplant rejection (n (%))
- unknown (n (%))
3 (2.2)
1 (0.7)
1 (0.7)
1 (0.7)
Death with functioning graft (n (%)) 10 (7.1)
Time to patient or graft failure (months) 40 [29-47] 
Change eGFR 3-12 months (ml/min/1.73m2)
Change eGFR 3 months-last FU(ml/min/1.73m2/yr)
Change eGFR 12 months-last FU(ml/min/1.73m2/yr)
-2.9 [-8.7-3.4]     
-0.2 [-3.3-2.3]      
0.6 [-2.0-3.5]    
Follow-up (months) 48 [36-48]    
Data are depicted as mean±standard deviation or median [interquartile range] where appropriate.
Abbreviations: BMI, body mass index; MAP, mean arterial pressure; FU, follow-up.
Urinary α1-microglobulin excretion was above 15 mg/10 mmol creatinine in 86% of 
patients at three months and in 78% of patients at twelve months after transplantation. 
Increased urinary α1-microglobulin at twelve months was associated with the type of 
donor, gender of the recipient, eGFR, albuminuria, α1-microglobulin at 3 months and 
prior rejections (Table 3). Median change in eGFR between 12 months and end of 
follow-up was 0.6 ml/min/1.73m2/yr, indicating that renal function remained relatively 
stable during follow-up. 
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Table 3. Urinary α1-microglobulin per quartile at 12 months after renal transplantation 
α1-microglobulin ratio (mg/10 mmol creatinine) at 12 months
2.7-15.6
(n=35)
15.6-29.4
(n=35)
29.4-50.0
(n=34)
50.0-311.9
(n=35)
P
Postmortal donor (n (%)) 12 (34) 15 (43) 8 (24) 20 (57) 0.03
Gender (male:female) 17:18 18:17 24:10 26:9 0.06
Recipient age at transplantation (yr) 47 ± 14 45 ± 13 45 ± 14 49 ± 14 0.36
Calcineurin inhibitors (%)
- 3 months
- 12 months
- Last follow-up
100
100
63
100
94
49
100
91
62
100
86
43
0.13
0.25
Smoking during follow-up (n (%)) 1 (3) 2 (6) 3 (9) 9 (26) 0.04
eGFR (ml/min/1.73 m2)
- 3 months
- 12 months
- Last follow-up
58 ± 16
60 ± 15
61 ± 18
50 ± 16
50 ± 15
53 ± 15
47 ± 12
47 ± 12
49 ± 16
43 ± 13
44 ± 1
46 ± 16
<0.01
<0.01
<0.01
Albuminuria (mg/10 mmol creatinine)
- 3 months
- 12 months
28 [10-51]
15 [5-41]
39 [12-81]
28 [9-89]
47 [27-115]
34 [17-117]
43 [16-94]
60 [17-177]
0.22
0.08
α1-microglobulin (mg/10 mmol 
creatinine)
- 3 months
- 12 months
- Delta 3-12 months
17 [12-38]
10 [6-14]
-9[-27- - 2]
28 [23-45]
22 [21-28]
-5 [-27-0]
46 [34-63]
38 [33-43]
-6 [-26-2]
79 [53-135]
75 [55-113]
-1 [-35-29]
<0.01
<0.01
0.35
Rejection (n (%)
- < 3 months after transplantation
- > 3 months after transplantation
6 (17)
6 (17)
0 (0)
7 (20)
6 (17)
1 (3)
8 (24)
8 (24)
0 (0)
15 (43)
14 (40)
1 (3)
0.06
0.09
0.57
Graft failure at max follow-up (n (%)) 1 (3) 0 (0) 0 (0) 2 (6) 0.30
Death with functioning graft (n (%)) 2 (6) 0 (0) 5 (15) 3 (9) 0.12
Change eGFR
- 3 -12 months  
(ml/min/1.73m2)
- 3 months-last follow-up 
(ml/min/1.73m2/yr)
- 12 months-last follow-up 
(ml/min/1.73m2/yr)
 
-2.9 [-9.1-3.2]
-0.9 [-3.6-2.8]
1.0 [-1.4-6.0]
-3.9 [-10.0- -1.4]
-1.0 [-3.3-2.1]
0.2 [-2.3-3.6]
-2.1 [-6.9-3.8]
-0.3 [-3.3-2.3]
0.3 [-3.0-2.5]
-2.6 [-8.4-4.5]
0.9 [-3.0-2.9]
0.4 [-0.9-4.0]
0.97
0.94
0.63
Follow-up (months) 36 [36-48] 48 [36-60] 36 [27-48] 48 [36-48] 0.10
Data are depicted as mean ± standard deviation or median [interquartile range] where appropriate.
Three patients (2%) developed graft failure and 10 patients (7%) died with a functioning 
graft. Median time to patient or graft failure was 40 months. There was no association 
between urinary α1-microglobulin and change in eGFR during follow-up. Because only 
three patients developed graft failure nothing can be concluded about the predictive 
value of α1-microglobulin on graft failure. 
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In a subgroup of 68 patients with α1-microglobulin > 30mg/10mmol creatinine at 12 
months after transplantation renal function deteriorated in 31 patients and improved 
in 37 patients. Patients with renal function deterioration did differ significantly from 
patients with renal function improvement with respect to albuminuria (77 [21-321] 
versus 35 [16-68] mg/10 mmol creatinine; P=0.019).
dIscussIon
In the cross sectional study micro-albuminuria was noted in most patients. As expected, 
patients with chronic allograft nephropathy and to a lesser extent patient with earlier 
transplant rejection showed higher levels of urinary albumin and IgG, reflecting 
glomerular damage. This observation seems to be very reliable because urinary IgG was 
very well correlated with albuminuria in these patient categories. 
Not unexpectedly, these patients also excreted larger amounts of α1-microglobulin, 
compatible with the known tubulointerstitial scarring that is observed in biopsies of 
patients with chronic allograft nephropathy. Of note, renal function deteriorated in most 
patients, with the exception of the 5 patients with normal α1-microglobulin excretion. 
Our hypothesis that urine α1-microglobulin excretion could be a predictor of outcome 
was further supported by the observation that in patients without a previous rejection 
increased α1-microglobulin excretion predicted an unfavourable outcome. However, 
increased α1-microglobulin excretion can also reflect earlier acquired damage, because 
in some patients eGFR was already decreasing prior to the measurement.
Surprisingly, 50% of patients who received an HLA-compatible living related kidney 
also showed urinary α1-microglobulin excretion exceeding 20 mg/10 mmol creatinine. 
In this category, even in patients with the highest values of urinary α1-microglobulin, 
renal function did not deteriorate during follow-up. These findings suggest that higher 
values of urinary α1-microglobulin can sometimes be accepted as “normal” after renal 
transplantation and do not necessarily reflect active, progressive tubulointerstitial 
injury.
In view of these somewhat contrasting results, and the limitations of a cross sectional 
study, we planned a prospective study to evaluate the potential of urinary α1-
microglobulin and IgG for predicting outcome after kidney transplantation. Most 
importantly, we found no significant correlation between α1-microglobulin at 3 or 12 
months and future graft failure or change in eGFR during follow-up. This apparent lack 
of predictive power might relate at least in part to limitations of the study, in particular 
the small number of events (only three graft failures) and the relatively short follow-up 
period with relatively stable renal function.
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Although we included quite a large amount of patients, our study may be criticized 
because we collected urine samples at three and twelve months after transplantation 
in only 30% of all patients transplanted between 2006-2010. The study was done 
during routine patient care. This caused missing data due to patient and physician 
incompliance. This might have caused some selection bias. Patients with graft failure 
within one year after transplantation were also not studied, because we only included 
patients where we collected urine at 3 and 12 months after transplantation. However 
we intended to investigate the long-term value of α1-microglobulin on renal function, 
future transplant rejection and graft failure and did not want to find a marker for already 
existing renal damage. Unfortunately, we were not able to draw any conclusion on the 
prognostic value of α1-microglobulin on graft failure because of the very limited events 
that took place in the relatively short follow-up. Renal function remained relatively stable 
during follow-up with a small improvement in median eGFR between 12 months and 
end of follow-up of 0.6 ml/min/1.73m2/yr. Our study might have been underpowered 
to proof an existing association between urinary α1-microglobulin and change in eGFR 
during follow-up, because in only 19 patients (14%) eGFR decreased more than 3 ml/
min/1.73m2/yr.
Urinary α1-microglobulin excretion was above normal in 86% of patients at three months 
and in 78% of patients at twelve months after transplantation. Increased urinary α1-
microglobulin at twelve months was associated with the type of donor, gender of the 
recipient, eGFR, albuminuria and prior rejections. This suggests that in transplanted 
patients an elevated urinary α1-microglobulin reflects fibrosis and not active tubular 
cell injury.  How can we explain that urinary α1-microglobulin do predict renal failure 
in glomerular diseases, especially membranous nephropathy, but don’t predict renal 
failure in transplanted patients? We propose that increased α1-microglobulin excretion 
in glomerular diseases is more a reflection of ongoing tubulointerstitial inflammation 
instead of fibrosis.
Whether elevated urinary α1-microglobulin in transplanted patients might have 
implications for progression and outcome after longer observation periods will have to 
be explored in future studies with extended follow-up.
In conclusion the majority of patients after kidney transplantation has elevated levels 
of urinary α1-microglobulin at 3 and 12 months after transplantation. In the short term, 
urinary α1-microglobulin and IgG do not predict renal outcome in this relatively limited 
exploratory study. Our data suggest that elevated urinary α1-microglobulin reflects 
fibrosis and not active tubular cell injury. However, the value of α1-microglobulin and 
IgG in the setting of renal transplantation warrants a larger study involving more events 
and longer follow-up.
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AbsTrAcT
Introduction. As the beginning of living-donor kidney transplantation, physicians have 
expressed concern about the possibility that unilateral nephrectomy can be harmful to 
a healthy individual. To investigate whether the elevated intra-abdominal pressure (IAP) 
during laparoscopic donor nephrectomy causes early damage to the remaining kidney, 
we evaluated urine biomarkers after laparoscopic donor nephrectomy. 
Methods.  We measured albumin and alpha-1-microglobulin (α-1-MGB) in urine 
samples collected during and after open and laparoscopic donor nephrectomy and 
laparoscopic cholecystectomy and colectomy. Additionally, kidney injury molecule 1 
(KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) were measured in urine 
samples collected during and after laparoscopic donor nephrectomy and colectomy. 
The same biomarkers were studied in patients randomly assigned to standard or low 
IAP during laparoscopic donor nephrectomy. 
results. We observed a peak in urinary albumin excretion during all procedures. Urine 
α-1-MGB rose in the postoperative period with a peak on the third postoperative 
day after donor nephrectomy. Urine α-1-MGB did not increase after laparoscopic 
cholecystectomy and colectomy. After laparoscopic nephrectomy, we observed slight 
increases in urine KIM-1 during surgery and in urine NGAL at day 2-3 after the procedure. 
After laparoscopic colectomy, both KIM-1 and NGAL were increased in the postoperative 
period. There were no differences between the high- and low-pressure procedure. 
conclusion. Elevated urinary α-1-MGB suggests kidney damage after donor 
nephrectomy, occurring irrespective of IAP during the laparoscopic procedure. 
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InTroducTIon
Kidney transplantation remains the treatment of choice for patients with end-stage 
renal disease (ESRD). However, the gap between the demand and supply of deceased 
donor kidneys continues to grow. Living-donor programs have gradually become an 
attractive strategy to expand the donor pool for kidney transplantation. Grafts from 
living-related donors display superior function and longer survival than those obtained 
from deceased donors.1,2 Living-donor surgery has changed radically in the past decade 
as laparoscopic techniques have supplanted open nephrectomy. In a meta-analysis, 
laparoscopic donor nephrectomy was found to be associated with reduced analgetic 
consumption, shorter hospital stay, and faster return to normal physical functioning 
as compared to the open technique.3 As the beginning of living-donor kidney 
transplantation, physicians have expressed concern about the possibility that unilateral 
nephrectomy can be harmful to a healthy individual although survival and the risk of 
ESRD in carefully screened kidney donors appear to be similar to those in the general 
population.4 To monitor renal problems after donor nephrectomy, we closely monitored 
the urine of the donor after donor nephrectomy. 
We observed increased levels of urinary alpha-1-microglobulin (α-1-MGB), a marker of 
renal tubular dysfunction, in several patients after laparoscopic donor nephrectomy. 
This suggested that the procedure may cause some harm to the remaining kidney. It 
is well known that the kidney is especially vulnerable to the effects of intra-abdominal 
pressure (IAP) due to its anatomical position and blood supply. It is now also accepted 
that the adverse effects of elevated IAP on renal function can occur at lower levels of IAP, 
long before development of overt abdominal compartment syndrome.5 To investigate 
whether the IAP during laparoscopic donor nephrectomy causes early damage to the 
remaining kidney, we evaluated urine biomarkers after laparoscopic donor nephrectomy 
in two studies.
PATIenTs And MeTHods
study 1
Patients
Between January 2010 and July 2011, we included 10 donors who underwent a 
laparoscopic donor nephrectomy at the Radboud University Medical Centre. For 
comparison, we studied nine patients who underwent a laparoscopic cholecystectomy 
in the Isala Zwolle, and 12 donors who underwent an open donor nephrectomy in the 
University Medical Centre Utrecht. Inclusion criteria were as follows: age>18 years and 
estimated GFR>60 ml/min/1.73m2 (abbreviated MDRD formula). Exclusion criteria were 
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as follows: blood pressure>160/90 mmHg and/or use of antihypertensive medication 
and/or the presence of (micro) albuminuria before kidney donation.
Between July and September 2014, we additionally included eight patients who 
underwent a laparoscopic colectomy as a second control group, because of the 
short duration of laparoscopic cholecystectomy in comparison with laparoscopic 
nephrectomy.
Procedure
In all patients, a urinary catheter was inserted directly preoperatively. In laparoscopic 
procedures, IAP during the period of pneumoperitoneum was maintained at 12-14 
mmHg. A combination of remifentanil, fentanyl, sufentanil, propofol, and rocuronium 
was used for anesthesia.
Urine samples were obtained preoperative, at start operation (after insertion of the 
urinary catheter), directly postoperative (all urine produced during the procedure), 
on the first, second, and third postoperative day and finally at about 4-6 weeks 
postoperatively. 
Outcome measures 
Serum creatinine was measured at baseline (day 0) and postoperative at day 1, 2, 3, 
and at about 4-6 weeks postoperatively. Urine samples were centrifuged and urine 
supernatants were stored in 1 ml aliquots at -80 ºC until further use. Creatinine, albumin 
and α-1-MGB   were measured in all collected urine samples. After analysis of all data, 
frozen-stored urine samples of the laparoscopic procedures were used for measurement 
of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin 
(NGAL).
Patients provided informed consent. The local ethical committee waived the requirement 
for formal approval of this study.
study 2
Patients
The second study was performed using stored urine samples obtained from 20 donors 
who participated in the recent Leopard study.6 In summary, this randomized, double-
blinded study included 20 donors undergoing a laparoscopic donor nephrectomy 
between September 2011 and January 2012 at the Radboud University Medical Center. 
This study investigated the effect of low-pressure pneumoperitoneum (7 mmHg) versus 
normal pressure pneumoperitoneum (14 mmHg) on donors’ comfort [6]. All Dutch 
speaking individuals who were medically suitable for donation were eligible. Exclusion 
criteria were a history of kidney or adrenal gland surgery at the side of donation. 
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Potential participants were informed about the study at the outpatient clinic. Informed 
consent was mandatory for inclusion. Approval for this study was given by the Central 
Committee on Research involving Human Subjects of the Radboud University Medical 
Centre Nijmegen and has therefore been performed in accordance with the ethical 
standards laid down in an appropriate version of the 2000 Declaration of Helsinki as 
well as the Declaration of Istanbul 2008.
Procedure
Randomization using a single block was used to create 20 sealed envelopes numbered 
from 1 to 20, containing instructions for the setting of the carbon dioxide inflator, 
at, respectively 7 mmHg for the experimental and 14 mmHg for the control arm. 
Prior to the operation a nurse who was not involved in the operation installed the 
pneumoperitoneum pressure. All other personnel were blinded for the allocation of 
treatment.
General anesthesia was induced using a standardized protocol, which included 
remifentanil, propofol, and rocuronium. Further details concerning the randomization, 
operation, and anesthesia procedures were described earlier.6
Urine samples were taken preoperatively (day -1), directly postoperatively (urine 
produced during the procedure from insertion of a urinary catheter till closure), the first, 
second, and third postoperative day, and finally 1 week postoperative. All samples were 
centrifuged and urine supernatants were stored in 1 ml aliquots at -80 ºC until further 
use. No urine samples were obtained directly preoperatively (after insertion of a urinary 
catheter) in this study. 
Outcome measures
Donor serum creatinine was measured at baseline (day -1) and postoperative at day 1, 
2, and 7. Urinary output and saline infusion were also registered carefully in the periods 
from first incision to insufflation, from insufflation to desufflation (pneumoperitoneum 
phase), and from desufflation to closure. 
Creatinine, albumin, α-1-MGB, KIM-1, and NGAL were measured in all collected urine 
samples. All outcome assessments were performed on coded samples by investigators 
who were blinded for the treatment group to which each sample belonged.
statistical analysis 
Parameters between groups were compared using independent t-test or ANOVA for 
parametric continuous data. Mann-Whitney U-test or Kruskal-Wallis test was used 
for nonparametric continuous data. Chi-square test was used for categorical data. 
Parameters within groups were compared using related-samples Wilcoxon’s signed-rank 
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test. Categorical variables are presented as numbers and continuous variables as mean 
values (± standard deviation) or median values [range]. P-values <0.05 were considered 
significant. Data on urinary biomarkers are presented in figures as median values. To test 
significance of changes between groups, a quadratic mixed model analysis was used. All 
statistics were performed using SPSS software, version 20.0 (SPSS Inc., Chicago, IL, USA).
resulTs
study 1
Patients’ characteristics
Patients’ characteristics and outcome measures are presented in Table 1. The average 
time of elevated IAP was 34 ± 19 min in laparoscopic cholecystectomy compared with 99 
± 19 min in laparoscopic donor nephrectomy (p < 0.001). Most baseline characteristics 
of patients in the laparoscopic colectomy group, including the average time of elevated 
IAP of 86 ± 35 min, were comparable with the characteristics of the patients in the 
laparoscopic donor nephrectomy group, with the exception of older age (p = 0.026) 
and higher ASA classification (p = 0.023) in the colectomy group. 
Urinary biomarkers
Urinary biomarkers are presented in Table 1 and Figs 1a, 2a,3a and 4a. Increased levels of 
urine albumin were observed in the urine samples collected during the procedure in the 
open donor nephrectomy, laparoscopic donor nephrectomy as well as in laparoscopic 
cholecystectomy and colectomy group (Fig. 1a). Albuminuria disappeared rapidly after 
the procedure.
Urine α-1-MGB followed a different time course. We observed a significant increase 
of urine α-1-MGB after laparoscopic donor nephrectomy, with a peak on the third 
postoperative day (Fig. 2a). A similar although more variable pattern was observed in 
donors after open nephrectomy. In contrast, in patients who underwent a laparoscopic 
cholecystectomy or colectomy urine α-1-MGB was not significantly elevated in the 
postoperative period.
In view of these discordances, we analysed the recently identified urinary biomarkers 
KIM-1 and NGAL in the stored urine samples of patients in the laparoscopic nephrectomy 
and laparoscopic colectomy group. Remarkably, after laparoscopic nephrectomy, 
urinary excretion of KIM-1 increased slightly in the perioperative period, in parallel 
with the albuminuria. In contrast, urine KIM-1 increased more after laparoscopic 
colectomy and exceeded normal values in the postoperative period. After laparoscopic 
nephrectomy urine NGAL followed the pattern of α-1-MGB with a peak in excretion on 
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the 2nd or 3rd postoperative day. Similarly, variable increases in urine NGAL were noted 
after colectomy (Figs 3a and 4a).
There was no relationship between the duration of IAP during laparoscopic donor 
nephrectomy and the amount of urinary α-1-MGB excretion in the postoperative period. 
Urinary α-1-MGB excretion did not correlate with postoperative rise in serum creatinine 
after laparoscopic donor nephrectomy. There was no correlation between urine α-1-
MGB and urine NGAL.
study 2
Main outcome data have been reported.6
Patients’ characteristics
Patients’ characteristics and outcome measures are presented in Table 2. Operation time 
and time of elevated IAP were significantly longer in patients operated with low-pressure 
pneumoperitoneum compared with normal pressure pneumoperitoneum. Patients 
operated with low-pressure pneumoperitoneum showed a higher urine output during 
the pneumoperitoneum phase compared with normal pressure pneumoperitoneum (p 
= 0.041).
Urinary biomarkers
Urinary biomarkers are presented in Table 2 and Figs 1b, 2b, 3b and 4b. The data closely 
resembled the results of study 1. We observed a significant increase in urinary albumin 
excretion during the procedure, whereas urine α-1-MGB was not increased during 
surgery, but rose significantly in the postoperative period with a peak on the third 
postoperative day (Figs 1b and 2b). Urine KIM-1 paralleled albumin, whereas NGAL 
followed the same pattern as α-1-MGB.  
There were no significant differences between the high- and low-pressure procedure 
(Figs 1b, 2b, 3b and 4b).
Chapter 7
96
Ta
bl
e 
1.
 B
as
el
in
e 
ch
ar
ac
te
ris
tic
s 
an
d 
ou
tc
om
e 
m
ea
su
re
s 
st
ud
y 
1.
 
La
pa
ro
sc
op
ic
ch
ol
ec
ys
te
ct
om
y
(n
=9
)
La
pa
ro
sc
op
ic
co
le
ct
om
y
(n
=8
)
La
pa
ro
sc
op
ic
ne
ph
re
ct
om
y
 (n
=1
0)
O
pe
n
N
ep
hr
ec
to
m
y
(n
=1
2)
P-
va
lu
e
(b
et
w
ee
n 
gr
ou
ps
)
Ag
e 
(y
ea
rs
)
46
.6
 (1
6.
4)
65
.7
 (8
.9
)
55
.6
 (8
.1
)
47
.5
 (1
1.
3)
0.
00
5
M
al
e 
ge
nd
er
3
4
6
3
ns
BM
I (
kg
/m
2 )
26
.4
 (3
.7
)
28
.3
 (5
.5
)
25
.3
 (3
.3
)
26
.7
 (2
.5
)
ns
Se
ru
m
 c
re
at
in
in
e 
(µ
m
ol
/l)
66
 (1
2)
78
 (1
4)
69
 (1
0)
78
 (9
)*
ns
A
SA
 c
la
ss
ifi
ca
tio
n†
   
I (
he
al
th
y)
   
II 
or
 II
I
9 0
4 4
10 0
12 0
<0
.0
01
O
pe
ra
tio
n 
le
ng
th
 (m
in
)
   
Sk
in
-t
o-
sk
in
 ti
m
e
   
Pn
eu
m
op
er
ito
ne
um
61
 (1
8)
34
 (1
9)
13
2 
(5
7)
86
 (3
5)
13
6 
(2
2)
99
 (1
9)
17
9 
(2
6)
-
<0
.0
01
<0
.0
01
M
ea
n 
ar
te
ria
l p
re
ss
ur
e
   
D
ur
in
g 
op
er
at
io
n
75
 (1
1)
77
 (4
)
79
 (1
1)
71
 (6
)
ns
U
rin
e 
ou
tp
ut
 (m
l/h
)
   
D
ur
in
g 
op
er
at
io
n
12
1 
(8
1)
10
1 
(9
4)
55
 (2
9)
56
 (5
2)
ns
In
fu
si
on
 v
ol
um
e 
(m
l/h
)
   
D
ur
in
g 
op
er
at
io
n
10
98
 (3
87
)
45
9 
(3
18
)
48
5 
(2
24
)
77
6 
(1
85
)
<0
.0
01
Se
ru
m
 c
re
at
in
in
e 
(µ
m
ol
/l)
   
4-
6 
w
ee
ks
 p
os
to
pe
ra
tiv
el
y
75
 (1
7)
n.
d.
10
6 
(1
8)
11
3 
(1
7)
<0
.0
01
A
lb
um
in
ur
ia
 (m
g/
m
m
ol
 c
re
at
in
in
e)
 ‡
   
Pr
eo
pe
ra
tiv
e
   
St
ar
t o
pe
ra
tio
n
   
D
ur
in
g 
op
er
at
io
n
   
Fi
rs
t p
os
to
pe
ra
tiv
e 
da
y
   
Se
co
nd
 p
os
to
pe
ra
tiv
e 
da
y
   T
hi
rd
 p
os
to
pe
ra
tiv
e 
da
y
   
4-
6 
w
ee
ks
 p
os
to
pe
ra
tiv
e
n.
d.
0.
7 
[0
.0
-2
.9
]
3.
0 
[0
.2
-3
1.
2]
#
0.
6 
[0
.3
-6
.3
]
n.
d.
0.
7 
[0
.3
-1
.3
]
0.
6 
[0
.3
-2
.0
]
0.
5 
[0
.2
-8
.8
]
1.
3 
[0
.4
-1
4.
0]
9.
2 
[2
.3
-1
8.
6]
2.
0 
[1
.0
-1
4.
1]
3.
1 
[1
.2
-5
.2
]
1.
4 
[0
.6
-5
.8
]
0.
9 
[0
.4
-2
.0
]
0.
9 
[0
.4
-2
.1
]
1.
4 
[0
.3
-4
.2
]
10
.7
 [5
.5
-3
9.
9]
#
2.
6 
[0
.5
-7
.9
]#
4.
5 
[0
.7
-1
3.
5]
#
2.
1 
[0
.6
-2
2.
4]
0.
9 
[0
.5
-2
.8
]
0.
3 
[0
.2
-5
.0
]
0.
5 
[0
.2
-2
1.
6]
  
3.
4 
[0
.9
-2
5.
0]
#
1.
6 
[0
.4
-6
.8
] 
1.
9 
[0
.3
-8
.4
]
2.
2 
[0
.9
-1
3.
0]
0.
7 
[0
.2
-3
.5
]
ns ns ns
0.
04
1
ns
0.
01
3
ns
Urinary biomarkers after donor nephrectomy
97
Chapter
 7
Ta
bl
e 
1.
 B
as
el
in
e 
ch
ar
ac
te
ris
tic
s 
an
d 
ou
tc
om
e 
m
ea
su
re
s 
st
ud
y 
1.
  (
Co
nt
in
ue
d)
La
pa
ro
sc
op
ic
ch
ol
ec
ys
te
ct
om
y
(n
=9
)
La
pa
ro
sc
op
ic
co
le
ct
om
y
(n
=8
)
La
pa
ro
sc
op
ic
ne
ph
re
ct
om
y
 (n
=1
0)
O
pe
n
N
ep
hr
ec
to
m
y
(n
=1
2)
P-
va
lu
e
(b
et
w
ee
n 
gr
ou
ps
)
U
rin
ar
y 
α-
1-
M
G
B 
(m
g/
m
m
ol
) §
   
Pr
eo
pe
ra
tiv
e
   
St
ar
t o
pe
ra
tio
n
   
D
ur
in
g 
op
er
at
io
n
   
Fi
rs
t p
os
to
pe
ra
tiv
e 
da
y
   
Se
co
nd
 p
os
to
pe
ra
tiv
e 
da
y
   T
hi
rd
 p
os
to
pe
ra
tiv
e 
da
y
   
4-
6 
w
ee
ks
 p
os
to
pe
ra
tiv
e
n.
d.
0.
6 
[0
.4
-2
.6
]
0.
6 
[0
.2
-1
.4
]
0.
3 
[0
.2
-1
.0
]
n.
d.
0.
4 
[0
.2
-1
.2
]
0.
4 
[0
.2
-0
.9
]
0.
3 
[0
.2
-3
.1
]
1.
1 
[0
.1
-2
.3
]
0.
9 
[0
.1
-2
.6
] 
0.
7 
[0
.2
-3
.3
]
1.
9 
[0
.4
-1
0.
6]
2.
1 
[0
.1
-9
.4
]
0.
4 
[0
.3
-2
.3
]
0.
7 
[0
.3
-1
.6
]
0.
3 
[0
.1
-1
.0
]
0.
4 
[0
.1
-0
.9
]
7.
6 
[3
.5
-1
2.
1]
#
10
.5
 [5
.3
-1
9.
1]
#
11
.2
 [3
.1
-1
3.
9]
#
2.
3 
[1
.2
-5
.9
]#
0.
6 
[0
.1
-2
.5
]
0.
3 
[0
.1
-6
.3
]
0.
8 
[0
.2
-8
.6
]
5.
6 
[1
.9
-1
6.
4]
#
7.
2 
[1
.7
-2
5.
5]
#
7.
2 
[3
.0
-2
1.
6]
#
2.
9 
[0
.9
-1
7.
5]
ns ns ns
<0
.0
01
0.
00
3
<0
.0
01
0.
00
1
KI
M
-1
 (µ
g/
m
m
ol
 c
re
at
in
in
e)
 ¶
   
Pr
eo
pe
ra
tiv
e
   
St
ar
t o
pe
ra
tio
n
   
D
ur
in
g 
op
er
at
io
n
   
Fi
rs
t p
os
to
pe
ra
tiv
e 
da
y
   
Se
co
nd
 p
os
to
pe
ra
tiv
e 
da
y
   T
hi
rd
 p
os
to
pe
ra
tiv
e 
da
y
   
4-
6 
w
ee
ks
 p
os
to
pe
ra
tiv
e
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
0.
16
 [0
.0
8-
0.
33
]
0.
03
 [0
.0
0-
0.
38
]
0.
23
 [0
.0
4-
0.
73
]#
0.
24
 [0
.0
7-
1.
51
]#
0.
86
 [0
.0
2-
4.
93
]#
0.
23
 [0
.0
0-
0.
44
]#
0.
10
 [0
.0
3-
0.
31
]
0.
02
 [0
.0
0-
0.
09
]
0.
08
 [0
.0
0-
0.
15
]
0.
08
 [0
.0
0-
0.
28
]
0.
03
 [0
.0
0-
0.
20
]
0.
05
 [0
.0
0-
0.
17
]
0.
04
 [0
.0
0-
0.
17
]
0.
00
 [0
.0
0-
0.
05
]
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
<0
.0
01
ns ns
0.
00
3
0.
00
1
0.
01
2
0.
00
5
N
G
A
L 
(µ
g/
m
m
ol
 c
re
at
in
in
e)
 ¶
   
Pr
eo
pe
ra
tiv
e
   
St
ar
t o
pe
ra
tio
n
   
D
ur
in
g 
op
er
at
io
n
   
Fi
rs
t p
os
tp
er
at
iv
e 
da
y
   
Se
co
nd
 p
os
to
pe
ra
tiv
e 
da
y
   T
hi
rd
 p
os
to
pe
ra
tiv
e 
da
y
   
4-
6 
w
ee
ks
 p
os
to
pe
ra
tiv
e
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
0.
7 
[0
.0
-3
.5
]
0.
5 
[0
.0
-2
.1
]
0.
2 
[0
.0
-1
2.
0]
0.
0 
[0
.0
-2
.6
]
5.
2 
[0
.0
-1
9.
4]
#
1.
6 
[0
.0
-2
7.
1]
#
1.
7 
[0
.0
-2
.3
]
0.
9 
[0
.0
-3
.2
]
0.
3 
[0
.0
-3
.3
]
0.
0 
[0
.0
-3
.3
]
1.
5 
[0
.0
-4
.9
]#
2.
6 
[0
.0
-1
8.
2]
#
1.
8 
[0
.8
-7
.3
]#
0.
7 
[0
.0
-2
0.
5]
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
n.
d.
ns ns ns ns ns ns ns
Ca
te
go
ric
al
 v
ar
ia
bl
es
 a
re
 p
re
se
nt
ed
 a
s 
nu
m
be
rs
 a
nd
 c
on
tin
uo
us
 v
ar
ia
bl
es
 a
s 
m
ea
n 
va
lu
es
 (s
ta
nd
ar
d 
de
vi
at
io
n)
 o
r m
ed
ia
n 
va
lu
es
 [r
an
ge
]. 
n.
d.
, n
ot
 d
et
er
m
in
ed
; 
KI
M
-1
, k
id
ne
y 
in
ju
ry
 m
ol
ec
ul
e 
1;
 α
-1
-M
G
B,
 a
lp
ha
-1
-m
ic
ro
gl
ob
ul
in
; N
G
A
L,
 n
eu
tr
op
hi
l g
el
at
in
as
e-
as
so
ci
at
ed
 li
po
ca
lin
.
* 
Se
ru
m
 c
re
at
in
in
e 
w
as
 im
ba
la
nc
ed
 b
et
w
ee
n 
gr
ou
ps
 d
ue
 to
 d
iff
er
en
ce
s 
in
 d
et
er
m
in
at
io
n 
m
et
ho
d 
(J
aff
e 
m
et
ho
d 
in
 o
pe
n 
ne
ph
re
ct
om
y 
gr
ou
p)
.
†A
m
er
ic
an
 S
oc
ie
ty
 o
f A
ne
st
he
si
ol
og
is
ts
 c
la
ss
ifi
ca
tio
n.
In
 so
m
e 
ca
se
s, 
th
e 
ur
in
e 
sa
m
pl
e 
fo
r a
 p
ar
tic
ul
ar
 ti
m
e 
po
in
t c
ou
ld
 n
ot
 b
e 
co
lle
ct
ed
 d
ue
 to
 in
su
ffi
ci
en
t u
rin
e 
pr
od
uc
tio
n 
du
rin
g 
su
rg
er
y,
 o
r b
ec
au
se
 it
 w
as
 im
po
ss
ib
le
 
to
 c
ol
le
ct
 a
 u
rin
e 
sa
m
pl
e 
on
 a
 s
pe
ci
fic
 p
os
to
pe
ra
tiv
e 
da
y:
 ‡
 2
4 
of
 2
25
 s
am
pl
es
 m
is
si
ng
; §
 2
9 
of
 2
25
 s
am
pl
es
 m
is
si
ng
; ¶
 4
 o
f 1
08
 s
am
pl
es
 m
is
si
ng
.
# 
p<
 0
.0
5 
co
m
pa
re
d 
w
ith
 s
ta
rt
 o
pe
ra
tio
n.
Chapter 7
98
Ta
bl
e 
2.
 B
as
el
in
e 
ch
ar
ac
te
ris
tic
s 
an
d 
ou
tc
om
e 
m
ea
su
re
s 
st
ud
y 
2.
 St
an
da
rd
 p
re
ss
ur
e
(n
=1
0)
Lo
w
-p
re
ss
ur
e
 (n
=1
0)
P-
va
lu
e
Ag
e 
(y
ea
rs
)
50
.7
 (8
.9
)
51
.6
 (1
0.
2)
ns
M
al
e 
ge
nd
er
3
7
ns
BM
I (
kg
/m
2 )
24
.9
 (2
.5
)
25
.7
 (3
.9
)
ns
Se
ru
m
 c
re
at
in
in
e 
(µ
m
ol
/l)
64
 (1
3)
70
 (1
4)
ns
A
SA
 c
la
ss
ifi
ca
tio
n*
   
I (
he
al
th
y)
   
II 
or
 II
I
10 0
10 0
ns
O
pe
ra
tio
n 
le
ng
th
 (m
in
)
   
Sk
in
-t
o-
sk
in
 ti
m
e
   
Pn
eu
m
op
er
ito
ne
um
11
1 
(1
9)
86
 (1
6)
14
9 
(8
6)
12
6 
(2
7)
0.
00
3
0.
00
1
M
ea
n 
ar
te
ria
l p
re
ss
ur
e
   
Pn
eu
m
op
er
ito
ne
um
 p
ha
se
73
 (8
)
76
 (9
)
ns
U
rin
e 
ou
tp
ut
 (m
l/h
)
   
Pn
eu
m
op
er
ito
ne
um
 p
ha
se
11
 (2
0)
23
 (3
5)
0.
04
1
In
fu
si
on
 v
ol
um
e 
(m
l/h
)
   
Pn
eu
m
op
er
ito
ne
um
 p
ha
se
74
6 
(2
53
)
69
3 
(1
34
)
ns
D
on
or
 e
G
FR
 (m
l/m
in
/1
.7
3 
m
2 )
   
Po
st
op
er
at
iv
e 
w
ee
k 
1
56
.3
 (1
0.
6)
56
.0
 (1
0.
4)
ns
A
lb
um
in
ur
ia
 (m
g/
m
m
ol
 c
re
at
in
in
e)
†
   
Pr
eo
pe
ra
tiv
e
   
D
ur
in
g 
op
er
at
io
n
   
Fi
rs
t p
os
to
pe
ra
tiv
e 
da
y
   
Se
co
nd
 p
os
to
pe
ra
tiv
e 
da
y
   T
hi
rd
 p
os
to
pe
ra
tiv
e 
da
y
   
O
ne
 w
ee
k 
po
st
op
er
at
iv
e
1.
0 
[0
.3
-2
.4
]
13
.6
 [8
.2
-9
5]
#
1.
4 
[0
.4
-5
.8
]
2.
4 
[0
.7
-8
.5
]
1.
5 
[0
.5
-4
.0
]
1.
8 
[0
.3
-2
1.
3]
1.
4 
[0
.2
-4
.7
]
17
.3
 [1
0.
0-
43
.0
]#
2.
0 
[0
.2
-3
5.
4]
3.
1 
[0
.8
-1
1.
2]
#
3.
1 
[1
.0
-1
1.
9]
1.
4 
[0
.5
-4
.9
]
ns ns ns ns ns ns
Urinary biomarkers after donor nephrectomy
99
Chapter
 7
Ta
bl
e 
2.
 B
as
el
in
e 
ch
ar
ac
te
ris
tic
s 
an
d 
ou
tc
om
e 
m
ea
su
re
s 
st
ud
y 
2.
 (C
on
tin
ue
d)
St
an
da
rd
 p
re
ss
ur
e
(n
=1
0)
Lo
w
-p
re
ss
ur
e
 (n
=1
0)
P-
va
lu
e
U
rin
ar
y 
α-
1-
M
G
B 
(m
g/
m
m
ol
) †
   
Pr
eo
pe
ra
tiv
e
   
D
ur
in
g 
op
er
at
io
n
   
Fi
rs
t p
os
to
pe
ra
tiv
e 
da
y
   
Se
co
nd
 p
os
to
pe
ra
tiv
e 
da
y
   T
hi
rd
 p
os
to
pe
ra
tiv
e 
da
y
   
O
ne
 w
ee
k 
po
st
op
er
at
iv
e
0.
1 
[0
.0
-0
.5
]
0.
1 
[0
.1
-0
.4
]
2.
3 
[0
.1
-1
2.
3]
#
3.
1 
[0
.3
-2
3.
7]
#
4.
7 
[0
.7
-8
.2
]#
0.
7 
[0
.1
-5
.4
]#
0.
3 
[0
.1
-0
.6
]
0.
1 
[0
.0
-0
.2
]
2.
8 
[0
.1
-9
.3
]
2.
1 
[0
.5
-1
0.
1]
#
8.
0 
[0
.5
-3
1.
5]
#
0.
4 
[0
.1
-6
.7
]
ns ns ns ns ns ns
KI
M
-1
 (µ
g/
m
m
ol
 c
re
at
in
in
e)
‡
   
Pr
eo
pe
ra
tiv
e
   
D
ur
in
g 
op
er
at
io
n
   
Fi
rs
t p
os
to
pe
ra
tiv
e 
da
y
   
Se
co
nd
 p
os
to
pe
ra
tiv
e 
da
y
   T
hi
rd
 p
os
to
pe
ra
tiv
e 
da
y
   
O
ne
 w
ee
k 
po
st
op
er
at
iv
e
0.
02
 [0
.0
0-
0.
07
]
0.
26
 [0
.0
2-
0.
52
]#
0.
04
 [0
.0
0-
0.
28
]
0.
01
 [0
.0
0-
0.
10
]
0.
04
 [0
.0
0-
0.
08
]
0.
00
 [0
.0
0-
0.
31
]
0.
00
 [0
.0
0-
0.
12
]
0.
20
 [0
.0
8-
0.
41
]#
0.
04
 [0
.0
0-
0.
21
]
0.
09
 [0
.0
0-
0.
12
]#
0.
04
 [0
.0
0-
0.
13
]#
0.
03
 [0
.0
0-
0.
06
]
ns ns ns ns ns ns
N
G
A
L 
(µ
g/
m
m
ol
 c
re
at
in
in
e)
‡
   
Pr
eo
pe
ra
tiv
e
   
D
ur
in
g 
op
er
at
io
n
   
Fi
rs
t p
os
to
pe
ra
tiv
e 
da
y
   
Se
co
nd
 p
os
to
pe
ra
tiv
e 
da
y
   T
hi
rd
 p
os
to
pe
ra
tiv
e 
da
y
   
O
ne
 w
ee
k 
po
st
op
er
at
iv
e
1.
0 
[0
.0
-1
2.
0]
0.
6 
[0
.0
-1
.7
]
1.
6 
[0
.5
-1
0.
1]
2.
0 
[0
.5
-1
0.
7]
3.
2 
[0
.6
-7
.0
]
2.
5 
[0
.0
-5
.7
]
1.
5 
[0
.0
-5
.7
]
0.
4 
[0
.1
-2
.2
]
1.
6 
[0
.0
-8
.2
]
3.
1 
[0
.7
-1
1.
4]
3.
5 
[0
.7
-2
7.
1]
0.
7 
[0
.0
-5
.0
]
ns ns ns ns ns ns
Ca
te
go
ric
al
 v
ar
ia
bl
es
 a
re
 p
re
se
nt
ed
 a
s 
nu
m
be
rs
 a
nd
 c
on
tin
uo
us
 v
ar
ia
bl
es
 a
s 
m
ea
n 
va
lu
es
 (s
ta
nd
ar
d 
de
vi
at
io
n)
 o
r 
m
ed
ia
n 
va
lu
es
 [r
an
ge
]. 
KI
M
-1
, k
id
ne
y 
in
ju
ry
 
m
ol
ec
ul
e 
1;
 α
-1
-M
G
B,
 a
lp
ha
-1
-m
ic
ro
gl
ob
ul
in
; N
G
A
L,
 n
eu
tr
op
hi
l g
el
at
in
as
e-
as
so
ci
at
ed
 li
po
ca
lin
.
*A
m
er
ic
an
 S
oc
ie
ty
 o
f A
ne
st
he
si
ol
og
is
ts
 c
la
ss
ifi
ca
tio
n.
In
 so
m
e 
ca
se
s, 
th
e 
ur
in
e 
sa
m
pl
e 
fo
r a
 p
ar
tic
ul
ar
 ti
m
e 
po
in
t c
ou
ld
 n
ot
 b
e 
co
lle
ct
ed
 d
ue
 to
 in
su
ffi
ci
en
t u
rin
e 
pr
od
uc
tio
n 
du
rin
g 
su
rg
er
y,
 o
r b
ec
au
se
 it
 w
as
 im
po
ss
ib
le
 
to
 c
ol
le
ct
 a
 u
rin
e 
sa
m
pl
e 
on
 a
 s
pe
ci
fic
 d
ay
 p
os
to
pe
ra
tiv
e:
 †
 1
1 
of
 6
0 
sa
m
pl
es
 m
is
si
ng
; ‡
 8
 o
f 6
0 
sa
m
pl
es
 m
is
si
ng
.
# 
p<
 0
.0
5 
co
m
pa
re
d 
w
ith
 p
re
op
er
at
iv
e.
Chapter 7
100
  
        








 
 
 
 


 

 










 




  
        




   
  


 










 




figure 1. Albuminuria during the perioperative period (mg/mmol creatinine; median)
* p < 0.05 versus baseline.
(1a) study 1: laparoscopic cholecystectomy, laparoscopic colectomy, open donor nephrectomy and 
laparoscopic donor nephrectomy.
(1b) study 2: laparoscopic donor nephrectomy with standard pressure pneumoperitoneum (14 mmHg) and 
laparoscopic donor nephrectomy with low-pressure pneumoperitoneum (7mmHg).
Urinary biomarkers after donor nephrectomy
101
Chapter
 7
  
        





 
 
 
 


 

 


 



 








 





  
        






   
  



 
 



 








 




figure 2. Urinary excretion of α-1-microglobulin (α-1-MGB) (mg/mmol creatinine; median)
* p < 0.05 versus baseline. # p < 0.05 laparoscopic nephrectomy versus laparoscopic cholecystectomy and 
laparoscopic colectomy in quadratic mixed model analysis.
(2a) study 1: laparoscopic cholecystectomy, laparoscopic colectomy, open donor nephrectomy and 
laparoscopic donor nephrectomy.
(2b) study 2: laparoscopic donor nephrectomy with standard pressure pneumoperitoneum (14 mmHg) and 
laparoscopic donor nephrectomy with low-pressure pneumoperitoneum (7mmHg).
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figure 3. Urinary excretion of kidney injury molecule 1 (KIM-1) (µg/mmol creatinine; median)
* p < 0.05 versus baseline. # p < 0.05 laparoscopic nephrectomy versus laparoscopic colectomy in quadratic 
mixed model analysis.
(3a) study 1: laparoscopic donor nephrectomy and laparoscopic colectomy 
(3b) study 2: laparoscopic donor nephrectomy with standard pressure pneumoperitoneum (14 mmHg) and 
laparoscopic donor nephrectomy with low-pressure pneumoperitoneum (7mmHg).
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figure 4. Urinary excretion of neutrophil gelatinase-associated lipocalin (NGAL) (µg/mmol creatinine; median)
* p < 0.05 versus baseline.
(4a) study 1: laparoscopic donor nephrectomy and laparoscopic colectomy 
(4b) study 2: laparoscopic donor nephrectomy with standard pressure pneumoperitoneum (14 mmHg) and 
laparoscopic donor nephrectomy with low-pressure pneumoperitoneum (7mmHg).
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dIscussIon
Our study illustrates the effect of laparoscopic donor nephrectomy on urinary biomarker 
excretion. A short-lasting increase of albumin and KIM-1 excretion was noted during the 
procedure. In contrast, there was a slow rise in urine α-1-MGB and NGAL, which peaked 
on day 2 or 3, and in some patients remained elevated at 4-6 weeks after the procedure. 
The latter finding is suggestive for the occurrence of subtle tubular damage after donor 
nephrectomy, a finding that warrants further study. Of note, there was no evidence of 
acute kidney injury in any patient.
Serum creatinine and e-GFR are imprecise and insensitive markers of kidney injury. 
Therefore, urine biomarkers are advocated to allow an early diagnosis of acute kidney 
injury. For many years, albumin and low molecular weight proteins such as α-1-MGB 
have been used as markers of kidney injury. Urine albumin reflects glomerular injury, 
although increased urine albumin excretion can be observed in patients with severe 
tubular injury. The excretion of urine low molecular weight proteins reflects tubular 
injury. 
The observation that urinary albumin excretion but not α-1-MGB excretion was elevated 
during surgery indicates that during surgery glomerular permeability is altered. The 
rapid normalization suggests that this is a reversible process, either the result of the 
anesthesia or hemodynamic changes that occur during surgery.
In addition to glomerular changes, there was also the suggestion of tubular injury 
after open and laparoscopic donor nephrectomy, as indicated by a peak in α-1-MGB 
excretion on the third postoperative day. Remarkably α-1-MGB excretion was still 
elevated 4-6 weeks postoperative. To support these findings, we performed additional 
studies. We analyzed novel biomarkers of kidney injury. In addition, we studied a control 
group of patients who underwent a laparoscopic procedure either cholecystectomy or 
colectomy.
The novel biomarkers included KIM-1 and NGAL. KIM-1 is a type 1 transmembrane 
protein, not detectable in normal kidney tissue, but is expressed at high levels in kidneys 
with dedifferentiated proximal tubule epithelial cells after ischemic or toxic injury. NGAL 
is synthesized mostly in the distal nephron of the kidney in response to nephrotoxic 
and/or ischemic injury. However, in response to renal injury, NGAL is also systemically 
produced. After glomerular filtration, most of this NGAL is endocytosed by the proximal 
tubule epithelia, and little is secreted in the urine. NGAL is an early predictor of acute 
kidney injury after cardiac surgery, contrast-induced nephropathy, and in critically ill 
patients.7 After laparoscopic nephrectomy, we observed a slight increase of urinary 
excretion of KIM-1 in the immediate perioperative period, in parallel with albuminuria. In 
contrast, urine NGAL followed the pattern of α-1-MGB after laparoscopic nephrectomy 
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with a peak in excretion on the 2nd or 3rd postoperative day. It has been shown that 
anesthesia can be associated with increased urinary excretion of biomarkers. Patients 
undergoing breast surgery, anesthetized with ketorolac and sevoflurane, developed 
increased urinary excretion of α-1-MGB in the first postoperative day.8 Another study 
after elective surgery showed elevated excretion of total protein, β-2-microglobulin, 
and N-acetyl-β-d-glucosaminidase after anesthesia with sevoflurane.9  
It is unclear whether the anesthetics used in our studies could be responsible for the 
increased excretion of the biomarkers that we have observed. To further evaluate 
this, we have performed additional studies in patients who underwent laparoscopic 
cholecystectomy and colectomy. The laparoscopic cholecystectomy patients showed 
a slight increase in albuminuria during the operative procedure. There was no increase 
in urinary α-1-MGB. However, the laparoscopic cholecystectomy group might not be 
a good control group because the laparoscopic procedure was of significantly shorter 
duration. Therefore, we performed additional studies in patients who underwent 
laparoscopic colectomy. These patients also showed the perioperative increase in 
albuminuria. However, the patterns of urinary excretion of the tubular biomarkers were 
clearly different from that observed after laparoscopic nephrectomy. Specifically, after 
laparoscopic colectomy, there was no increase in urinary α-1-MGB excretion, and there 
were clear increases in urinary KIM-1 and NGAL occurring in the 2nd and 3rd day after the 
procedure. Taken all together, our data indicate that the increase in urinary α-1-MGB 
excretion is specific for nephrectomy. The typical and unique pattern of increased urinary 
α-1-MGB after nephrectomy is supported by the absence of a correlation between the 
excretion of α-1-MGB and the excretion of urine NGAL. Clearly, the increased urinary 
α-1-MGB excretion thus cannot be attributed to the anesthesia, nor to the elevated 
intra-abdominal pressure.  
This points to a specific injury after donor nephrectomy, situated in the proximal tubules. 
We can only hypothesize that an alteration in blood supply, possibly mediated by renal 
reflexes, to the remaining kidney might be an explanation for the damage observed. 
Another possible explanation might be that nephrectomy causes hypertrophy and 
dedifferentiation of tubular cells in the remaining kidney. These dedifferentiated tubular 
cells may have more limited reabsorption capacity resulting in an increased urinary 
excretion of otherwise reabsorbed low molecular weight proteins. Our study also 
illustrates that the new biomarkers of kidney injury respond differently to the various 
operative procedures. More detailed studies are needed to find explanations for these 
specific expression patterns.
In adult patients undergoing elective cardiac surgery, Koyner et al. measured urinary 
biomarkers, such as KIM-1 and NGAL.10 They demonstrated that the 6-h postoperative 
urinary NGAL best detected early stage 3 acute kidney injury. They also demonstrated 
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that preoperative KIM-1 was predictive for the development of stage 1 and stage 3 
acute kidney injury. Potential sources of this preoperative elevation include exposure 
to radiocontrast, hypotensive events, or pre-existing chronic kidney disease. The 
population of healthy kidney donors included in the present study differs from patients 
undergoing cardiac surgery or critically ill patients in which most biomarker studies 
were performed. Therefore, profiles which accurately detect cardiac surgery-related 
acute kidney injury or acute kidney injury in septic patients are not necessarily useful in 
other patient groups such as kidney donors. 
Limitations of our study are mainly related to its design as a pilot. Without a power 
calculation, the conclusions are preliminary and should be confirmed in a larger trial.
Urinary biomarkers are very sensitive for true histological tubular damage, and in research 
conditions, these high-sensitivity markers accurately predict potential nephrotoxicity. 
However, in clinical practice, we need to define what degree of subclinical damage 
as detected by biomarkers is clinically relevant, in terms of complications and long-
term renal function. Therefore, studies linking acute tubular damage as assessed by 
biomarkers to long-term outcomes are needed.
conclusIon
Elevated α-1-MGB suggests kidney damage after open and laparoscopic donor 
nephrectomy. This occurs irrespective of intra-abdominal pressure during the 
laparoscopic procedure. Further studies are required to assess the mechanism 
underlying biomarker elevation after donor nephrectomy.
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suMMAry
Kidney transplantation is the preferred treatment option for most patients with end 
stage renal disease. A major drawback of kidney transplantation is the need for lifelong 
immunosuppressive therapy to prevent rejection episodes. The development of potent 
immunosuppressive drugs, especially calcineurin inhibitors (CNI) reduced the rate of 
acute rejections and improved short-term results of kidney transplantation. However, 
long-term results have not been improved to the same extent. Nephrotoxicity is a major 
side effect of CNI, and contributes to graft function loss. The use of immunosuppressive 
therapy after kidney transplantation is also responsible for the increased incidence 
of cancer, particularly skin cancer. The immunosuppressive drug sirolimus has been 
reported to be less nephrotoxic and may offer an opportunity to avoid exposure to 
CNI and thus prevent the associated nephrotoxicity. Sirolimus has also important anti-
neoplastic properties, and may prove to be a drug that can be safely continued to 
prevent allograft rejection in transplant recipients who have developed a malignancy. 
Another possibility to improve the long-term results of kidney transplantation is to 
develop biomarkers that predict late allograft loss, thus allowing to identify and treat 
patients at highest risk in an early stage. A completely different problem with kidney 
transplantation is the shortage of organs and the long waiting time. Transplantation 
with a kidney of a living-donor may circumvent this problem, but the question is 
whether this procedure is safe for the donor, particularly in light of the now broadly 
used laparoscopic nephrectomy.
In 2005 we started a prospective randomized controlled trial that was aimed to investigate 
whether the nephrotoxicity that occurs under the current standard immunosuppressive 
treatment regimen with tacrolimus, low-dose steroids and mycophenolate mofetil 
(MMF) can be decreased by using a regimen with sirolimus, daclizumab, low-dose 
steroids and MMF without an increased incidence of acute rejections. As described in 
chapter 2, this study was prematurely ended because of an unacceptable high rate of 
acute rejections. After a mean follow-up of 15 weeks, seven of 10 patients developed 
an acute rejection in the sirolimus group compared with three of 20 patients in the 
tacrolimus group (P < 0.01). Three of the seven rejections in the sirolimus group occurred 
between 8 and 15 weeks after transplantation, at the time the prednisolone dose was 
reduced to below 10 mg/day. In all these cases the trough sirolimus level appeared to be 
below the target range at the time of rejection, which certainly could have contributed 
to the high rejection rate. Still, the data suggested that the treatment regimen was not 
suitable. We conducted a pilot study in 9 patients, to determine if a comparable CNI free 
treatment protocol with sirolimus could be suitable if higher doses of steroids where 
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used. In these 9 patients no acute rejection occurred. However, in this pilot study most 
patients experienced serious adverse events, such as delayed wound healing, infection, 
pulmonary embolus, proteinuria and diarrhoea. Based on this experience we concluded 
that at this time point there is no place for a sirolimus-based CNI free regimen in the 
direct post-transplant period. 
Studies have reported a significant increase of proteinuria in kidney transplant 
recipients who were switched from a CNI to sirolimus. This has (partly) been attributed 
to the renal hemodynamic effects of CNI withdrawal. In chapter 3 we have evaluated 
the evolution of proteinuria in renal transplant recipients who underwent conversion 
from azathioprine to sirolimus. In our centre 25 patients were included in a randomized 
study that evaluated the efficacy and safety of conversion to sirolimus in stable renal 
transplant recipients (RTR) with a cutaneous squamous cell carcinoma (SCC). After a 
mean follow-up of 360 days, mean proteinuria increased from 0.37±0.34 to 1.81±1.73 
g/24h after conversion to sirolimus (P<0.005). In the control group with patients 
who continued their current immunosuppressive treatment there was no change in 
proteinuria. A significant increase of proteinuria was observed in all seven patients 
with proteinuria before conversion, whereas proteinuria remained absent in all patients 
without previous proteinuria. Two of the patients with proteinuria were converted from 
cyclosporine and five patients were converted from azathioprine to sirolimus. Sirolimus 
was discontinued in five patients with proteinuria, and in all of them proteinuria 
declined to baseline values. This study demonstrates that conversion from azathioprine 
to sirolimus after kidney transplantation is associated with an increase in proteinuria 
that is often reversible. The mechanism of this effect is unclear, but must be related to a 
direct effect of sirolimus.
Proteinuria can be the consequence of tubular and glomerular injury, and sirolimus 
thus could induce proteinuria by several mechanisms. Based on the findings in the 
above mentioned study, we performed experimental studies to examine the effect 
of sirolimus on proteinuria in a mouse model of focal segmental glomerulosclerosis 
(FSGS) as described in chapter 4. Heterozygous Thy-1.1 transgenic mice express the 
Thy-1.1 antigen on the podocytes. These mice slowly and spontaneously develop 
albuminuria and focal glomerulosclerosis over a period of 26 weeks. Importantly, the 
process of FSGS development can be accelerated. Injection of anti-Thy-1.1 monoclonal 
antibodies in Thy-1.1 transgenic mice induces an acute albuminuria, which is followed 
by a rapid development of FSGS within 3 weeks after injection of the monoclonal 
antibody. Use of this mouse model allowed us to investigate the effect of sirolimus 
both in non-proteinuric mice (experiment 1), as well as in mice made proteinuric before 
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start of sirolimus (experiment 2).  We did not observe any increase in proteinuria after 
administration of sirolimus: neither in experiment 1 nor in experiment 2. We also did 
not detect differences in the occurrence of glomerulosclerosis. Thus, we were unable to 
replicate the finding of increased proteinuria that was observed in patients treated with 
sirolimus. Of note, we even observed some reduction of proteinuria in transgenic mice 
treated with sirolimus. Thus, our data might suggest a dose dependent protective effect 
of sirolimus on proteinuria in Thy-1.1 transgenic mice. The mechanisms responsible for 
this protective effect were not further evaluated.
In light of the significant morbidity and mortality of cutaneous invasive squamous 
cell carcinomas (SCCs) in renal transplant recipients we performed a prospective, 
multicentre study to examine if conversion to sirolimus-based immunosuppression 
can reduce the recurrence rate of these skin cancers. In chapter 5 data are presented 
of a two-year randomized controlled trial in which 155 RTRs in the Netherlands and 
the United Kingdom with at least one biopsy-confirmed SCC were stratified according 
to age and number of previous SCCs and randomly assigned to conversion to 
sirolimus (n=74) or continuation of their original immunosuppressive therapy (n=81). 
Development of a new SCC within 2 years after random assignment was the primary 
end point. After 2 years of follow-up, there was no significant reduction of new SCCs in 
the sirolimus group, with a hazard ratio (HR) in multivariable analysis of 0.76 (95% CI, 
0.48 to 1.2; P=0.255). Unfortunately, analysis of the efficacy of sirolimus was confounded 
by high 53% drop-out rate in the sirolimus group. When analyzing the data after the 
first year, there was a significant 50% risk reduction, with an HR of 0.50 (95% CI, 0.28 
to 0.90; P=0.021). Sirolimus was most effective in patients with only one previous 
SCC with an HR of 0.11 (95% CI, 0.01 to 0.94; P = 0.044). The tumor burden of SCC was 
reduced during the 2-year follow-up period in those receiving sirolimus (0.82 v 1.38 
per year, relative risk 0.51; 95% CI, 0.32 to 0.82; P=0.006) if adjusted for the number of 
previous SCCs and age. In retrospect the combination of high initial sirolimus levels 
and investigator caution led to early discontinuation of sirolimus in several participants 
with mild to moderate proteinuria and other adverse effects, who may have responded 
to dose adjustment and/or the addition of an angiotensin-converting enzyme 
inhibitor. There was no significant change in renal function or increase in proteinuria 
in the patients who continued sirolimus treatment, suggesting the safety of sirolimus 
conversion in RTRs many years post-transplantation. In conclusion, conversion to low-
dose mTOR-inhibition with careful monitoring was not associated with increased risk 
of transplant dysfunction. However, in our study population, comprising patients with 
one or more previous SSCs, there was no benefit after two years in terms of SCC-free 
survival. Conversion in those with only one previous SCC should be carefully balanced 
Chapter 8
114
against toxicities that can lead to relatively high dropout rates. The benefit afforded by 
the mTOR-based regimen after conversion in the subgroup of patients with only one 
previous invasive SCC may suggest that an mTOR inhibitor has the potential to become 
an effective early immunosuppressive strategy to reduce the risk of cutaneous SCC in 
RTRs. 
In chapter 6 we investigated if graft function deterioration and graft loss can be 
predicted by measuring urinary protein markers. Albuminuria is a marker of glomerular 
damage and a predictor of renal outcome in patients with kidney disease. However, 
deterioration of renal function is best correlated with tubulointerstitial injury. Urinary 
excretion of α1-microglobulin reflects tubulointerstitial damage and improves prediction 
of outcome in patients with glomerular diseases. However, little is known about the 
possible value of α1-microglobulin for predicting graft outcome in RTRs. Therefore, in 
a cross sectional pilot study we evaluated urinary α1-microglobulin excretion in four 
different categories of RTRs (HLA-compatible, never transplant rejection, with transplant 
rejection and with chronic allograft nephropathy). We subsequently measured urinary 
α1-microglobulin excretion in a prospective cohort of RTRs three and 12 months after 
transplantation, and correlated the levels with graft loss, and progression of renal 
dysfunction. In the cross sectional study 41 patients were studied of which 14 received 
an HLA-compatible kidney. Urinary α1-microglobulin excretion exceeded normal values 
in the majority of patients who had received an HLA compatible kidney. In this category, 
even in patients with the highest values of urinary α1-microglobulin, renal function did 
not deteriorate during follow-up. These findings suggest that higher values of urinary 
α1-microglobulin can sometimes be accepted as “normal” after renal transplantation 
and do not necessarily reflect active, progressive tubulointerstitial injury. Urinary α1-
microglobulin excretion was higher in the patients with rejection or chronic allograft 
nephropathy and correlated with eGFR (r = -0.56; P < 0.001). In the prospective study 
139 patients were evaluated. Of these, 34 patients had graft rejection within 3 months 
after transplantation. Median follow-up after renal transplantation was 48 months, eGFR 
increased by 0.6 ml/min/1.73m2/yr during follow-up, 10 patients died and 3 patients 
developed graft failure. Urinary α1-microglobulin excretion was above normal in 86% of 
patients at three months and in 78% of patients at twelve months after transplantation. 
Increased urinary α1-microglobulin excretion at twelve months was associated with the 
type of donor, gender of the recipient, eGFR, albuminuria, α1-microglobulin at 3 months 
and prior rejections. Unfortunately, we were not able to draw any conclusion on the 
prognostic value of α1-microglobulin on graft failure because of the limited number of 
events during follow-up. There was no correlation between urinary α1-microglobulin 
excretion and the change in eGFR during follow-up. Our study might have been 
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underpowered to proof an association between urinary α1-microglobulin and change 
in eGFR during follow-up, because in only 19 patients (14%) eGFR decreased more than 
3 ml/min/1.73m2/yr. In conclusion, the majority of patients after kidney transplantation 
has elevated levels of urinary α1-microglobulin at 3 and 12 months after transplantation. 
In the short term, urinary α1-microglobulin does not predict renal outcome in this 
relatively limited exploratory study. Our data suggest that in RTRs elevated urinary α1-
microglobulin reflects fibrosis and not active tubular cell injury. However, the value of 
α1-microglobulin in the setting of renal transplantation warrants a larger study involving 
more events and longer follow-up.
As the beginning of living-donor kidney transplantation, physicians have expressed 
concern about the possibility that unilateral nephrectomy can be harmful to a healthy 
individual. In chapter 7 we investigated whether the elevated intra-abdominal pressure 
during laparoscopic donor nephrectomy causes early damage to the remaining kidney 
by evaluation of sensitive urine biomarkers after laparoscopic donor nephrectomy. 
We measured albumin and α1-microglobulin in urine samples collected during and 
after open and laparoscopic donor nephrectomy, laparoscopic cholecystectomy, and 
laparoscopic colectomy. Additionally, kidney injury molecule 1 (KIM-1) and neutrophil 
gelatinase-associated lipocalin (NGAL) were measured in frozen urine samples collected 
during and after laparoscopic donor nephrectomy and laparoscopic colectomy. The 
same biomarkers were studied in patients randomly assigned to standard (14 mmHg) 
or low (7 mmHg) intra-abdominal pressure during laparoscopic donor nephrectomy. 
We observed a peak in urinary albumin excretion during all procedures. Urine α1- 
microglobulin was not increased during surgery, but rose in the postoperative 
period with a peak on the third postoperative day after donor nephrectomy. Urine 
α1-microglobulin did not significantly increase after laparoscopic cholecystectomy 
and colectomy. In the laparoscopic nephrectomy group we observed slight increases 
in urine KIM-1 during surgery and in urine NGAL at day 2-3 after the procedure. After 
laparoscopic colectomy, both KIM-1 and NGAL were increased in the postoperative 
period. The observation that urinary albumin excretion but not α1-microglobulin 
excretion was elevated during surgery indicates that during surgery glomerular 
permeability is altered. The rapid normalization suggests that this is a reversible process, 
either the result of the anesthesia, or hemodynamic changes that occur during surgery. 
In addition to glomerular changes, there was also the suggestion of tubular injury after 
open and laparoscopic donor nephrectomy, as indicated by a peak in α1-microglobulin 
excretion on the third postoperative day. This occurred irrespective of intra-abdominal 
pressure during the laparoscopic procedure. Remarkably α1-microglobulin excretion 
was still elevated 4-6 weeks postoperative. Our data indicates that the increase in 
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urinary α1-microglobulin excretion is specific for nephrectomy. The typical and unique 
pattern of increased urinary α1-microglobulin after nephrectomy is supported by the 
absence of a correlation between the excretion of α1-microglobulin and the excretion 
of urine NGAL. Clearly, the increased urinary α1-microglobulin excretion thus cannot 
be attributed to the anesthesia, nor to the elevated intra-abdominal pressure.  Further 
studies are required to assess the mechanism underlying biomarker elevation after 
donor nephrectomy.  Our study also illustrates that the new biomarkers of kidney injury 
respond differently to the various operative procedures. More detailed studies are 
needed to find explanations for these specific expression patterns.
dIscussIon
We performed several studies to investigate whether an immunosuppressive regimen 
with sirolimus can improve long-term results after kidney transplantation. Calcineurin 
inhibitors (CNI) have become the cornerstone of immunosuppressive therapy after 
kidney transplantation. However these agents are nephrotoxic and often contribute to 
kidney allograft dysfunction. Therefore, we studied the efficacy and safety of a CNI free 
regimen in which sirolimus replaced the CNI. Unfortunately, this trial had to be stopped 
because of an unacceptably high rejection rate. Meanwhile large trials also have shown 
that induction therapy with a CNI free regimen containing sirolimus after transplantation 
is associated with an increased risk of acute rejections.1 Moreover, several studies have 
shown that sirolimus-containing regimens used after kidney transplantation attenuate 
recovery from delayed graft function when compared to other immunosuppressive 
regimens.2,3 Finally, overall the use of sirolimus in the immediate post-transplant period 
was associated with an increased risk of impaired wound healing and an increased 
incidence of lymphoceles, often resulting in withdrawal of sirolimus treatment. Based 
on the above findings it is clear that there is currently no place for a CNI free regimen 
with sirolimus-based immunosuppression immediately after kidney transplantation. 
However, it has been suggested that mTOR inhibitors can be safely used and replace CNI 
when conversion is started 3 months after transplantation.4 A recent review concluded 
that the use of sirolimus in combination with tacrolimus minimization therapy enables 
better preservation of kidney function, without increased risk of graft rejection.5 Future 
studies have to proof that the early withdrawal of CNI and replacement with sirolimus 
improves graft survival or decreases long-term side effects. It has been suggested that 
mTOR inhibitors could be used in the immediate post-transplant period, if used in low 
dosages, combined with low dose CNI. We will have to wait the results of ongoing 
studies. 
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Squamous cell carcinomas (SCCs) are a frequent complication after kidney 
transplantation. Although our study failed to show a benefit in terms of SCC-free survival 
at 2 years, subgroup analysis suggested a benefit in patients who received sirolimus 
after the first manifestation of a SCC. A similar conclusion was drawn by Euvrard et 
al., who also performed a randomized controlled trial evaluating the efficacy of an 
mTOR-based regimen in preventing the development of new skin carcinomas. These 
investigators also showed a benefit of mTOR treatment in the subgroup of patients 
with only one previous invasive SCC.6 Thus, both studies suggest that treatment with 
an mTOR inhibitor may reduce the risk of cutaneous SCC in renal transplant recipients. 
However, most benefit is gained in patients who were switched early, thus after the 
first manifestation of SCC. Based on these findings it can be hypothesized that the 
mammalian target of rapamycin (mTOR) inhibitor may be most effective when given 
early after transplantation in patients with high risks for SCCs. However, the very 
early use of sirolimus is associated with a higher rejection risk.  Future studies should 
demonstrate whether conversion of a CNI to an mTOR inhibitor 3 to 6 months after 
transplantation results in equal graft survival, and a lower malignancy rate. 
Although mTOR inhibitors might reduce the risk of nephrotoxicity and malignancy, their 
use was associated with many adverse events. One of the notable side effects was the 
occurrence of proteinuria. Our study clearly demonstrated that proteinuria also was 
observed in patients who started sirolimus as replacement for azathioprine. Sirolimus-
induced proteinuria therefore cannot be attributed to the hemodynamic effects of 
CNI withdrawal. Proteinuria was mostly observed in patients who were treated with 
sirolimus because of chronic allograft nephropathy and proteinuria.7
We recommend that all patients who start sirolimus therapy should be closely 
monitored for proteinuria. Risks of conversion are highest in patients with pre-
existing proteinuria (> 800 mg/day), lower eGFR (< 40 ml/min), or chronic allograft 
injury.8 Strategies for managing mild proteinuria include lowering blood pressure 
with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, 
dietary sodium and protein restriction, controlling obesity and lipids (with statins), 
and smoking cessation.8,9 If proteinuria increases, drug withdrawal may be necessary 
to reduce the risk of renal failure. Proteinuria generally decreases within a few months 
after mTOR inhibitor discontinuation, and the majority of patients show no long-term 
residual kidney damage.9 
The first reports of sirolimus induced proteinuria stimulated a search for the 
development of an animal model. However, we were unable to document increased 
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proteinuria in a mouse model for focal segmental glomerulosclerosis. Our studies even 
suggested some protective effects of sirolimus in this mouse model. A review of the 
literature data also disclosed contrasting findings, with some studies reporting an 
increase in proteinuria, however in the majority of studies a decrease of proteinuria was 
reported. The reasons for these seemingly discrepant findings have been elucidated by 
detailed studies of the role of the mTOR pathway in podocytes. Podocyte development 
and podocyte maintenance are dependent on a tight regulation of the mTORC1 and 
mTORC2 complexes. Both overactivation and complete inhibition of mTORC activity may 
cause podocyte dysfunction, glomerulosclerosis and proteinuria. The delicate balance 
likely explains the observed divergent effects of sirolimus. The effects of sirolimus on 
proteinuria are probably influenced by factors such as the nature and presence of pre-
existing renal damage, timing of administration of the drug, dosage of sirolimus used, 
and prior exposure to a CNI. More detailed studies of the mTOR pathway in podocytes, 
and development of more specific inhibitors are needed to develop better treatment 
strategies. 
Altogether, our studies indicate that at this moment there is no place for a CNI free 
regimen in the immediate post-transplant period. mTOR inhibitors such as sirolimus 
or everolimus should be considered in selected patients such as patients with 
posttransplant malignancies and patients with CNI nephrotoxicity. In each patient the 
risk and benefits of sirolimus therapy should be weight carefully on a case-by-case basis. 
Although the introduction of CNI has reduced the number of acute rejection episodes, 
long-term allograft survival has not improved at a similar rate. In many patients kidney 
allograft function deteriorates slowly but persistently, a process often called chronic 
allograft nephropathy. Many processes are involved in chronic allograft nephropathy 
including humoral rejection, hypertension, smoking, dyslipidemia, nephrotoxicity, 
recurrence of the original disease, and atherosclerosis. Clinically, this process is often 
difficult to detect. Most patients present with a slowly increasing serum creatinine. 
However at the time point that there is a significant increase of serum creatinine much 
damage already has occurred, and a kidney biopsy often discloses irreversible damage 
with interstitial fibrosis and tubular atrophy.  Early recognition of this continuous process 
of kidney damage would enable an early intervention, and multitargeted therapy. Based 
on findings in patients with glomerular diseases we hypothesized that measurement of 
the urinary excretion of the low molecular weight protein α1-microglobulin might help 
to predict late allograft failure. Our studies clearly showed that urinary α1-microglobulin 
is not a suitable parameter in kidney transplant recipients. In many patients increased 
levels of urinary α1-microglobulin were observed, even in patients with stable renal 
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function over a period of many years after measurement. These results suggested that 
increased urinary α1-microglobulin is not a reflection of active tubular injury, but more a 
reflection of established fibrosis and tubular atrophy. We cannot exclude that a repeated 
measurement of urinary α1-microglobulin, which would allow to calculate a change 
in its excretion might be better suited to predict future allograft failure. Alternatively, 
we should consider evaluating other tubular biomarkers. In recent years new kidney 
biomarkers have been studied, especially in the setting of acute kidney injury. It would 
be useful to evaluate these biomarkers such as KIM-1, NGAL, interleukin-18 in the setting 
of renal allograft nephropathy.
We evaluated changes in the excretion of several urinary biomarkers after kidney 
donation. We specifically questioned if a higher abdominal pressure could induce 
subtle kidney injury. Notably, we did not observe differences in biomarker excretion 
between laparoscopic procedures with lower or higher abdominal pressure. However, 
we observed an increased urinary excretion of α1-microglobulin occurring in the 
first days after the open and laparoscopic donor nephrectomy. Moreover, levels had 
not normalized 4-6 weeks after the nephrectomy. We do not know if the increased 
urinary α1-microglobulin excretion is the consequence of limited tubular damage, 
or a physiological response to hyperfiltration that occurs after nephrectomy. Clearly, 
long-term kidney injury is not the rule after kidney donation. Large studies have 
documented the overall good outcome of living kidney donors. Still, we suggest that 
more studies are needed to explain our observations. If the increased excretion of α1-
microglobulin is the consequence of hyperfiltration, then there is no reason for concern. 
Alternatively, it might well be that the procedure causes very limited injury. This should 
have no consequences for the long-term outcome. However, if some tubular injury is 
present in the immediate postoperative period, it may be important to limit the use of 
nephrotoxic agents or nephrotoxic procedures (contrast CT scans) in this period. We 
have not changed our current transplantation policy. However, the data have triggered 
new study proposals. Specifically, we aim at evaluating long-term α1-microglobulin 
excretion in kidney donors, at studying α1-microglobulin after partial nephrectomy, and 
at measuring other kidney injury markers.
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sAMenvATTIng
Er bestaan drie vormen van nierfunctievervangende therapie: hemodialyse, peritoneale 
dialyse en niertransplantatie. Niertransplantatie is de behandeling van voorkeur voor de 
meeste patiënten met eindstadium nierfalen, omdat dit een langere levensverwachting 
en een betere kwaliteit van leven geeft. Daarnaast is niertransplantatie ook minder 
kostbaar dan chronische dialysebehandeling. Omdat een transplantaatnier door 
het afweersysteem van de ontvanger herkend wordt als lichaamsvreemd kan er een 
afstotingsreactie ontstaan. Een belangrijk nadeel van niertransplantatie is dan ook 
de noodzaak tot levenslange behandeling met medicijnen die de afweer verzwakken 
(immunosuppressieve middelen) om een afstoting van het transplantaat te voorkomen. 
De ontwikkeling van krachtige immunosuppressieve geneesmiddelen, met name 
calcineurineremmers, hebben het aantal acute afstotingsreacties verminderd en 
daarmee de korte termijn resultaten van niertransplantatie enorm verbeterd. De lange 
termijn resultaten zijn echter niet in dezelfde mate verbeterd. Nefrotoxiciteit is een 
belangrijke bijwerking van calcineurineremmers en draagt daardoor bij aan het optreden 
van transplantaatverlies op de lange termijn. Het gebruik van immunosuppressieve 
geneesmiddelen na niertransplantatie is ook verantwoordelijk voor een verhoogde 
kans op het krijgen van kwaadaardige ziekten, met name huidkanker. Van het 
immunosuppressieve medicijn sirolimus is beschreven dat het minder nefrotoxisch 
is. Dit middel biedt daarmee een mogelijkheid om blootstelling aan de nefrotoxische 
calcineurineremmers te vermijden. Sirolimus heeft ook belangrijke antineoplastische 
eigenschappen. Theoretisch zou het dus een geneesmiddel kunnen zijn dat veilig 
gecontinueerd kan worden om transplantaatafstoting te voorkomen bij ontvangers 
van een niertransplantaat, die een kwaadaardige ziekte hebben ontwikkeld. Een andere 
manier om de lange termijn resultaten van niertransplantatie te verbeteren is het 
ontwikkelen van biomarkers die later transplantaatverlies kunnen voorspellen. Dit zou 
het mogelijk kunnen maken om patiënten met een hoog risico op transplantaatverlies 
in een eerder stadium op te sporen en te behandelen. Een heel ander probleem is het 
tekort aan donororganen en de daarmee samenhangende lange wachttijd tot een 
donororgaan beschikbaar is. Transplantatie met een nier van een levende donor kan dit 
probleem omzeilen. De vraag is echter of deze procedure veilig is voor de donor, vooral 
in het licht van de nu algemeen uitgevoerde laparoscopische donornefrectomie.
In 2005 is een prospectieve gerandomiseerde gecontroleerde studie gestart waarmee 
we wilden onderzoeken of de nefrotoxiciteit die optreedt onder het standaard 
immunosuppressieve behandelingsschema met tacrolimus, lage dosis steroïden en 
mycofenolaat mofetil (MMF) kan worden verminderd door een regime bestaande uit 
sirolimus, daclizumab, lage dosis steroïden en MMF zonder dat de incidentie van acute 
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afstotingen toeneemt. Zoals beschreven in hoofdstuk 2, werd deze studie voortijdig 
beëindigd vanwege een onaanvaardbaar hoog percentage acute afstotingsreacties. 
Na een gemiddelde follow-up van 15 weken, ontwikkelden 7 van de 10 patiënten 
een acute afstoting in de sirolimusgroep vergeleken met 3 van de 20 patiënten in de 
tacrolimusgroep (p < 0,01). Bij 3 van de 7 patiënten in de sirolimusgroep die een acute 
afstoting ontwikkelden trad die afstoting op tussen 8 en 15 weken na de transplantatie, op 
het moment dat de prednisolondosis was gereduceerd naar minder dan 10 mg/dag. Ten 
tijde van de afstoting was bij deze 3 patiënten de sirolimusspiegel lager dan het beoogde 
streefniveau. Dit kan zeker hebben bijgedragen aan het hoge afstotingspercentage. 
Desondanks suggereren de uitkomsten dat het onderzochte regime geen geschikt 
behandelingsschema is. Vervolgens is een pilotstudie uitgevoerd met 9 patiënten om 
na te gaan of een vergelijkbaar calcineurineremmervrij behandelschema met sirolimus 
wel geschikt is als hogere doses steroïden worden gebruikt. Bij deze 9 patiënten traden 
geen acute afstotingen op. In deze pilotstudie ontwikkelden patiënten echter wel 
veel ernstige bijwerkingen zoals vertraagde wondgenezing, infecties, longembolie, 
proteïnurie en diarree. Op basis van deze ervaringen hebben wij geconcludeerd dat er 
op dit moment geen plaats is voor een op sirolimus gebaseerd calcineurineremmervrij 
immunosuppressief regime in de eerste periode na niertransplantatie.
In diverse studies wordt melding gemaakt van een significante toename van eiwit 
in de urine, ook wel proteïnurie genoemd, bij niertransplantatiepatiënten waarbij 
de calcineurineremmer werd vervangen door sirolimus. Dit is (deels) toegeschreven 
aan de renale hemodynamische effecten die optreden bij het stoppen van de 
calcineurineremmer. In hoofdstuk 3 is de ontwikkeling van proteïnurie geëvalueerd bij 
niertransplantaatontvangers die behandeld werden met een calcineurineremmervrij 
regime, waarbij de azathioprine werd vervangen door sirolimus. In ons centrum 
werden 25 patiënten geïncludeerd in een gerandomiseerde studie, die de 
werkzaamheid en veiligheid onderzocht van conversie naar sirolimus in stabiele 
niertransplantaatontvangers met een cutaan plaveiselcelcarcinoom (PCC). Na een 
gemiddelde follow-up van 360 dagen steeg de proteïnurie na conversie naar sirolimus 
van gemiddeld 0,37±0,34 naar 1,81±1,73 g/24h (p < 0,005). In de controlegroep van 
patiënten waarin de immunosuppressieve behandeling niet aangepast werd trad 
geen verandering op in proteïnurie. Er werd een significante stijging in proteïnurie 
waargenomen bij alle zeven patiënten met proteïnurie voorafgaand aan de conversie, 
terwijl proteïnurie afwezig bleef bij alle patiënten die tevoren geen proteïnurie hadden. 
Twee van de patiënten met proteïnurie waren geconverteerd van ciclosporine en 5 
waren geconverteerd van azathioprine naar sirolimus. Bij vijf patiënten die proteïnurie 
ontwikkelden werd de sirolimus gestaakt, waarna bij alle vijf de proteïnurie weer naar 
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de uitgangswaarde daalde. Deze studie toont aan dat conversie van azathioprine naar 
sirolimus na niertransplantatie is geassocieerd met een toename van proteïnurie die 
vaak omkeerbaar is. Het mechanisme van dit effect blijft onopgehelderd, maar moet 
worden toegeschreven aan een direct effect van sirolimus.
Proteïnurie kan het gevolg zijn van tubulaire en glomerulaire schade en sirolimus kan dus 
proteïnurie veroorzaken via verschillende mechanismen. Gebaseerd op de bevindingen 
in de hierboven genoemde studie, zijn experimentele studies uitgevoerd in een 
muismodel van focale segmentale glomerulosclerose (FSGS) om het effect van sirolimus 
op proteïnurie te onderzoeken. Dit staat beschreven in hoofdstuk 4. Heterozygote Thy-
1.1 transgene muizen brengen het Thy-1.1 antigeen tot expressie op de podocyten. 
Deze muizen ontwikkelen spontaan langzaam progressieve albuminurie en focale 
glomerulosclerose binnen een periode van 26 weken. Dit proces van FSGS ontwikkeling 
kan worden versneld. Injectie van anti-Thy-1.1 monoclonale antilichamen in Thy-1.1 
transgene muizen induceert een acute albuminurie, die wordt gevolgd door een snelle 
ontwikkeling van FSGS binnen 3 weken na de injectie van het monoclonale antilichaam. 
Het gebruik van dit muismodel gaf ons de mogelijkheid om het effect te onderzoeken 
van sirolimus bij zowel niet proteïnurische muizen (experiment 1) als bij muizen die 
al proteïnurie hadden vóór de start van sirolimus (experiment 2). We zagen in beide 
experimenten geen toename van proteïnurie optreden na toediening van sirolimus. We 
konden ook geen verschillen detecteren in het ontstaan van glomerulosclerose. In dit 
diermodel waren we dus niet in staat de toename in proteïnurie, die werd waargenomen 
bij patiënten behandeld met sirolimus, te repliceren. We zagen juist zelfs een afname 
in proteïnurie bij de transgene muizen die met sirolimus behandeld werden. Onze 
gegevens suggereren dus een dosis afhankelijk beschermend effect van sirolimus 
op het ontstaan van proteïnurie bij Thy-1.1 transgene muizen. De mechanismen die 
verantwoordelijk zijn voor dit beschermend effect werden niet verder geëvalueerd.
In het licht van de significante morbiditeit en mortaliteit die cutane invasieve PCC’s 
veroorzaken bij niertransplantatiepatiënten is een prospectieve, multicenterstudie 
uitgevoerd om na te gaan of conversie naar een op sirolimus gebaseerd immuno-
suppressief regime het risico op recidief huidtumoren kan verminderen. In hoofdstuk 
5 worden de resultaten gepresenteerd van een tweejarige gerandomiseerde 
gecontroleerde studie waarin 155 niertransplantatieontvangers in Nederland en 
Engeland met tenminste één biopsie bevestigd PCC werden geïncludeerd. Deze 
patiënten werden gestratificeerd naar leeftijd en het aantal PCC’s tot aan inclusie 
en daarna gerandomiseerd in 2 groepen, te weten conversie naar sirolimus (n = 74) 
of voortzetting van hun oorspronkelijke immunosuppressieve therapie (n = 81). De 
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ontwikkeling van een nieuw PCC binnen 2 jaar na randomisatie was het primaire 
eindpunt. Na 2 jaar follow-up trad er geen significante vermindering op van nieuw 
ontstane PCC’s in de sirolimusgroep met een hazard ratio (HR) in de multivariabele 
analyse van 0,76 (95% CI, 0,48-1,2; p = 0,255). Helaas werd de beoordeling van de 
effectiviteit van sirolimus bemoeilijkt door het hoge percentage uitvallers in de 
sirolimusgroep (53%). Bij analyse van de data na het eerste jaar was er wel een 
significante risicovermindering op het ontstaan van een nieuw PCC, met een HR van 
0,50 (95% CI, 0,28-0,90; p = 0,021). Sirolimus bleek het meest effectief bij patiënten die 
slechts één PCC hadden gehad voorafgaand aan inclusie met een relatief risico van 
0,11 (95% CI, 0,01-0,94; p = 0,044). Het totale aantal tumoren dat patiënten per jaar 
ontwikkelden tijdens de follow-up periode van 2 jaar was lager in de sirolimusgroep 
(0,82 v 1,38 per jaar, HR 0,51; 95% CI, 0,32-0,82; p = 0,006) als gecorrigeerd werd voor 
het aantal eerdere PCC’s en leeftijd. In de sirolimusgroep traden veel bijwerkingen 
op, die bij 29 patiënten leidden tot het voortijdig staken van sirolimus. Terugkijkend 
heeft de combinatie van hoge initiële sirolimusspiegels en voorzichtigheid van de 
onderzoeker geleid tot vroegtijdig staken van sirolimus bij verschillende patiënten 
die een milde tot matige proteïnurie en andere bijwerkingen ontwikkelden, waar 
dit mogelijk ook zou hebben gereageerd op dosisaanpassing en/of de toevoeging 
van een angiotensine converterende enzymremmer. Er trad geen significante 
verandering in nierfunctie of toename van proteïnurie op bij de patiënten die de 
sirolimustherapie continueerden. Dit suggereert de veiligheid van conversie naar 
sirolimus bij niertransplantaatontvangers vele jaren na transplantatie. Concluderend 
kan worden gesteld dat conversie naar lage dosis mTOR-remming niet geassocieerd 
is met een verhoogd risico op transplantaatdysfunctie wanneer dit onder strikte 
controle plaatsvindt. In onze studiepopulatie, bestaande uit patiënten met één of 
meer eerdere PCC’s, was er na twee jaar geen aantoonbaar voordeel in termen van 
PCC vrije overleving. Het mogelijk gunstige effect van conversie naar sirolimus op de 
ontwikkeling van nieuwe PCC’s bij patiënten met slechts één eerder ontwikkeld PCC 
moet zorgvuldig worden afgewogen tegen de toxiciteit van sirolimus. De voordelen 
van conversie naar een op mTOR gebaseerd regime in de subgroep van patiënten 
met slechts één eerder ontwikkeld invasief PCC suggereert dat een mTOR-remmer de 
potentie heeft om een effectieve vroege immunosuppressieve strategie te worden ter 
reductie van cutane PCC bij niertransplantaatontvangers.
 
In hoofdstuk 6 is onderzocht of met het meten van eiwitten in de urine 
transplantaatfunctieverslechtering en transplantaatverlies kan worden voorspeld. 
Albuminurie is een marker voor glomerulaire schade en een voorspeller van 
nierfunctieverslechtering bij patiënten met nierziekten. Verslechtering van de 
nierfunctie is echter het beste gecorreleerd met tubulo-interstitiële schade. Excretie in 
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de urine van α1-microglobuline weerspiegelt tubulo-interstitiële schade en verbetert 
de uitkomstvoorspelling bij patiënten met glomerulaire ziekten. Er is echter weinig 
bekend over de mogelijke waarde van α1-microglobuline bij het voorspellen van 
transplantaatoverleving bij patiënten met een niertransplantaat. Daarom hebben we in 
een cross-sectionele pilotstudie de urine α1-microglobuline-uitscheiding geëvalueerd 
in vier verschillende categorieën van patiënten met een niertransplantaat (HLA-
compatibel, geen eerdere transplantaatafstoting, met eerdere transplantaatafstoting en 
chronische transplantaatnefropathie). Vervolgens maten we de urine α1-microglobuline-
uitscheiding in een prospectief cohort van niertransplantaatontvangers op 3 en 12 
maanden na de transplantatie. We correleerden de waarden met transplantaatverlies 
en achteruitgang van nierfunctie. In de cross-sectionele studie werden 41 patiënten 
bestudeerd, waarvan 14 een HLA-compatibele nier ontvingen. De urine α1-
microglobuline-uitscheiding was hoger dan normaal in de meerderheid van de patiënten 
die een HLA-compatibele nier had ontvangen. Zelfs bij patiënten in deze categorie met 
de hoogste urine α1-microglobuline-excretie verslechterde de nierfunctie niet tijdens 
follow-up. Deze bevindingen suggereren dat hogere waarden van α1-microglobuline in 
de urine soms geaccepteerd kunnen worden als “normaal” na niertransplantatie en niet 
noodzakelijkerwijs overeenkomen met actieve, progressieve tubulo-interstitiële schade. 
De urine α1-microglobuline-uitscheiding was hoger in de patiënten met een eerdere 
afstoting of een chronische transplantaatnefropathie en correleerde met de eGFR (r = 
0,56; p < 0,001). In de prospectieve studie werden 139 patiënten geëvalueerd. Van deze 
patiënten ontwikkelden 34 patiënten een transplantaatafstoting binnen 3 maanden na 
de transplantatie. De mediane follow-up na niertransplantatie bedroeg 48 maanden, 
de eGFR steeg met 0,6 ml/min/1,73m2/jaar gedurende de follow-up, 10 patiënten 
overleden en 3 patiënten ontwikkelden transplantaatfalen. De urine α1-microglobuline-
uitscheiding was drie maanden na transplantatie bij 86% van de patiënten hoger dan 
de normaalwaarde en twaalf maanden na transplantatie bij 78% van de patiënten. De 
verhoogde urine α1-microglobuline-uitscheiding op twaalf maanden was geassocieerd 
met het type donor, het geslacht van de ontvanger, de eGFR, albuminurie, α1-
microglobuline-uitscheiding op 3 maanden en voorafgaande afstotingen. Helaas 
konden we niets concluderen over de prognostische waarde van α1-microglobuline 
op transplantaatfalen vanwege het beperkte aantal falende transplantaten gedurende 
de follow-up. Er was geen correlatie tussen de urine α1-microglobuline-excretie en de 
verandering in eGFR tijdens follow-up. Onze studie kan te weinig power hebben gehad 
om een associatie aan te tonen tussen urine α1-microglobuline en de verandering in 
eGFR tijdens de follow-up, omdat bij slechts 19 patiënten (14%) de eGFR meer dan 3 ml/
min/1,73m2/jaar achteruitging. Concluderend heeft de meerderheid van de patiënten 
3 en 12 maanden na de transplantatie een verhoogde urine α1-microglobuline-
uitscheiding. Op de korte termijn voorspelt de urine α1-microglobuline-uitscheiding de 
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renale uitkomst niet in deze relatief kleine verkennende studie. De data suggereren dat 
een verhoogd urine α1-microglobuline meer een weerspiegeling is van fibrose dan van 
actieve tubuluscelschade. Om de waarde van α1-microglobuline na niertransplantatie 
beter te kunnen bepalen is een grotere studie nodig met een langere follow-up, waarbij 
meer transplantaatfalen zal optreden.
Sinds het begin van de uitvoering van levende-donorniertransplantaties hebben artsen 
hun bezorgdheid geuit over de mogelijkheid dat een eenzijdige nefrectomie schadelijk 
kan zijn voor een gezond persoon. In hoofdstuk 7 is onderzocht of de verhoogde 
intra-abdominale druk tijdens een laparoscopische donornefrectomie vroege schade 
veroorzaakt aan de resterende nier door evaluatie van gevoelige urinebiomarkers na 
laparoscopische donornefrectomie. Albumine en α1-microglobuline werden gemeten 
in urinemonsters, die verzameld werden tijdens en na een open en laparoscopische 
donornefrectomie, laparoscopische cholecystectomie en laparoscopische colectomie. 
Bovendien werd uit ingevroren urinemonsters, die tijdens en na de laparoscopische 
donornefrectomie en laparoscopische colectomie waren verzameld, aanvullend 
kidney injury molecule-1 (KIM-1) en neutrophil gelatinase-associated lipocalin (NGAL) 
gemeten. Dezelfde biomarkers werden bestudeerd bij patiënten die gerandomiseerd 
werden in een groep standaard (14 mmHg) of lage (7 mmHg) intra-abdominale druk 
tijdens laparoscopische donornefrectomie. We stelden een piek in de urine albumine-
uitscheiding vast tijdens alle procedures. Urine α1-microglobuline was niet verhoogd 
tijdens de operatie, maar steeg in de postoperatieve periode met een piek op de 
derde postoperatieve dag na donornefrectomie. Urine α1-microglobuline steeg niet 
significant na laparoscopische cholecystectomie en colectomie. In de laparoscopische 
nefrectomiegroep zagen we gedurende de operatie een geringe stijging optreden van 
KIM-1 in de urine en 2-3 dagen na de procedure in de uitscheiding van NGAL in de urine. 
Na laparoscopische colectomie steeg zowel KIM-1 als NGAL in de postoperatieve periode. 
De observatie dat de urine albumine-uitscheiding maar niet de α1-microglobuline-
uitscheiding steeg tijdens de operatie geeft aan dat tijdens de operatie de glomerulaire 
permeabiliteit verandert. De snelle normalisatie suggereert dat dit een omkeerbaar 
proces is, ofwel het resultaat van de narcose, ofwel ten gevolge van hemodynamische 
veranderingen die zich voordoen tijdens de operatie. Een onverwachte bevinding 
was dat de excretie van de tubulaire schademarker KIM-1 ook verhoogd was tijdens 
de operatie. Naast glomerulaire veranderingen waren er ook aanwijzingen voor 
tubulaire schade na de open en laparoscopische donornefrectomie, die zich uitte in 
een piek in de α1-microglobuline-uitscheiding op de derde postoperatieve dag. Dit 
trad onafhankelijk van de intra-abdominale druk tijdens de laparoscopische procedure 
op. Opmerkelijk was dat de α1-microglobuline-uitscheiding 6 weken postoperatief nog 
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steeds verhoogd was. Onze data maken duidelijk dat de verhoogde α1-microglobuline-
uitscheiding specifiek optreedt bij een nefrectomie. Dit typische en unieke patroon 
van een verhoogde urine α1-microglobuline-uitscheiding na nefrectomie wordt 
ondersteund door het ontbreken van een correlatie tussen de uitscheiding van α1-
microglobuline en de uitscheiding van urine NGAL. Het is duidelijk dat de verhoogde 
excretie van α1-microglobuline dus niet is toe te schrijven aan de narcose of aan de 
verhoogde intra-abdominale druk. Toekomstige studies zijn nodig om de mechanismen 
te ontrafelen die ten grondslag liggen aan de biomarkerstijging na donornefrectomie. 
Onze studie toont ook aan dat de nieuwe biomarkers voor nierschade anders op de 
verschillende operatieve procedures reageren. Meer gedetailleerde studies zijn nodig 
om de verklaringen voor deze specifieke expressiepatronen te vinden.
dIscussIe
We voerden verschillende studies uit om te onderzoeken of een immunosuppressief 
regime met sirolimus de lange termijn resultaten na niertransplantatie kan verbeteren. 
Calcineurineremmers zijn de hoeksteen van de immunosuppressieve therapie na 
niertransplantatie geworden. Deze calcineurineremmers zijn echter nefrotoxisch 
en dragen vaak bij aan het disfunctioneren van het niertransplantaat. Daarom 
bestudeerden wij de werkzaamheid en veiligheid van een calcineurineremmervrij 
regime waarbij de calcineurineremmer wordt vervangen door sirolimus. Helaas 
moest deze studie gestaakt worden vanwege een onaanvaardbaar hoog aantal 
acute transplantaatafstotingen. Inmiddels hebben grote studies ook aangetoond dat 
inductietherapie met een sirolimus bevattend, calcineurineremmervrij, regime na 
transplantatie geassocieerd is met een verhoogd risico op acute afstotingen. Bovendien 
is in verschillende studies aangetoond dat bij sirolimus bevattende regimes direct na 
niertransplantatie het herstel van een vertraagd op gang komend niertransplantaat 
langer duurt in vergelijking met andere immunosuppressieve regimes. Tenslotte is het 
gebruik van sirolimus in de periode onmiddellijk na de transplantatie geassocieerd 
met een verhoogd risico op slechte wondgenezing en een verhoogde incidentie van 
lymfocèles, vaak resulterend in het moeten beëindigen van de sirolimusbehandeling. Op 
basis van bovenstaande bevindingen is het duidelijk geworden dat er momenteel geen 
plaats is voor een op sirolimus gebaseerd calcineurineremmervrij immunosuppressief 
regime in de periode onmiddellijk na niertransplantatie. Er is echter gesuggereerd 
dat mTOR-remmers veilig kunnen worden gebruikt en wel de calcineurineremmer 
kunnen vervangen als conversie pas 3 maanden na transplantatie wordt gestart. Een 
recente review concludeerde dat het mogelijk moet zijn met het gebruik van sirolimus 
in combinatie met een geminimaliseerde dosering tacrolimus de nierfunctie beter te 
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behouden, zonder verhoogd risico op transplantaatafstoting. Toekomstige studies 
moeten uitwijzen of vervroegde onttrekking van de calcineurineremmer en vervanging 
door sirolimus de transplantaatoverleving verbetert en of deze conversie het aantal 
bijwerkingen op de lange termijn vermindert. Er is gesuggereerd dat mTOR-remmers 
ook gebruikt kunnen worden in de periode onmiddellijk na de transplantatie, als deze in 
lage doseringen gegeven worden, gecombineerd met lage dosis calcineurineremmer. 
We zullen de resultaten van lopende studies moeten afwachten om hierover meer 
duidelijkheid te krijgen.
PCC’s treden frequent op als complicatie na niertransplantatie. Hoewel onze studie niet 
aan kon tonen dat er een voordeel optrad in termen van een PCC-vrije overleving na 2 
jaar, suggereerde een subgroepanalyse wel een voordeel bij patiënten die al na de eerste 
manifestatie van een PCC sirolimus kregen. Een soortgelijke conclusie werd getrokken 
door de groep van Euvrard, die ook een gerandomiseerd gecontroleerd onderzoek 
uitvoerden waarbij de effectiviteit werd bekeken van een op mTOR gebaseerd regime bij 
het voorkomen van de ontwikkeling van nieuwe huidcarcinomen. Deze onderzoekers 
stelden ook een voordeel van mTOR-behandeling vast in de subgroep van patiënten met 
slechts één eerdere manifestatie van een invasief PCC. Beide studies suggereren dus dat 
de behandeling met een mTOR-remmer het risico kan verminderen op het ontwikkelen 
van cutane PCC’s bij niertransplantatie-ontvangers. Het grootste voordeel lijkt te 
kunnen worden bereikt wanneer patiënten vroeg worden geconverteerd, dus al na de 
eerste manifestatie van een PCC. Op basis van deze bevindingen kan worden gesteld 
dat een mTOR-remmer het meest effectief is wanneer deze vroeg na transplantatie 
gegeven wordt bij patiënten met een hoog risico op PCC’s. Dit gebruik van sirolimus 
vroeg na transplantatie is echter geassocieerd met een hoger risico op afstotingen. 
Toekomstige studies moeten uitwijzen of conversie van een calcineurineremmer 
naar een mTOR-remmer 3 tot 6 maanden na de transplantatie resulteert in dezelfde 
transplantaatoverleving en een lager percentage maligniteiten. 
Hoewel mTOR-remmers mogelijk het risico op nefrotoxiciteit en het ontwikkelen van 
een maligniteit kunnen verminderen, was het gebruik hiervan geassocieerd met veel 
bijwerkingen. Een van de bekende bijwerkingen was het optreden van proteïnurie. Onze 
studie heeft duidelijk gemaakt dat proteïnurie ook werd waargenomen bij patiënten 
die van azathioprine naar sirolimus werden geconverteerd. Sirolimus geïnduceerde 
proteïnurie kan daarom niet worden toegeschreven aan de hemodynamische effecten 
van calcineurineremmeronttrekking. Proteïnurie werd vooral waargenomen bij 
patiënten die werden behandeld met sirolimus vanwege chronisch transplantaatfalen 
met proteïnurie.
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Het is raadzaam alle patiënten die met sirolimustherapie starten strikt te controleren 
op het ontstaan van proteïnurie. De risico’s van conversie zijn het grootst bij patiënten 
met al bestaande proteïnurie (> 800 mg / dag), een lagere eGFR (< 40 ml / min), of een 
chronisch transplantaatfalen. Strategieën voor het behandelen van milde proteïnurie 
omvatten verlaging van de bloeddruk met angiotensine converterende enzymremmers 
of angiotensine II receptorblokkers, een natrium- en eiwitbeperkt dieet, bestrijding 
van overgewicht, het corrigeren van stoornissen in de vetstofwisseling (met statines) 
en stoppen met roken. Als de proteïnurie toeneemt, kan het nodig zijn om de mTOR-
remmer te staken om het risico op nierfalen te verminderen. De proteïnurie vermindert 
dan over het algemeen binnen een paar maanden na het staken van de mTOR-remmer en 
levert dan in de meerderheid van de patiënten op de lange termijn geen nierschade op.
De eerste verslagleggingen over sirolimus geïnduceerde proteïnurie stimuleerden een 
zoektocht naar de ontwikkeling van een diermodel. Wij waren echter niet in staat om 
het ontstaan van proteïnurie te reproduceren in een muismodel voor focaal segmentale 
glomerulosclerose. Onze studies suggereerden zelfs een beschermend effect van 
sirolimus in dit muismodel. Een overzicht van de in de literatuur gerapporteerde data 
bevat ook contrasterende bevindingen, met een aantal studies die een toename van 
proteïnurie vermeldden, maar waarbij de meeste studies een daling van proteïnurie 
rapporteerden. De redenen voor deze schijnbare discrepanties zijn toegelicht in 
gedetailleerde studies naar de rol van mTOR in podocyten. De ontwikkeling en de 
overleving van de podocyt zijn afhankelijk van een strakke regulering van de mTORC1- 
en mTORC2-complexen. Zowel overactivatie als volledige remming van mTORC 
activiteit kan proteïnurie, glomerulosclerose en podocytdysfunctie veroorzaken. Het 
delicate evenwicht verklaart waarschijnlijk de waargenomen uiteenlopende effecten 
van sirolimus. De effecten van sirolimus op proteïnurie worden waarschijnlijk beïnvloed 
door factoren zoals de aard en aanwezigheid van al bestaande nierschade, het tijdstip 
van toediening en de dosering van sirolimus, evenals de voorafgaande blootstelling 
aan een calcineurineremmer. Meer gedetailleerde studies naar de effecten van mTOR 
op podocyten en de ontwikkeling van meer specifieke remmers zijn nodig om betere 
behandelingsstrategieën te ontwikkelen.
Het geheel beschouwend tonen onze studies aan dat er op dit moment geen plaats is 
voor een calcineurineremmervrij regime in de periode onmiddellijk na de transplantatie. 
Het gebruik van mTOR-remmers zoals sirolimus of everolimus moet worden overwogen 
in geselecteerde patiënten, zoals patiënten met posttransplantatiemaligniteiten en 
patiënten met calcineurineremmernefrotoxiciteit. Bij elke patiënt zullen de risico’s en 
voordelen van sirolimustherapie voor die specifieke patiënt zorgvuldig moeten worden 
afgewogen.
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Hoewel de invoering van de calcineurineremmer het aantal acute afstotingsepisoden 
heeft verminderd is de transplantaatoverleving op de lange termijn niet in vergelijkbare 
mate verbeterd. Bij veel patiënten verslechtert de transplantaatnierfunctie langzaam 
maar zeker welk proces vaak chronisch transplantaatfalen wordt genoemd. Veel 
processen zijn betrokken bij chronisch transplantaatfalen inclusief humorale rejectie, 
hoge bloeddruk, roken, dyslipidemie, nefrotoxiciteit, terugkeer van de oorspronkelijke 
nierziekte en atherosclerose. Klinisch is dit proces vaak moeilijk op te sporen. De meeste 
patiënten presenteren zich met een langzaam oplopend serumkreatinine. Op het 
moment dat het serumkreatinine duidelijk gestegen is, is er al veel schade aanwezig. Een 
nierbiopsie laat dan vaak onomkeerbare schade met interstitiële fibrose en tubulaire 
atrofie zien. Vroege herkenning van dit voortgaande proces van nierschade zou een 
vroege interventie en een op meerdere aspecten gerichte therapie mogelijk maken. 
Gebaseerd op bevindingen bij patiënten met glomerulaire ziekten veronderstelden 
wij dat het meten van de excretie in de urine van het kleinmoleculaire eiwit α1-
microglobuline kan helpen bij het voorspellen van laat optredend transplantaatfalen. 
Uit onze studies is duidelijk gebleken dat de uitscheiding van α1-microglobuline in de 
urine hiervoor geen geschikte parameter is bij niertransplantaatontvangers. Bij veel 
patiënten werd een verhoogde waarde van α1-microglobuline in de urine waargenomen, 
zelfs bij patiënten met een nog jarenlang stabiele nierfunctie na de meting. Deze 
resultaten suggereerden dat een verhoogde excretie van α1-microglobuline niet een 
weerspiegeling is van actieve tubulaire schade, maar meer een weerspiegeling is van 
ontstane fibrose en tubulaire atrofie. We kunnen niet uitsluiten dat het herhaald meten 
van α1-microglobuline in de urine, waarmee een verandering in de uitscheiding kan 
worden berekend, wellicht beter geschikt is om toekomstig transplantaatfalen te 
voorspellen. Anderzijds moeten we het evalueren van andere tubulaire biomarkers 
overwegen. In de afgelopen jaren zijn nieuwe renale biomarkers bestudeerd, met name 
bij acuut nierletsel. Het zou zinvol zijn om de rol van deze biomarkers, zoals KIM-1, NGAL 
en interleukine-18, na te gaan bij het voorspellen van niertransplantaatfalen.
We onderzochten veranderingen in de uitscheiding van verschillende urinebiomarkers 
na nierdonatie. Wij vroegen ons specifiek af of een hogere intra-abdominale druk subtiel 
nierletsel kan induceren. We hebben geen verschillen waargenomen in de uitscheiding 
van biomarkers tussen laparoscopische procedures met lage en hoge abdominale 
druk. We detecteerden echter wel een verhoogde excretie van α1-microglobuline in de 
urine in de eerste dagen na de open en laparoscopische donornefrectomie. Bovendien 
waren deze waarden 4-6 weken na de nefrectomie nog niet genormaliseerd. We weten 
niet of de verhoogde uitscheiding van α1-microglobuline het gevolg is van beperkte 
tubulaire schade, of dat dit een fysiologische reactie is op hyperfiltratie die na de 
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nefrectomie ontstaat. Duidelijk is dat nierschade ook op de lange termijn niet de regel 
is na nierdonatie. Grote studies hebben gedocumenteerd dat de uitkomst van levende 
nierdonoren over het algemeen goed is. Toch stellen wij voor dat er meer onderzoek 
nodig is om onze bevindingen te verklaren. Als de verhoogde uitscheiding van α1-
microglobuline het gevolg is van hyperfiltratie, is er geen reden tot bezorgdheid. 
Anderzijds zou het goed kunnen zijn dat de procedure toch geringe schade veroorzaakt. 
Dit hoeft op de lange termijn geen gevolgen te hebben. Als er echter in de onmiddellijke 
postoperatieve periode enige tubulaire schade aanwezig is, kan het mogelijk belangrijk 
zijn om het gebruik van nefrotoxische middelen of nefrotoxische procedures (contrast 
CT-scans) in deze periode te beperken. We hebben ons huidige transplantatiebeleid 
niet gewijzigd. De data hebben echter geleid tot nieuwe studievoorstellen. Deze zijn 
specifiek gericht op het onderzoeken van de α1-microglobuline-excretie op de langere 
termijn na nierdonatie, op het bestuderen van de α1-microglobuline-excretie na een 
gedeeltelijke nefrectomie en op het meten van andere nierschademarkers. 
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Mijn dank gaat uit naar iedereen die aan de totstandkoming van dit proefschrift heeft 
bijgedragen. Een aantal mensen wil ik in het bijzonder bedanken:
In de allereerste plaats natuurlijk de vele patiënten die deelnamen aan de verschillende 
studies. Zonder hun medewerking waren de beschreven onderzoeken nooit verricht. 
Mijn promotor prof. dr. Andries Hoitsma. Het heeft om vele redenen lang geduurd, maar 
mede dankzij jouw optimisme en enthousiasme is het uiteindelijk toch tot een goed 
einde gekomen. Bedankt voor al je hulp en steun de afgelopen jaren en het vertrouwen 
dat je in me hield. Mijn promotor prof. dr. Jack Wetzels, die mij vooral in de laatste fase 
heeft gestimuleerd. Je bent in staat om een encyclopedische kennis te combineren met 
een scherpzinnig inzicht. Mijn ingebrachte stukken verbeterde je met de snelheid van 
het licht wat maakte dat ik na een impasse weer verder kon. 
Alle dokters en gespecialiseerde verpleegkundigen die een bijdrage hebben geleverd 
aan de multicenter studies dank ik voor de goede samenwerking. 
De collega’s van de afdeling Nefrologie in Nijmegen wil ik bedanken voor de fijne 
samenwerking tijdens de opleiding en de onderzoeksperiode. Ook wil ik jullie bedanken 
voor de hulp bij het uitvoeren van de onderzoeken en de inclusie van de patiënten. Ook 
de medewerkers van het secretariaat en de verpleegafdeling van de afdeling Nefrologie 
en de transplantatieverpleegkundigen wil ik bedanken voor hun hulp. In het bijzonder 
was Marjo van Helden, research verpleegkundige, van onschatbare waarde.
Collega nefrologen in Zwolle. Dank voor jullie steun de afgelopen jaren. Zonder jullie 
was er geen proefschrift geweest. Ik ben dan ook heel blij dat Sabine en Karlijn vandaag 
mijn paranimfen willen zijn en dat ik deze bijzondere periode met een duo promotie 
met Hilde mag afsluiten. Ik hoop dat we nog lang collega’s en vriendinnen mogen 
blijven. Dank voor jullie steun en aanwezigheid vandaag.
Vrienden en (schoon)familie, bedankt voor jullie betrokkenheid de afgelopen jaren en 
voor de vele mooie momenten samen. Hopelijk volgen er nog velen.
Lieve papa en mama, mede dankzij jullie sta ik hier. Jullie hebben me altijd gestimuleerd. 
Dank voor jullie liefde en alle praktische en emotionele steun.
Lieve Thijs en Lianne, jullie begrepen niet altijd waarom mama zoveel tijd nodig had om 
een boekje te schrijven. Bedankt voor jullie geduld. Nu het af is komt er eindelijk meer 
tijd om samen leuke dingen te doen. Lieve Stefan, je stond altijd voor me klaar om mij 
de gelegenheid te geven om naast mijn werk ook dit proefschrift te schrijven, ondanks 
een druk gezinsleven. Ik heb hier zeer veel bewondering voor en wil je bedanken voor 
je onvoorwaardelijke steun de afgelopen jaren. Ik houd van jullie.
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Judith Hoogendijk-van den Akker werd op 17 mei 1972 geboren te Delft. In 1990 werd 
het VWO-diploma behaald aan het Christelijk Lyceum te Veenendaal. In datzelfde jaar 
begon zij met de studie biomedische gezondheidswetenschappen aan de Katholieke 
Universiteit Nijmegen, waar in 1994 de doctorale fase werd afgesloten in de richting 
klinische epidemiologie. Eveneens aan de Katholieke Universiteit Nijmegen werd in 
1996 de doctorale fase van de studie geneeskunde afgesloten (cum laude). Na haar 
co-assistentschappen werd in 1998 het artsexamen behaald. Aansluitend was zij 1 jaar 
werkzaam als AGNIO op de afdeling interne geneeskunde van het Rijnstate Ziekenhuis 
te Arnhem. In 1999 startte zij met de opleiding tot internist in het Rijnstate Ziekenhuis 
te Arnhem (opleider dr. R. van Leusen). In 2003 werd de opleiding voortgezet in het 
Universitair Medisch Centrum St. Radboud te Nijmegen (opleider prof. dr. J.W.M. van der 
Meer). De registratie als internist volgde op 1-11-2005, waarna de opleiding tot nefroloog 
werd afgerond op 1-11-2006 (opleider prof. dr. J.H.M. Berden). Vanaf november 2006 is 
zij als internist-nefroloog werkzaam in de Isala te Zwolle.
Judith is getrouwd met Stefan Hoogendijk met wie zij twee kinderen heeft, Thijs (2001) 
en Lianne (2005).

